CZ282038B6 - Chinazolinové deriváty, způsob jejich přípravy a farmaceutické kompozice tyto deriváty obsahující - Google Patents
Chinazolinové deriváty, způsob jejich přípravy a farmaceutické kompozice tyto deriváty obsahující Download PDFInfo
- Publication number
- CZ282038B6 CZ282038B6 CZ9343A CZ4393A CZ282038B6 CZ 282038 B6 CZ282038 B6 CZ 282038B6 CZ 9343 A CZ9343 A CZ 9343A CZ 4393 A CZ4393 A CZ 4393A CZ 282038 B6 CZ282038 B6 CZ 282038B6
- Authority
- CZ
- Czechia
- Prior art keywords
- carbon atoms
- group
- radical contains
- alkyl
- alkyl radical
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 62
- 238000002360 preparation method Methods 0.000 title claims abstract description 23
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 8
- 230000008569 process Effects 0.000 title claims abstract description 7
- 125000002294 quinazolinyl group Chemical class N1=C(N=CC2=CC=CC=C12)* 0.000 title abstract description 5
- -1 amino, carboxyl Chemical group 0.000 claims abstract description 974
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract description 787
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 119
- 150000001875 compounds Chemical class 0.000 claims abstract description 107
- 125000003545 alkoxy group Chemical group 0.000 claims abstract description 53
- 150000003839 salts Chemical class 0.000 claims abstract description 50
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 22
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims abstract description 22
- 125000003277 amino group Chemical group 0.000 claims abstract description 20
- 125000005843 halogen group Chemical group 0.000 claims abstract description 16
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims abstract description 15
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims abstract description 14
- 125000005530 alkylenedioxy group Chemical group 0.000 claims abstract description 13
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 13
- 125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 claims abstract description 9
- 125000004093 cyano group Chemical group *C#N 0.000 claims abstract description 9
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract description 8
- 125000005118 N-alkylcarbamoyl group Chemical group 0.000 claims abstract description 6
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims abstract description 5
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims abstract description 5
- 125000000033 alkoxyamino group Chemical group 0.000 claims abstract description 4
- 125000002349 hydroxyamino group Chemical group [H]ON([H])[*] 0.000 claims abstract description 4
- 150000003246 quinazolines Chemical class 0.000 claims description 87
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 54
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 36
- 150000003254 radicals Chemical class 0.000 claims description 32
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical group NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims description 26
- 125000001424 substituent group Chemical group 0.000 claims description 25
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 claims description 24
- 239000002253 acid Substances 0.000 claims description 20
- 229910052739 hydrogen Inorganic materials 0.000 claims description 20
- 125000004414 alkyl thio group Chemical group 0.000 claims description 19
- 125000003282 alkyl amino group Chemical group 0.000 claims description 18
- 239000001257 hydrogen Substances 0.000 claims description 18
- 125000004644 alkyl sulfinyl group Chemical group 0.000 claims description 15
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 15
- 241001465754 Metazoa Species 0.000 claims description 14
- 125000005236 alkanoylamino group Chemical group 0.000 claims description 14
- 230000001093 anti-cancer Effects 0.000 claims description 14
- JFDWMFYUKLPRSP-UHFFFAOYSA-N 6-methyl-n-phenylquinazolin-4-amine Chemical compound C12=CC(C)=CC=C2N=CN=C1NC1=CC=CC=C1 JFDWMFYUKLPRSP-UHFFFAOYSA-N 0.000 claims description 13
- VKOGLNSKGDTRGH-UHFFFAOYSA-N 4-[(6-methoxyquinazolin-4-yl)amino]phenol Chemical compound C12=CC(OC)=CC=C2N=CN=C1NC1=CC=C(O)C=C1 VKOGLNSKGDTRGH-UHFFFAOYSA-N 0.000 claims description 12
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 12
- 125000005083 alkoxyalkoxy group Chemical group 0.000 claims description 11
- GBJXFMREUNFKRX-UHFFFAOYSA-N 4-n-(4-aminophenyl)quinazoline-4,6-diamine Chemical compound C1=CC(N)=CC=C1NC1=NC=NC2=CC=C(N)C=C12 GBJXFMREUNFKRX-UHFFFAOYSA-N 0.000 claims description 10
- MJKCGAHOCZLYDG-UHFFFAOYSA-N 6,7-dimethoxy-n-phenylquinazolin-4-amine Chemical compound C=12C=C(OC)C(OC)=CC2=NC=NC=1NC1=CC=CC=C1 MJKCGAHOCZLYDG-UHFFFAOYSA-N 0.000 claims description 10
- KHBQMWCZKVMBLN-IDEBNGHGSA-N benzenesulfonamide Chemical group NS(=O)(=O)[13C]1=[13CH][13CH]=[13CH][13CH]=[13CH]1 KHBQMWCZKVMBLN-IDEBNGHGSA-N 0.000 claims description 10
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 10
- CRZPVSMPJCPEPP-UHFFFAOYSA-N 4-([1,3]dioxolo[4,5-g]quinazolin-8-ylamino)phenol Chemical compound C1=CC(O)=CC=C1NC(C1=C2)=NC=NC1=CC1=C2OCO1 CRZPVSMPJCPEPP-UHFFFAOYSA-N 0.000 claims description 9
- 125000005113 hydroxyalkoxy group Chemical group 0.000 claims description 9
- 125000006524 alkoxy alkyl amino group Chemical group 0.000 claims description 8
- 125000005085 alkoxycarbonylalkoxy group Chemical group 0.000 claims description 8
- 125000004984 dialkylaminoalkoxy group Chemical group 0.000 claims description 8
- 125000001188 haloalkyl group Chemical group 0.000 claims description 8
- 125000005191 hydroxyalkylamino group Chemical group 0.000 claims description 8
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 claims description 8
- ZFSSJGZFLIOOKN-UHFFFAOYSA-N 4-(4-methoxyanilino)quinazolin-8-ol Chemical compound C1=CC(OC)=CC=C1NC1=NC=NC2=C(O)C=CC=C12 ZFSSJGZFLIOOKN-UHFFFAOYSA-N 0.000 claims description 7
- YPBYGBLLRMWZAF-UHFFFAOYSA-N 4-[(6,7,8-trimethoxyquinazolin-4-yl)amino]phenol Chemical compound N1=CN=C2C(OC)=C(OC)C(OC)=CC2=C1NC1=CC=C(O)C=C1 YPBYGBLLRMWZAF-UHFFFAOYSA-N 0.000 claims description 7
- URJYCHBAPFKHRE-UHFFFAOYSA-N 8-methoxy-n-(4-methoxyphenyl)quinazolin-4-amine Chemical compound C1=CC(OC)=CC=C1NC1=NC=NC2=C(OC)C=CC=C12 URJYCHBAPFKHRE-UHFFFAOYSA-N 0.000 claims description 7
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims description 7
- 125000000278 alkyl amino alkyl group Chemical group 0.000 claims description 7
- 125000004656 alkyl sulfonylamino group Chemical group 0.000 claims description 7
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 7
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 7
- MPIHIJBPYYKLEA-UHFFFAOYSA-N n-(4-chlorophenyl)-8-methoxyquinazolin-4-amine Chemical compound N1=CN=C2C(OC)=CC=CC2=C1NC1=CC=C(Cl)C=C1 MPIHIJBPYYKLEA-UHFFFAOYSA-N 0.000 claims description 7
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 7
- 125000006016 2-bromoethoxy group Chemical group 0.000 claims description 6
- BYBQXGBBLHNCIR-UHFFFAOYSA-N 4-(4-chloroanilino)quinazolin-8-ol Chemical compound N1=CN=C2C(O)=CC=CC2=C1NC1=CC=C(Cl)C=C1 BYBQXGBBLHNCIR-UHFFFAOYSA-N 0.000 claims description 6
- 125000006350 alkyl thio alkyl group Chemical group 0.000 claims description 6
- 125000004103 aminoalkyl group Chemical group 0.000 claims description 6
- 125000004985 dialkyl amino alkyl group Chemical group 0.000 claims description 6
- 125000004438 haloalkoxy group Chemical group 0.000 claims description 6
- 229910052736 halogen Inorganic materials 0.000 claims description 6
- 229940080818 propionamide Drugs 0.000 claims description 6
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims description 5
- 125000005041 acyloxyalkyl group Chemical group 0.000 claims description 5
- 125000005084 alkoxyalkylaminoalkyl group Chemical group 0.000 claims description 5
- 125000005078 alkoxycarbonylalkyl group Chemical group 0.000 claims description 5
- 125000004466 alkoxycarbonylamino group Chemical group 0.000 claims description 5
- 125000005122 aminoalkylamino group Chemical group 0.000 claims description 5
- 125000005111 carboxyalkoxy group Chemical group 0.000 claims description 5
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 5
- 125000004966 cyanoalkyl group Chemical group 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 125000004992 haloalkylamino group Chemical group 0.000 claims description 5
- 150000002367 halogens Chemical class 0.000 claims description 5
- 125000005181 hydroxyalkylaminoalkyl group Chemical group 0.000 claims description 5
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 claims description 5
- 230000009467 reduction Effects 0.000 claims description 5
- OAAKFAXUEYTMHF-UHFFFAOYSA-N 2-ethoxyacetamide Chemical compound CCOCC(N)=O OAAKFAXUEYTMHF-UHFFFAOYSA-N 0.000 claims description 4
- MTEZLAATISORQK-UHFFFAOYSA-N 2-methoxyacetamide Chemical compound COCC(N)=O MTEZLAATISORQK-UHFFFAOYSA-N 0.000 claims description 4
- 125000005081 alkoxyalkoxyalkyl group Chemical group 0.000 claims description 4
- 125000003418 alkyl amino alkoxy group Chemical group 0.000 claims description 4
- 125000005242 carbamoyl alkyl group Chemical group 0.000 claims description 4
- 125000001589 carboacyl group Chemical group 0.000 claims description 4
- 125000004181 carboxyalkyl group Chemical group 0.000 claims description 4
- 238000003776 cleavage reaction Methods 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 4
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 claims description 4
- 125000001153 fluoro group Chemical group F* 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
- 125000002071 phenylalkoxy group Chemical group 0.000 claims description 4
- TZGPACAKMCUCKX-UHFFFAOYSA-N 2-hydroxyacetamide Chemical compound NC(=O)CO TZGPACAKMCUCKX-UHFFFAOYSA-N 0.000 claims description 3
- ULUILBSHRZPHGK-UHFFFAOYSA-N 6-(2-methoxyethoxymethyl)-n-(3-methylphenyl)quinazolin-4-amine Chemical compound C12=CC(COCCOC)=CC=C2N=CN=C1NC1=CC=CC(C)=C1 ULUILBSHRZPHGK-UHFFFAOYSA-N 0.000 claims description 3
- YMQNMNWEDFTMTJ-UHFFFAOYSA-N 6-n,6-n-dimethyl-4-n-(3-methylphenyl)quinazoline-4,6-diamine Chemical compound C12=CC(N(C)C)=CC=C2N=CN=C1NC1=CC=CC(C)=C1 YMQNMNWEDFTMTJ-UHFFFAOYSA-N 0.000 claims description 3
- BWENYVDMLAZGTP-UHFFFAOYSA-N 7-methoxy-4-n-(3-methylphenyl)quinazoline-4,6-diamine Chemical compound C=12C=C(N)C(OC)=CC2=NC=NC=1NC1=CC=CC(C)=C1 BWENYVDMLAZGTP-UHFFFAOYSA-N 0.000 claims description 3
- WLGDTJBSQGRVRX-UHFFFAOYSA-N [4-(3-methylanilino)quinazolin-6-yl]urea Chemical compound CC1=CC=CC(NC=2C3=CC(NC(N)=O)=CC=C3N=CN=2)=C1 WLGDTJBSQGRVRX-UHFFFAOYSA-N 0.000 claims description 3
- 150000001412 amines Chemical class 0.000 claims description 3
- 125000002431 aminoalkoxy group Chemical group 0.000 claims description 3
- 230000007062 hydrolysis Effects 0.000 claims description 3
- 238000006460 hydrolysis reaction Methods 0.000 claims description 3
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 claims description 3
- 125000004092 methylthiomethyl group Chemical group [H]C([H])([H])SC([H])([H])* 0.000 claims description 3
- 125000001064 morpholinomethyl group Chemical group [H]C([H])(*)N1C([H])([H])C([H])([H])OC([H])([H])C1([H])[H] 0.000 claims description 3
- BIGXXKQBMRKUJG-UHFFFAOYSA-N n-(3-methylphenyl)-7,8-dihydro-[1,4]dioxino[2,3-g]quinazolin-4-amine Chemical compound CC1=CC=CC(NC=2C3=CC=4OCCOC=4C=C3N=CN=2)=C1 BIGXXKQBMRKUJG-UHFFFAOYSA-N 0.000 claims description 3
- VQIWZLBIZSXBLT-UHFFFAOYSA-N n-[4-(3-methylanilino)quinazolin-6-yl]benzamide Chemical compound CC1=CC=CC(NC=2C3=CC(NC(=O)C=4C=CC=CC=4)=CC=C3N=CN=2)=C1 VQIWZLBIZSXBLT-UHFFFAOYSA-N 0.000 claims description 3
- 125000005359 phenoxyalkyl group Chemical group 0.000 claims description 3
- 230000007017 scission Effects 0.000 claims description 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 2
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 2
- UFQQKRSIOKGSIU-UHFFFAOYSA-N 6,7-bis(2-methoxyethoxy)-n-(3-methylphenyl)quinazolin-4-amine Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C)=C1 UFQQKRSIOKGSIU-UHFFFAOYSA-N 0.000 claims description 2
- BCZUPYLJRTXVOY-UHFFFAOYSA-N 6,7-diethoxy-n-(3-methylphenyl)quinazolin-4-amine Chemical compound C=12C=C(OCC)C(OCC)=CC2=NC=NC=1NC1=CC=CC(C)=C1 BCZUPYLJRTXVOY-UHFFFAOYSA-N 0.000 claims description 2
- ZJCCYDYNZMGIHC-UHFFFAOYSA-N 6-methoxy-n-(3-methylphenyl)quinazolin-4-amine Chemical compound C12=CC(OC)=CC=C2N=CN=C1NC1=CC=CC(C)=C1 ZJCCYDYNZMGIHC-UHFFFAOYSA-N 0.000 claims description 2
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 claims description 2
- 230000029936 alkylation Effects 0.000 claims description 2
- 238000005804 alkylation reaction Methods 0.000 claims description 2
- 125000004429 atom Chemical group 0.000 claims description 2
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 claims description 2
- VOPNWXZDJKCCRE-UHFFFAOYSA-N n-(3-chloro-4-fluorophenyl)-6,7-dimethoxyquinazolin-4-amine Chemical compound C=12C=C(OC)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 VOPNWXZDJKCCRE-UHFFFAOYSA-N 0.000 claims description 2
- 230000001590 oxidative effect Effects 0.000 claims description 2
- 125000004768 (C1-C4) alkylsulfinyl group Chemical group 0.000 claims 1
- 125000004769 (C1-C4) alkylsulfonyl group Chemical group 0.000 claims 1
- FAUYSBITBLFUOX-UHFFFAOYSA-N 10,12-dioxa-8,13-diazatricyclo[7.3.1.02,7]trideca-1(13),2,4,6,8-pentaene Chemical compound C1=CC=CC2=NC(OCO3)=NC3=C21 FAUYSBITBLFUOX-UHFFFAOYSA-N 0.000 claims 1
- KHBQMWCZKVMBLN-UHFFFAOYSA-N Benzenesulfonamide Chemical group NS(=O)(=O)C1=CC=CC=C1 KHBQMWCZKVMBLN-UHFFFAOYSA-N 0.000 claims 1
- OCXSVYSGSKIORX-UHFFFAOYSA-N C1(=CC=CC=C1)NC(NC(C(=O)N)Cl)=O Chemical compound C1(=CC=CC=C1)NC(NC(C(=O)N)Cl)=O OCXSVYSGSKIORX-UHFFFAOYSA-N 0.000 claims 1
- 101100348017 Drosophila melanogaster Nazo gene Proteins 0.000 claims 1
- KMBHYOPMKJLNMX-UHFFFAOYSA-N N-(4-chlorophenyl)-8-methoxyquinazolin-2-amine Chemical compound ClC1=CC=C(NC2=NC3=C(C=CC=C3C=N2)OC)C=C1 KMBHYOPMKJLNMX-UHFFFAOYSA-N 0.000 claims 1
- ZVMHFEYAUBCJDQ-UHFFFAOYSA-N OC=1C=CC=C2C(=CC=NC=12)NC1=CC=C(C=C1)Cl Chemical compound OC=1C=CC=C2C(=CC=NC=12)NC1=CC=C(C=C1)Cl ZVMHFEYAUBCJDQ-UHFFFAOYSA-N 0.000 claims 1
- LSPANGZZENHZNJ-UHFFFAOYSA-N PD-153035 Chemical compound C=12C=C(OC)C(OC)=CC2=NC=NC=1NC1=CC=CC(Br)=C1 LSPANGZZENHZNJ-UHFFFAOYSA-N 0.000 claims 1
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 claims 1
- 125000001246 bromo group Chemical group Br* 0.000 claims 1
- NZHRGFLNIISRAV-UHFFFAOYSA-N n-(3,4-dichlorophenyl)-6,7-dimethoxyquinazolin-4-amine Chemical compound C=12C=C(OC)C(OC)=CC2=NC=NC=1NC1=CC=C(Cl)C(Cl)=C1 NZHRGFLNIISRAV-UHFFFAOYSA-N 0.000 claims 1
- 125000003386 piperidinyl group Chemical group 0.000 claims 1
- XMVJITFPVVRMHC-UHFFFAOYSA-N roxarsone Chemical group OC1=CC=C([As](O)(O)=O)C=C1[N+]([O-])=O XMVJITFPVVRMHC-UHFFFAOYSA-N 0.000 claims 1
- 125000003396 thiol group Chemical class [H]S* 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 abstract description 4
- 239000000203 mixture Substances 0.000 description 225
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 210
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 135
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 121
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 92
- 238000000921 elemental analysis Methods 0.000 description 86
- 239000011541 reaction mixture Substances 0.000 description 81
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 73
- 230000008018 melting Effects 0.000 description 67
- 238000002844 melting Methods 0.000 description 67
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 67
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 59
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 56
- 239000000243 solution Substances 0.000 description 55
- 238000004440 column chromatography Methods 0.000 description 54
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 48
- 239000000047 product Substances 0.000 description 47
- 239000007858 starting material Substances 0.000 description 44
- 235000019439 ethyl acetate Nutrition 0.000 description 41
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 39
- 238000012360 testing method Methods 0.000 description 33
- 238000010992 reflux Methods 0.000 description 29
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 28
- 235000019341 magnesium sulphate Nutrition 0.000 description 28
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 27
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 26
- 239000002244 precipitate Substances 0.000 description 26
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 25
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 24
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 22
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 22
- 239000012258 stirred mixture Substances 0.000 description 21
- JJYPMNFTHPTTDI-UHFFFAOYSA-N 3-methylaniline Chemical compound CC1=CC=CC(N)=C1 JJYPMNFTHPTTDI-UHFFFAOYSA-N 0.000 description 20
- 206010028980 Neoplasm Diseases 0.000 description 19
- 238000004458 analytical method Methods 0.000 description 19
- 239000012074 organic phase Substances 0.000 description 19
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 18
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 16
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 16
- NFBCSWGEYDCCDW-UHFFFAOYSA-N 4-n-(3-methylphenyl)quinazoline-4,6-diamine Chemical compound CC1=CC=CC(NC=2C3=CC(N)=CC=C3N=CN=2)=C1 NFBCSWGEYDCCDW-UHFFFAOYSA-N 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 15
- 239000007787 solid Substances 0.000 description 15
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 14
- 238000006243 chemical reaction Methods 0.000 description 14
- 238000003756 stirring Methods 0.000 description 14
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 13
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 13
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 12
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 12
- 201000011510 cancer Diseases 0.000 description 12
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 12
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 12
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 11
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 11
- 230000002401 inhibitory effect Effects 0.000 description 11
- 229910000027 potassium carbonate Inorganic materials 0.000 description 11
- 239000003480 eluent Substances 0.000 description 10
- 239000012071 phase Substances 0.000 description 10
- 230000002441 reversible effect Effects 0.000 description 10
- 239000000126 substance Substances 0.000 description 10
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 10
- CMYBAHRLNADCKS-UHFFFAOYSA-N 6-(bromomethyl)-n-(3-methylphenyl)quinazolin-4-amine Chemical compound CC1=CC=CC(NC=2C3=CC(CBr)=CC=C3N=CN=2)=C1 CMYBAHRLNADCKS-UHFFFAOYSA-N 0.000 description 9
- 239000002585 base Substances 0.000 description 9
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 9
- 239000003921 oil Substances 0.000 description 9
- LLLHRNQLGUOJHP-UHFFFAOYSA-N 4-chloro-6,7-dimethoxyquinazoline Chemical compound C1=NC(Cl)=C2C=C(OC)C(OC)=CC2=N1 LLLHRNQLGUOJHP-UHFFFAOYSA-N 0.000 description 8
- KPHNOFBKQHPSGB-UHFFFAOYSA-N 6-methoxy-4-(3-methylanilino)quinazolin-7-ol Chemical compound N1=CN=C2C=C(O)C(OC)=CC2=C1NC1=CC=CC(C)=C1 KPHNOFBKQHPSGB-UHFFFAOYSA-N 0.000 description 8
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 8
- PQLVXDKIJBQVDF-UHFFFAOYSA-N acetic acid;hydrate Chemical compound O.CC(O)=O PQLVXDKIJBQVDF-UHFFFAOYSA-N 0.000 description 8
- 239000003054 catalyst Substances 0.000 description 8
- 239000012458 free base Substances 0.000 description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- 239000012044 organic layer Substances 0.000 description 8
- 229960000583 acetic acid Drugs 0.000 description 7
- 150000002431 hydrogen Chemical class 0.000 description 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 238000011282 treatment Methods 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 6
- 102400001368 Epidermal growth factor Human genes 0.000 description 6
- 101800003838 Epidermal growth factor Proteins 0.000 description 6
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 6
- JLTDJTHDQAWBAV-UHFFFAOYSA-N N,N-dimethylaniline Chemical compound CN(C)C1=CC=CC=C1 JLTDJTHDQAWBAV-UHFFFAOYSA-N 0.000 description 6
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 6
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 6
- 229910052783 alkali metal Inorganic materials 0.000 description 6
- 229910052801 chlorine Inorganic materials 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000000706 filtrate Substances 0.000 description 6
- 239000003701 inert diluent Substances 0.000 description 6
- 239000012442 inert solvent Substances 0.000 description 6
- 239000000543 intermediate Substances 0.000 description 6
- 229920006395 saturated elastomer Polymers 0.000 description 6
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 6
- AHGSPAKNJWCSRF-UHFFFAOYSA-N 4-n-(3-methylphenyl)quinazoline-4,7-diamine Chemical compound CC1=CC=CC(NC=2C3=CC=C(N)C=C3N=CN=2)=C1 AHGSPAKNJWCSRF-UHFFFAOYSA-N 0.000 description 5
- RSVNNWQHWIOIOC-UHFFFAOYSA-N 6,7-dimethoxy-n-(3-methylphenyl)quinazolin-4-amine Chemical compound C=12C=C(OC)C(OC)=CC2=NC=NC=1NC1=CC=CC(C)=C1 RSVNNWQHWIOIOC-UHFFFAOYSA-N 0.000 description 5
- FUWFVMHHNPEPHD-UHFFFAOYSA-N 6-(bromomethyl)-4-chloroquinazoline Chemical compound C1=C(CBr)C=C2C(Cl)=NC=NC2=C1 FUWFVMHHNPEPHD-UHFFFAOYSA-N 0.000 description 5
- BUYIXGTWVMBDLP-UHFFFAOYSA-N 7-chloro-n-(3-methylphenyl)-6-nitroquinazolin-4-amine Chemical compound CC1=CC=CC(NC=2C3=CC(=C(Cl)C=C3N=CN=2)[N+]([O-])=O)=C1 BUYIXGTWVMBDLP-UHFFFAOYSA-N 0.000 description 5
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 5
- 108700020796 Oncogene Proteins 0.000 description 5
- 239000000908 ammonium hydroxide Substances 0.000 description 5
- 239000000460 chlorine Substances 0.000 description 5
- 229940116977 epidermal growth factor Drugs 0.000 description 5
- 229910052731 fluorine Inorganic materials 0.000 description 5
- 239000012362 glacial acetic acid Substances 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- QJDUDPQVDAASMV-UHFFFAOYSA-M sodium;ethanethiolate Chemical compound [Na+].CC[S-] QJDUDPQVDAASMV-UHFFFAOYSA-M 0.000 description 5
- PAAZPARNPHGIKF-UHFFFAOYSA-N 1,2-dibromoethane Chemical compound BrCCBr PAAZPARNPHGIKF-UHFFFAOYSA-N 0.000 description 4
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 4
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 4
- ZFXHOCBCURBSDT-UHFFFAOYSA-N 2-[6-methoxy-4-(3-methylanilino)quinazolin-7-yl]oxyethanol Chemical compound N1=CN=C2C=C(OCCO)C(OC)=CC2=C1NC1=CC=CC(C)=C1 ZFXHOCBCURBSDT-UHFFFAOYSA-N 0.000 description 4
- JJKWHOSQTYYFAE-UHFFFAOYSA-N 2-methoxyacetyl chloride Chemical compound COCC(Cl)=O JJKWHOSQTYYFAE-UHFFFAOYSA-N 0.000 description 4
- MBEQLZLCWSXTPD-UHFFFAOYSA-N 4-(3-methylanilino)quinazoline-6,7-diol Chemical compound CC1=CC=CC(NC=2C3=CC(O)=C(O)C=C3N=CN=2)=C1 MBEQLZLCWSXTPD-UHFFFAOYSA-N 0.000 description 4
- XNILKVADCMYCQT-UHFFFAOYSA-N 4-chloro-6-methylquinazoline Chemical compound N1=CN=C(Cl)C2=CC(C)=CC=C21 XNILKVADCMYCQT-UHFFFAOYSA-N 0.000 description 4
- LZOSFEDULGODDH-UHFFFAOYSA-N 4-chloro-6-nitroquinazoline Chemical compound N1=CN=C(Cl)C2=CC([N+](=O)[O-])=CC=C21 LZOSFEDULGODDH-UHFFFAOYSA-N 0.000 description 4
- GVRRXASZZAKBMN-UHFFFAOYSA-N 4-chloroquinazoline Chemical class C1=CC=C2C(Cl)=NC=NC2=C1 GVRRXASZZAKBMN-UHFFFAOYSA-N 0.000 description 4
- AWAYNEMCHILZCF-UHFFFAOYSA-N 4-n-(3-chlorophenyl)quinazoline-4,6-diamine Chemical compound C12=CC(N)=CC=C2N=CN=C1NC1=CC=CC(Cl)=C1 AWAYNEMCHILZCF-UHFFFAOYSA-N 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 4
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 4
- 229920004890 Triton X-100 Polymers 0.000 description 4
- 150000008064 anhydrides Chemical class 0.000 description 4
- 239000002246 antineoplastic agent Substances 0.000 description 4
- 239000012298 atmosphere Substances 0.000 description 4
- PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 4
- 239000012267 brine Substances 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 230000010261 cell growth Effects 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 239000003102 growth factor Substances 0.000 description 4
- 150000003840 hydrochlorides Chemical class 0.000 description 4
- 238000005984 hydrogenation reaction Methods 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 230000003647 oxidation Effects 0.000 description 4
- 238000007254 oxidation reaction Methods 0.000 description 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 4
- 239000012047 saturated solution Substances 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 4
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 4
- YZUPZGFPHUVJKC-UHFFFAOYSA-N 1-bromo-2-methoxyethane Chemical compound COCCBr YZUPZGFPHUVJKC-UHFFFAOYSA-N 0.000 description 3
- 238000005160 1H NMR spectroscopy Methods 0.000 description 3
- OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-dimethylpyridine Chemical compound CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 description 3
- UMKSAURFQFUULT-UHFFFAOYSA-N 2-Amino-5-methoxybenzoic acid Chemical compound COC1=CC=C(N)C(C(O)=O)=C1 UMKSAURFQFUULT-UHFFFAOYSA-N 0.000 description 3
- LDLCZOVUSADOIV-UHFFFAOYSA-N 2-bromoethanol Chemical compound OCCBr LDLCZOVUSADOIV-UHFFFAOYSA-N 0.000 description 3
- ZKUYSJHXBFFGPU-UHFFFAOYSA-N 2516-95-2 Chemical compound OC(=O)C1=CC(Cl)=CC=C1[N+]([O-])=O ZKUYSJHXBFFGPU-UHFFFAOYSA-N 0.000 description 3
- MJLHSJRIMKQIFP-UHFFFAOYSA-N 3-n-(6,7-dimethoxyquinazolin-4-yl)benzene-1,3-diamine;hydrochloride Chemical compound Cl.C=12C=C(OC)C(OC)=CC2=NC=NC=1NC1=CC=CC(N)=C1 MJLHSJRIMKQIFP-UHFFFAOYSA-N 0.000 description 3
- YIEFGGZKSXIYFW-UHFFFAOYSA-N 4-(3-methylanilino)quinazoline-7-carboxylic acid Chemical compound CC1=CC=CC(NC=2C3=CC=C(C=C3N=CN=2)C(O)=O)=C1 YIEFGGZKSXIYFW-UHFFFAOYSA-N 0.000 description 3
- ATRZVHJSCCURLJ-UHFFFAOYSA-N 4-(4-chloroquinazolin-6-yl)morpholine Chemical compound C1=C2C(Cl)=NC=NC2=CC=C1N1CCOCC1 ATRZVHJSCCURLJ-UHFFFAOYSA-N 0.000 description 3
- ASLFKOTWRWCLSK-UHFFFAOYSA-N 4-chloro-6-piperidin-1-ylquinazoline Chemical compound C1=C2C(Cl)=NC=NC2=CC=C1N1CCCCC1 ASLFKOTWRWCLSK-UHFFFAOYSA-N 0.000 description 3
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 3
- JHWXBNQNSFQNPY-UHFFFAOYSA-N 7-(2-bromoethoxy)-6-methoxy-n-(3-methylphenyl)quinazolin-4-amine Chemical compound N1=CN=C2C=C(OCCBr)C(OC)=CC2=C1NC1=CC=CC(C)=C1 JHWXBNQNSFQNPY-UHFFFAOYSA-N 0.000 description 3
- PMLONMIODRHERC-UHFFFAOYSA-N 7-chloro-1h-quinazolin-4-one Chemical compound N1C=NC(=O)C=2C1=CC(Cl)=CC=2 PMLONMIODRHERC-UHFFFAOYSA-N 0.000 description 3
- WZLMWRBGVYVLDZ-UHFFFAOYSA-N 7-methoxy-n-(3-methylphenyl)-6-nitroquinazolin-4-amine Chemical compound C=12C=C([N+]([O-])=O)C(OC)=CC2=NC=NC=1NC1=CC=CC(C)=C1 WZLMWRBGVYVLDZ-UHFFFAOYSA-N 0.000 description 3
- HQQMBKAUTNDSQY-UHFFFAOYSA-N 7-n-[3-(dimethylamino)propyl]-4-n-(3-methylphenyl)-6-nitroquinazoline-4,7-diamine Chemical compound C=12C=C([N+]([O-])=O)C(NCCCN(C)C)=CC2=NC=NC=1NC1=CC=CC(C)=C1 HQQMBKAUTNDSQY-UHFFFAOYSA-N 0.000 description 3
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 201000009030 Carcinoma Diseases 0.000 description 3
- 229920002261 Corn starch Polymers 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 3
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 3
- 108091000080 Phosphotransferase Proteins 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 3
- 239000013504 Triton X-100 Substances 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000008120 corn starch Substances 0.000 description 3
- 229940099112 cornstarch Drugs 0.000 description 3
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- PQJJJMRNHATNKG-UHFFFAOYSA-N ethyl bromoacetate Chemical compound CCOC(=O)CBr PQJJJMRNHATNKG-UHFFFAOYSA-N 0.000 description 3
- 239000012894 fetal calf serum Substances 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 210000003494 hepatocyte Anatomy 0.000 description 3
- 208000032839 leukemia Diseases 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- DNZMCCLHPQTXJQ-UHFFFAOYSA-N methyl 4-(3-methylanilino)quinazoline-7-carboxylate Chemical compound N=1C=NC2=CC(C(=O)OC)=CC=C2C=1NC1=CC=CC(C)=C1 DNZMCCLHPQTXJQ-UHFFFAOYSA-N 0.000 description 3
- CSOBGYJJXIKZGA-UHFFFAOYSA-N n-(3-methylphenyl)-6-nitroquinazolin-4-amine Chemical compound CC1=CC=CC(NC=2C3=CC(=CC=C3N=CN=2)[N+]([O-])=O)=C1 CSOBGYJJXIKZGA-UHFFFAOYSA-N 0.000 description 3
- IVUMMNZRJFAFQP-UHFFFAOYSA-N n-(3-methylphenyl)-7-methylsulfanyl-6-nitroquinazolin-4-amine Chemical compound C=12C=C([N+]([O-])=O)C(SC)=CC2=NC=NC=1NC1=CC=CC(C)=C1 IVUMMNZRJFAFQP-UHFFFAOYSA-N 0.000 description 3
- HGIWILAPVIDGKH-UHFFFAOYSA-N n-(3-methylphenyl)-7-nitroquinazolin-4-amine Chemical compound CC1=CC=CC(NC=2C3=CC=C(C=C3N=CN=2)[N+]([O-])=O)=C1 HGIWILAPVIDGKH-UHFFFAOYSA-N 0.000 description 3
- ZNHMGZYTJLEROX-UHFFFAOYSA-N n-[4-(3-methylanilino)quinazolin-6-yl]acetamide Chemical compound C12=CC(NC(=O)C)=CC=C2N=CN=C1NC1=CC=CC(C)=C1 ZNHMGZYTJLEROX-UHFFFAOYSA-N 0.000 description 3
- 239000007800 oxidant agent Substances 0.000 description 3
- 102000020233 phosphotransferase Human genes 0.000 description 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 238000010898 silica gel chromatography Methods 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- RMVRSNDYEFQCLF-UHFFFAOYSA-N thiophenol Chemical compound SC1=CC=CC=C1 RMVRSNDYEFQCLF-UHFFFAOYSA-N 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- 239000008215 water for injection Substances 0.000 description 3
- LSBGXLOBLBWVEN-UHFFFAOYSA-N (4-chloroquinazolin-6-yl) acetate Chemical compound N1=CN=C(Cl)C2=CC(OC(=O)C)=CC=C21 LSBGXLOBLBWVEN-UHFFFAOYSA-N 0.000 description 2
- HJVAVGOPTDJYOJ-UHFFFAOYSA-N 2-amino-4,5-dimethoxybenzoic acid Chemical compound COC1=CC(N)=C(C(O)=O)C=C1OC HJVAVGOPTDJYOJ-UHFFFAOYSA-N 0.000 description 2
- JYYLQSCZISREGY-UHFFFAOYSA-N 2-amino-4-chlorobenzoic acid Chemical compound NC1=CC(Cl)=CC=C1C(O)=O JYYLQSCZISREGY-UHFFFAOYSA-N 0.000 description 2
- RUYCUDHAVDCXIX-UHFFFAOYSA-N 2-chloro-n-[4-(3-methylanilino)quinazolin-6-yl]acetamide Chemical compound CC1=CC=CC(NC=2C3=CC(NC(=O)CCl)=CC=C3N=CN=2)=C1 RUYCUDHAVDCXIX-UHFFFAOYSA-N 0.000 description 2
- KUOMDAPBHJIEKP-UHFFFAOYSA-N 2-methoxy-n-[4-(3-methylanilino)quinazolin-7-yl]acetamide Chemical compound N=1C=NC2=CC(NC(=O)COC)=CC=C2C=1NC1=CC=CC(C)=C1 KUOMDAPBHJIEKP-UHFFFAOYSA-N 0.000 description 2
- ZQIWRIWTTKXCIO-UHFFFAOYSA-N 4-(3-methylanilino)quinazolin-7-ol Chemical compound CC1=CC=CC(NC=2C3=CC=C(O)C=C3N=CN=2)=C1 ZQIWRIWTTKXCIO-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- QNLKPXGXCBGDDC-UHFFFAOYSA-N 4-chloro-6-(dibromomethyl)quinazoline Chemical compound C1=C(C(Br)Br)C=C2C(Cl)=NC=NC2=C1 QNLKPXGXCBGDDC-UHFFFAOYSA-N 0.000 description 2
- CCCGYXZEVXWXAU-UHFFFAOYSA-N 4-chloro-7-nitroquinazoline Chemical compound ClC1=NC=NC2=CC([N+](=O)[O-])=CC=C21 CCCGYXZEVXWXAU-UHFFFAOYSA-N 0.000 description 2
- SBGUQHNSYZGPLX-UHFFFAOYSA-N 4-n-(3-methylphenyl)-7-morpholin-4-ylquinazoline-4,6-diamine Chemical compound CC1=CC=CC(NC=2C3=CC(N)=C(N4CCOCC4)C=C3N=CN=2)=C1 SBGUQHNSYZGPLX-UHFFFAOYSA-N 0.000 description 2
- DLVMGJPGJHCIJW-UHFFFAOYSA-N 4-n-[3-(trifluoromethyl)phenyl]quinazoline-4,6-diamine Chemical compound C12=CC(N)=CC=C2N=CN=C1NC1=CC=CC(C(F)(F)F)=C1 DLVMGJPGJHCIJW-UHFFFAOYSA-N 0.000 description 2
- DMSRMHGCZUXCMJ-UHFFFAOYSA-N 6,7-dimethoxy-1h-quinazolin-4-one Chemical compound C1=NC(O)=C2C=C(OC)C(OC)=CC2=N1 DMSRMHGCZUXCMJ-UHFFFAOYSA-N 0.000 description 2
- HDXUENATWBWIRX-UHFFFAOYSA-N 6,7-dimethoxy-n-(3-methylphenyl)-5-nitroquinazolin-4-amine Chemical compound C=12C([N+]([O-])=O)=C(OC)C(OC)=CC2=NC=NC=1NC1=CC=CC(C)=C1 HDXUENATWBWIRX-UHFFFAOYSA-N 0.000 description 2
- TWDBGKCEJPCGEK-UHFFFAOYSA-N 6-(2-bromoethoxy)-n-(3-methylphenyl)quinazolin-4-amine Chemical compound CC1=CC=CC(NC=2C3=CC(OCCBr)=CC=C3N=CN=2)=C1 TWDBGKCEJPCGEK-UHFFFAOYSA-N 0.000 description 2
- VVNQBWHRGUXZNH-UHFFFAOYSA-N 6-methoxy-7-(2-methoxyethoxy)-n-(3-methylphenyl)quinazolin-4-amine Chemical compound C=12C=C(OC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C)=C1 VVNQBWHRGUXZNH-UHFFFAOYSA-N 0.000 description 2
- JUCDXPIFJIVICL-UHFFFAOYSA-N 6-methyl-1h-quinazolin-4-one Chemical compound N1C=NC(=O)C2=CC(C)=CC=C21 JUCDXPIFJIVICL-UHFFFAOYSA-N 0.000 description 2
- AHEHMDXRXAAMGF-UHFFFAOYSA-N 6-methyl-n-(3-methylphenyl)quinazolin-4-amine Chemical compound CC1=CC=CC(NC=2C3=CC(C)=CC=C3N=CN=2)=C1 AHEHMDXRXAAMGF-UHFFFAOYSA-N 0.000 description 2
- KHYGXPXJZPATPD-UHFFFAOYSA-N 6-n-(2-methoxyethyl)-4-n-(3-methylphenyl)quinazoline-4,6-diamine Chemical compound C12=CC(NCCOC)=CC=C2N=CN=C1NC1=CC=CC(C)=C1 KHYGXPXJZPATPD-UHFFFAOYSA-N 0.000 description 2
- MOBNCKURXDGQCB-UHFFFAOYSA-N 6-nitro-1h-quinazolin-4-one Chemical compound N1C=NC(=O)C2=CC([N+](=O)[O-])=CC=C21 MOBNCKURXDGQCB-UHFFFAOYSA-N 0.000 description 2
- FKOOZPWZRRDRTK-UHFFFAOYSA-N 6-nitro-n-[3-(trifluoromethyl)phenyl]quinazolin-4-amine Chemical compound C12=CC([N+](=O)[O-])=CC=C2N=CN=C1NC1=CC=CC(C(F)(F)F)=C1 FKOOZPWZRRDRTK-UHFFFAOYSA-N 0.000 description 2
- KCLLIYLLKJSXGQ-UHFFFAOYSA-N 7-methoxy-4-(3-methylanilino)quinazolin-6-ol Chemical compound C=12C=C(O)C(OC)=CC2=NC=NC=1NC1=CC=CC(C)=C1 KCLLIYLLKJSXGQ-UHFFFAOYSA-N 0.000 description 2
- GHEITLVPLGZZQI-UHFFFAOYSA-N 7-methoxy-n-(3-methylphenyl)quinazolin-4-amine Chemical compound N=1C=NC2=CC(OC)=CC=C2C=1NC1=CC=CC(C)=C1 GHEITLVPLGZZQI-UHFFFAOYSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- 230000006820 DNA synthesis Effects 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 102000001301 EGF receptor Human genes 0.000 description 2
- 108060006698 EGF receptor Proteins 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 238000004566 IR spectroscopy Methods 0.000 description 2
- 238000003820 Medium-pressure liquid chromatography Methods 0.000 description 2
- LKJPYSCBVHEWIU-UHFFFAOYSA-N N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanamide Chemical compound C=1C=C(C#N)C(C(F)(F)F)=CC=1NC(=O)C(O)(C)CS(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-UHFFFAOYSA-N 0.000 description 2
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 2
- 102000043276 Oncogene Human genes 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- KFSLWBXXFJQRDL-UHFFFAOYSA-N Peracetic acid Chemical compound CC(=O)OO KFSLWBXXFJQRDL-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 description 2
- 102000006747 Transforming Growth Factor alpha Human genes 0.000 description 2
- 101800004564 Transforming growth factor alpha Proteins 0.000 description 2
- 230000010933 acylation Effects 0.000 description 2
- 238000005917 acylation reaction Methods 0.000 description 2
- 125000004423 acyloxy group Chemical group 0.000 description 2
- 150000001340 alkali metals Chemical class 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 150000001347 alkyl bromides Chemical class 0.000 description 2
- 150000001351 alkyl iodides Chemical class 0.000 description 2
- 239000002168 alkylating agent Substances 0.000 description 2
- 229940100198 alkylating agent Drugs 0.000 description 2
- 230000002152 alkylating effect Effects 0.000 description 2
- 125000002947 alkylene group Chemical group 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 235000019270 ammonium chloride Nutrition 0.000 description 2
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 230000003182 bronchodilatating effect Effects 0.000 description 2
- 229940124630 bronchodilator Drugs 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 description 2
- 125000006222 dimethylaminomethyl group Chemical group [H]C([H])([H])N(C([H])([H])[H])C([H])([H])* 0.000 description 2
- USIUVYZYUHIAEV-UHFFFAOYSA-N diphenyl ether Chemical compound C=1C=CC=CC=1OC1=CC=CC=C1 USIUVYZYUHIAEV-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- WGDFCNRIGUMPIC-UHFFFAOYSA-N ethyl 2-[6-methoxy-4-(3-methylanilino)quinazolin-7-yl]oxyacetate Chemical compound C=12C=C(OC)C(OCC(=O)OCC)=CC2=NC=NC=1NC1=CC=CC(C)=C1 WGDFCNRIGUMPIC-UHFFFAOYSA-N 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 230000001077 hypotensive effect Effects 0.000 description 2
- 238000000099 in vitro assay Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- BYHDRGRVVXBJIP-UHFFFAOYSA-N methyl 4-chloroquinazoline-7-carboxylate Chemical compound ClC1=NC=NC2=CC(C(=O)OC)=CC=C21 BYHDRGRVVXBJIP-UHFFFAOYSA-N 0.000 description 2
- QNNZNPUJXPQPJI-UHFFFAOYSA-N n-(3-methylphenyl)-7-morpholin-4-yl-6-nitroquinazolin-4-amine Chemical compound CC1=CC=CC(NC=2C3=CC(=C(N4CCOCC4)C=C3N=CN=2)[N+]([O-])=O)=C1 QNNZNPUJXPQPJI-UHFFFAOYSA-N 0.000 description 2
- 150000002828 nitro derivatives Chemical class 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- 201000002528 pancreatic cancer Diseases 0.000 description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- DGTNSSLYPYDJGL-UHFFFAOYSA-N phenyl isocyanate Chemical compound O=C=NC1=CC=CC=C1 DGTNSSLYPYDJGL-UHFFFAOYSA-N 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 229910052697 platinum Inorganic materials 0.000 description 2
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 2
- 229950008882 polysorbate Drugs 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 125000006308 propyl amino group Chemical group 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000012279 sodium borohydride Substances 0.000 description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 description 2
- ZVCDLGYNFYZZOK-UHFFFAOYSA-M sodium cyanate Chemical compound [Na]OC#N ZVCDLGYNFYZZOK-UHFFFAOYSA-M 0.000 description 2
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 2
- RMBAVIFYHOYIFM-UHFFFAOYSA-M sodium methanethiolate Chemical compound [Na+].[S-]C RMBAVIFYHOYIFM-UHFFFAOYSA-M 0.000 description 2
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- 238000004611 spectroscopical analysis Methods 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 150000003440 styrenes Chemical class 0.000 description 2
- 125000000547 substituted alkyl group Chemical group 0.000 description 2
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 2
- IOGXOCVLYRDXLW-UHFFFAOYSA-N tert-butyl nitrite Chemical compound CC(C)(C)ON=O IOGXOCVLYRDXLW-UHFFFAOYSA-N 0.000 description 2
- 239000012414 tert-butyl nitrite Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 2
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- QHSILJZBWLFQGR-UHFFFAOYSA-N (4-oxo-1h-quinazolin-6-yl) acetate Chemical compound N1=CNC(=O)C2=CC(OC(=O)C)=CC=C21 QHSILJZBWLFQGR-UHFFFAOYSA-N 0.000 description 1
- ODIGIKRIUKFKHP-UHFFFAOYSA-N (n-propan-2-yloxycarbonylanilino) acetate Chemical compound CC(C)OC(=O)N(OC(C)=O)C1=CC=CC=C1 ODIGIKRIUKFKHP-UHFFFAOYSA-N 0.000 description 1
- SCZNXLWKYFICFV-UHFFFAOYSA-N 1,2,3,4,5,7,8,9-octahydropyrido[1,2-b]diazepine Chemical compound C1CCCNN2CCCC=C21 SCZNXLWKYFICFV-UHFFFAOYSA-N 0.000 description 1
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 1
- WZCQRUWWHSTZEM-UHFFFAOYSA-N 1,3-phenylenediamine Chemical compound NC1=CC=CC(N)=C1 WZCQRUWWHSTZEM-UHFFFAOYSA-N 0.000 description 1
- CBCKQZAAMUWICA-UHFFFAOYSA-N 1,4-phenylenediamine Chemical compound NC1=CC=C(N)C=C1 CBCKQZAAMUWICA-UHFFFAOYSA-N 0.000 description 1
- ZQRROVFSALJMMI-UHFFFAOYSA-N 1-[4-(3-methylanilino)quinazolin-6-yl]-3-phenylurea Chemical compound CC1=CC=CC(NC=2C3=CC(NC(=O)NC=4C=CC=CC=4)=CC=C3N=CN=2)=C1 ZQRROVFSALJMMI-UHFFFAOYSA-N 0.000 description 1
- UDJDCUHZIBKBJL-UHFFFAOYSA-N 1-[4-(3-methylanilino)quinazolin-6-yl]pyrrolidin-2-one Chemical compound CC1=CC=CC(NC=2C3=CC(=CC=C3N=CN=2)N2C(CCC2)=O)=C1 UDJDCUHZIBKBJL-UHFFFAOYSA-N 0.000 description 1
- LLAPDLPYIYKTGQ-UHFFFAOYSA-N 1-aminoethyl Chemical group C[CH]N LLAPDLPYIYKTGQ-UHFFFAOYSA-N 0.000 description 1
- 125000004066 1-hydroxyethyl group Chemical group [H]OC([H])([*])C([H])([H])[H] 0.000 description 1
- LDKSCZJUIURGMW-UHFFFAOYSA-N 1-isothiocyanato-3-methylsulfanylpropane Chemical group CSCCCN=C=S LDKSCZJUIURGMW-UHFFFAOYSA-N 0.000 description 1
- JQCSUVJDBHJKNG-UHFFFAOYSA-N 1-methoxy-ethyl Chemical group C[CH]OC JQCSUVJDBHJKNG-UHFFFAOYSA-N 0.000 description 1
- 125000000586 2-(4-morpholinyl)ethoxy group Chemical group [H]C([H])(O*)C([H])([H])N1C([H])([H])C([H])([H])OC([H])([H])C1([H])[H] 0.000 description 1
- PPQDYOBQQWPTIS-UHFFFAOYSA-N 2-(diethylamino)acetamide Chemical compound CCN(CC)CC(N)=O PPQDYOBQQWPTIS-UHFFFAOYSA-N 0.000 description 1
- YGRTYMUFCRBWIK-UHFFFAOYSA-N 2-(dimethylamino)-n-[4-(3-methylanilino)quinazolin-6-yl]acetamide Chemical compound C12=CC(NC(=O)CN(C)C)=CC=C2N=CN=C1NC1=CC=CC(C)=C1 YGRTYMUFCRBWIK-UHFFFAOYSA-N 0.000 description 1
- WKJOQYHMXRVQDK-UHFFFAOYSA-N 2-(dimethylamino)acetamide Chemical compound CN(C)CC(N)=O WKJOQYHMXRVQDK-UHFFFAOYSA-N 0.000 description 1
- SNFFHBJWQFQMBC-UHFFFAOYSA-N 2-(ethylamino)acetamide Chemical compound CCNCC(N)=O SNFFHBJWQFQMBC-UHFFFAOYSA-N 0.000 description 1
- CBBFWSMELCDMPZ-UHFFFAOYSA-N 2-(methylamino)acetamide Chemical compound CNCC(N)=O CBBFWSMELCDMPZ-UHFFFAOYSA-N 0.000 description 1
- LKZRYXDGZQOPNA-UHFFFAOYSA-N 2-(propylamino)acetamide Chemical compound CCCNCC(N)=O LKZRYXDGZQOPNA-UHFFFAOYSA-N 0.000 description 1
- HYNQTSZBTIOFKH-UHFFFAOYSA-N 2-Amino-5-hydroxybenzoic acid Chemical compound NC1=CC=C(O)C=C1C(O)=O HYNQTSZBTIOFKH-UHFFFAOYSA-N 0.000 description 1
- XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 description 1
- JXSIKEXWVFQUAR-UHFFFAOYSA-N 2-[4-(3-methylanilino)quinazolin-6-yl]acetonitrile Chemical compound CC1=CC=CC(NC=2C3=CC(CC#N)=CC=C3N=CN=2)=C1 JXSIKEXWVFQUAR-UHFFFAOYSA-N 0.000 description 1
- JJRIZRKUNDUATE-UHFFFAOYSA-N 2-[6-methoxy-4-(3-methylanilino)quinazolin-7-yl]oxyacetic acid Chemical compound N1=CN=C2C=C(OCC(O)=O)C(OC)=CC2=C1NC1=CC=CC(C)=C1 JJRIZRKUNDUATE-UHFFFAOYSA-N 0.000 description 1
- HVOXXLLDKLJFND-UHFFFAOYSA-N 2-[7-(2-hydroxyethoxy)-4-(3-methylanilino)quinazolin-6-yl]oxyethanol Chemical compound CC1=CC=CC(NC=2C3=CC(OCCO)=C(OCCO)C=C3N=CN=2)=C1 HVOXXLLDKLJFND-UHFFFAOYSA-N 0.000 description 1
- KBCHMLUJHCFUST-UHFFFAOYSA-N 2-[[4-(3-methylanilino)quinazolin-7-yl]amino]ethanol Chemical compound CC1=CC=CC(NC=2C3=CC=C(NCCO)C=C3N=CN=2)=C1 KBCHMLUJHCFUST-UHFFFAOYSA-N 0.000 description 1
- REBBDMHTSKPGCO-UHFFFAOYSA-N 2-amino-4,5-dimethylbenzoic acid Chemical compound CC1=CC(N)=C(C(O)=O)C=C1C REBBDMHTSKPGCO-UHFFFAOYSA-N 0.000 description 1
- HHNWXQCVWVVVQZ-UHFFFAOYSA-N 2-amino-4-methoxybenzoic acid Chemical compound COC1=CC=C(C(O)=O)C(N)=C1 HHNWXQCVWVVVQZ-UHFFFAOYSA-N 0.000 description 1
- UXNGDCBPIGOZFO-UHFFFAOYSA-N 2-amino-5-(trifluoromethoxy)benzoic acid Chemical compound NC1=CC=C(OC(F)(F)F)C=C1C(O)=O UXNGDCBPIGOZFO-UHFFFAOYSA-N 0.000 description 1
- HFHMPAKMODSNJN-UHFFFAOYSA-N 2-amino-5-morpholin-4-ylbenzoic acid Chemical compound C1=C(C(O)=O)C(N)=CC=C1N1CCOCC1 HFHMPAKMODSNJN-UHFFFAOYSA-N 0.000 description 1
- DNABDRZWPKYYTH-UHFFFAOYSA-N 2-amino-5-piperidin-1-ylbenzoic acid Chemical compound C1=C(C(O)=O)C(N)=CC=C1N1CCCCC1 DNABDRZWPKYYTH-UHFFFAOYSA-N 0.000 description 1
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 1
- GPNNOCMCNFXRAO-UHFFFAOYSA-N 2-aminoterephthalic acid Chemical compound NC1=CC(C(O)=O)=CC=C1C(O)=O GPNNOCMCNFXRAO-UHFFFAOYSA-N 0.000 description 1
- JUIKUQOUMZUFQT-UHFFFAOYSA-N 2-bromoacetamide Chemical group NC(=O)CBr JUIKUQOUMZUFQT-UHFFFAOYSA-N 0.000 description 1
- 125000005999 2-bromoethyl group Chemical group 0.000 description 1
- NAMYKGVDVNBCFQ-UHFFFAOYSA-N 2-bromopropane Chemical compound CC(C)Br NAMYKGVDVNBCFQ-UHFFFAOYSA-N 0.000 description 1
- 125000000143 2-carboxyethyl group Chemical group [H]OC(=O)C([H])([H])C([H])([H])* 0.000 description 1
- VXIVSQZSERGHQP-HQMMCQRPSA-N 2-chloroacetamide Chemical group N[14C](=O)CCl VXIVSQZSERGHQP-HQMMCQRPSA-N 0.000 description 1
- 125000001340 2-chloroethyl group Chemical group [H]C([H])(Cl)C([H])([H])* 0.000 description 1
- 125000001731 2-cyanoethyl group Chemical group [H]C([H])(*)C([H])([H])C#N 0.000 description 1
- 125000003635 2-dimethylaminoethoxy group Chemical group [H]C([H])([H])N(C([H])([H])[H])C([H])([H])C([H])([H])O* 0.000 description 1
- 125000003006 2-dimethylaminoethyl group Chemical group [H]C([H])([H])N(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004777 2-fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- JDTUPLBMGDDPJS-UHFFFAOYSA-N 2-methoxy-2-phenylethanol Chemical compound COC(CO)C1=CC=CC=C1 JDTUPLBMGDDPJS-UHFFFAOYSA-N 0.000 description 1
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 1
- XWKFPIODWVPXLX-UHFFFAOYSA-N 2-methyl-5-methylpyridine Natural products CC1=CC=C(C)N=C1 XWKFPIODWVPXLX-UHFFFAOYSA-N 0.000 description 1
- FMTHDYACPOHXSC-UHFFFAOYSA-N 2-n-(6,7-dimethoxyquinazolin-4-yl)benzene-1,2-diamine;hydrochloride Chemical compound Cl.C=12C=C(OC)C(OC)=CC2=NC=NC=1NC1=CC=CC=C1N FMTHDYACPOHXSC-UHFFFAOYSA-N 0.000 description 1
- RPNHCXPJSUGRAB-UHFFFAOYSA-N 2-nitro-5-(piperidin-1-yl)benzoic acid Chemical compound C1=C([N+]([O-])=O)C(C(=O)O)=CC(N2CCCCC2)=C1 RPNHCXPJSUGRAB-UHFFFAOYSA-N 0.000 description 1
- JWDAQACFBLXJBZ-UHFFFAOYSA-N 2-propoxyacetamide Chemical compound CCCOCC(N)=O JWDAQACFBLXJBZ-UHFFFAOYSA-N 0.000 description 1
- SDYWXFYBZPNOFX-UHFFFAOYSA-N 3,4-dichloroaniline Chemical compound NC1=CC=C(Cl)C(Cl)=C1 SDYWXFYBZPNOFX-UHFFFAOYSA-N 0.000 description 1
- FTZIQBGFCYJWKA-UHFFFAOYSA-N 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium Chemical compound S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 FTZIQBGFCYJWKA-UHFFFAOYSA-N 0.000 description 1
- NIXQLMVKRBUSPF-UHFFFAOYSA-N 3-(dimethylamino)propanamide Chemical compound CN(C)CCC(N)=O NIXQLMVKRBUSPF-UHFFFAOYSA-N 0.000 description 1
- PPUXNQHLNOVQRG-UHFFFAOYSA-N 3-(ethylamino)propanamide Chemical compound CCNCCC(N)=O PPUXNQHLNOVQRG-UHFFFAOYSA-N 0.000 description 1
- FFJLSBFLTYYWII-UHFFFAOYSA-N 3-(methylamino)propanamide Chemical compound CNCCC(N)=O FFJLSBFLTYYWII-UHFFFAOYSA-N 0.000 description 1
- VIUDTWATMPPKEL-UHFFFAOYSA-N 3-(trifluoromethyl)aniline Chemical compound NC1=CC=CC(C(F)(F)F)=C1 VIUDTWATMPPKEL-UHFFFAOYSA-N 0.000 description 1
- CWLKGDAVCFYWJK-UHFFFAOYSA-N 3-aminophenol Chemical compound NC1=CC=CC(O)=C1 CWLKGDAVCFYWJK-UHFFFAOYSA-N 0.000 description 1
- 229940018563 3-aminophenol Drugs 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- DBIVLAVBOICUQX-UHFFFAOYSA-N 3-bromopropanamide Chemical group NC(=O)CCBr DBIVLAVBOICUQX-UHFFFAOYSA-N 0.000 description 1
- PNPCRKVUWYDDST-UHFFFAOYSA-N 3-chloroaniline Chemical compound NC1=CC=CC(Cl)=C1 PNPCRKVUWYDDST-UHFFFAOYSA-N 0.000 description 1
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
- JQDXZJYAUSVHDH-UHFFFAOYSA-N 3-chloropropanamide Chemical group NC(=O)CCCl JQDXZJYAUSVHDH-UHFFFAOYSA-N 0.000 description 1
- 229940105325 3-dimethylaminopropylamine Drugs 0.000 description 1
- SOYBEXQHNURCGE-UHFFFAOYSA-N 3-ethoxypropan-1-amine Chemical compound CCOCCCN SOYBEXQHNURCGE-UHFFFAOYSA-N 0.000 description 1
- WGVNJQHQQWPGJL-UHFFFAOYSA-N 3-ethoxypropanamide Chemical compound CCOCCC(N)=O WGVNJQHQQWPGJL-UHFFFAOYSA-N 0.000 description 1
- SMGLHFBQMBVRCP-UHFFFAOYSA-N 3-hydroxypropanamide Chemical group NC(=O)CCO SMGLHFBQMBVRCP-UHFFFAOYSA-N 0.000 description 1
- 125000001137 3-hydroxypropoxy group Chemical group [H]OC([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- QOXOZONBQWIKDA-UHFFFAOYSA-N 3-hydroxypropyl Chemical group [CH2]CCO QOXOZONBQWIKDA-UHFFFAOYSA-N 0.000 description 1
- FAXDZWQIWUSWJH-UHFFFAOYSA-N 3-methoxypropan-1-amine Chemical compound COCCCN FAXDZWQIWUSWJH-UHFFFAOYSA-N 0.000 description 1
- BPXCLLWXDHBFRH-UHFFFAOYSA-N 3-methoxypropanamide Chemical compound COCCC(N)=O BPXCLLWXDHBFRH-UHFFFAOYSA-N 0.000 description 1
- 125000005977 3-phenylpropyloxy group Chemical group 0.000 description 1
- BTBVSLMBNRBDIR-UHFFFAOYSA-N 4-(3-chloroanilino)quinazoline-6,7-diol Chemical compound C=12C=C(O)C(O)=CC2=NC=NC=1NC1=CC=CC(Cl)=C1 BTBVSLMBNRBDIR-UHFFFAOYSA-N 0.000 description 1
- ZLNPUJYIVLCGAY-UHFFFAOYSA-N 4-(3-methylanilino)quinazolin-6-ol Chemical compound CC1=CC=CC(NC=2C3=CC(O)=CC=C3N=CN=2)=C1 ZLNPUJYIVLCGAY-UHFFFAOYSA-N 0.000 description 1
- YGTHBVOCTPFJHQ-UHFFFAOYSA-N 4-(dimethylamino)butanamide Chemical compound CN(C)CCCC(N)=O YGTHBVOCTPFJHQ-UHFFFAOYSA-N 0.000 description 1
- COTFQUPGWBMXMW-UHFFFAOYSA-N 4-(methylamino)butanamide Chemical compound CNCCCC(N)=O COTFQUPGWBMXMW-UHFFFAOYSA-N 0.000 description 1
- RWLYIYZYVWCDJW-UHFFFAOYSA-N 4-(quinazolin-4-ylamino)phenol Chemical class C1=CC(O)=CC=C1NC1=NC=NC2=CC=CC=C12 RWLYIYZYVWCDJW-UHFFFAOYSA-N 0.000 description 1
- BNDYIYYKEIXHNK-UHFFFAOYSA-N 4-[3-hydroxyanilino]-6,7-dimethoxyquinazoline Chemical compound C=12C=C(OC)C(OC)=CC2=NC=NC=1NC1=CC=CC(O)=C1 BNDYIYYKEIXHNK-UHFFFAOYSA-N 0.000 description 1
- WCVPFJVXEXJFLB-UHFFFAOYSA-N 4-aminobutanamide Chemical group NCCCC(N)=O WCVPFJVXEXJFLB-UHFFFAOYSA-N 0.000 description 1
- WIKQNBCDJYNKED-UHFFFAOYSA-N 4-chloro-6,7-dimethylquinazoline Chemical compound C1=NC(Cl)=C2C=C(C)C(C)=CC2=N1 WIKQNBCDJYNKED-UHFFFAOYSA-N 0.000 description 1
- ZGIDAXLBBURWOL-UHFFFAOYSA-N 4-chloro-6-(trifluoromethoxy)quinazoline Chemical compound N1=CN=C(Cl)C2=CC(OC(F)(F)F)=CC=C21 ZGIDAXLBBURWOL-UHFFFAOYSA-N 0.000 description 1
- MREJJMASIQVOTH-UHFFFAOYSA-N 4-chloro-6-methoxyquinazoline Chemical compound N1=CN=C(Cl)C2=CC(OC)=CC=C21 MREJJMASIQVOTH-UHFFFAOYSA-N 0.000 description 1
- GUQZHZBMDPEBQG-UHFFFAOYSA-N 4-chloro-7-methoxyquinazoline Chemical compound ClC1=NC=NC2=CC(OC)=CC=C21 GUQZHZBMDPEBQG-UHFFFAOYSA-N 0.000 description 1
- LOESDOAIWSCMKM-UHFFFAOYSA-N 4-hydroxybutanamide Chemical group NC(=O)CCCO LOESDOAIWSCMKM-UHFFFAOYSA-N 0.000 description 1
- XJXBWJFUCWOLSY-UHFFFAOYSA-N 4-methoxybutanamide Chemical compound COCCCC(N)=O XJXBWJFUCWOLSY-UHFFFAOYSA-N 0.000 description 1
- 125000004195 4-methylpiperazin-1-yl group Chemical group [H]C([H])([H])N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 description 1
- SQSSULVYIBYQSG-UHFFFAOYSA-N 4-n-(3-methylphenyl)-7-methylsulfanylquinazoline-4,6-diamine Chemical compound C=12C=C(N)C(SC)=CC2=NC=NC=1NC1=CC=CC(C)=C1 SQSSULVYIBYQSG-UHFFFAOYSA-N 0.000 description 1
- WIEWJZVAKXFUTG-UHFFFAOYSA-N 4-n-(6,7-dimethoxyquinazolin-4-yl)benzene-1,4-diamine;hydrochloride Chemical compound Cl.C=12C=C(OC)C(OC)=CC2=NC=NC=1NC1=CC=C(N)C=C1 WIEWJZVAKXFUTG-UHFFFAOYSA-N 0.000 description 1
- UEALKTCRMBVTFN-UHFFFAOYSA-N 4-nitroanthranilic acid Chemical compound NC1=CC([N+]([O-])=O)=CC=C1C(O)=O UEALKTCRMBVTFN-UHFFFAOYSA-N 0.000 description 1
- ICASWNVSUDFGRH-UHFFFAOYSA-N 4-oxo-1h-quinazoline-7-carboxylic acid Chemical compound N1C=NC(=O)C=2C1=CC(C(=O)O)=CC=2 ICASWNVSUDFGRH-UHFFFAOYSA-N 0.000 description 1
- AGQATLDTZCPZJT-UHFFFAOYSA-N 4-quinazolin-6-ylmorpholine Chemical compound C1COCCN1C1=CC=C(N=CN=C2)C2=C1 AGQATLDTZCPZJT-UHFFFAOYSA-N 0.000 description 1
- YLZSNFZNVCUXMM-UHFFFAOYSA-N 5-morpholin-4-yl-2-nitrobenzoic acid Chemical compound C1=C([N+]([O-])=O)C(C(=O)O)=CC(N2CCOCC2)=C1 YLZSNFZNVCUXMM-UHFFFAOYSA-N 0.000 description 1
- RUCHWTKMOWXHLU-UHFFFAOYSA-N 5-nitroanthranilic acid Chemical compound NC1=CC=C([N+]([O-])=O)C=C1C(O)=O RUCHWTKMOWXHLU-UHFFFAOYSA-N 0.000 description 1
- RHISQWTXRCBOBJ-UHFFFAOYSA-N 6,7,8-trimethoxyquinazoline Chemical class N1=CN=C2C(OC)=C(OC)C(OC)=CC2=C1 RHISQWTXRCBOBJ-UHFFFAOYSA-N 0.000 description 1
- GQZJIWRQFUXHGZ-UHFFFAOYSA-N 6,7-bis(2-methoxyethoxy)-n-(3-methylphenyl)quinazolin-4-amine;hydrochloride Chemical compound Cl.C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C)=C1 GQZJIWRQFUXHGZ-UHFFFAOYSA-N 0.000 description 1
- NJPNKDPGKPSJPR-UHFFFAOYSA-N 6,7-dimethoxy-4-n-(3-methylphenyl)quinazoline-4,5-diamine Chemical compound C=12C(N)=C(OC)C(OC)=CC2=NC=NC=1NC1=CC=CC(C)=C1 NJPNKDPGKPSJPR-UHFFFAOYSA-N 0.000 description 1
- JBTUFBGGRVLCFF-UHFFFAOYSA-N 6,7-dimethoxy-5-nitro-1h-quinazolin-4-one Chemical compound N1=CNC(=O)C2=C1C=C(OC)C(OC)=C2[N+]([O-])=O JBTUFBGGRVLCFF-UHFFFAOYSA-N 0.000 description 1
- PBHYWXWANPMYSG-UHFFFAOYSA-N 6,7-dimethoxy-n-(3-methylphenyl)quinazolin-4-amine;hydrochloride Chemical compound Cl.C=12C=C(OC)C(OC)=CC2=NC=NC=1NC1=CC=CC(C)=C1 PBHYWXWANPMYSG-UHFFFAOYSA-N 0.000 description 1
- KEQCEKUDWPXRRQ-UHFFFAOYSA-N 6,7-dimethoxy-n-[3-(trifluoromethyl)phenyl]quinazolin-4-amine Chemical compound C=12C=C(OC)C(OC)=CC2=NC=NC=1NC1=CC=CC(C(F)(F)F)=C1 KEQCEKUDWPXRRQ-UHFFFAOYSA-N 0.000 description 1
- JRDRXNJUOHNEAQ-UHFFFAOYSA-N 6,7-dimethoxy-n-phenylquinazolin-4-amine;hydrochloride Chemical compound Cl.C=12C=C(OC)C(OC)=CC2=NC=NC=1NC1=CC=CC=C1 JRDRXNJUOHNEAQ-UHFFFAOYSA-N 0.000 description 1
- FYMQPWWNOCENRN-UHFFFAOYSA-N 6,7-dimethoxyquinazoline Chemical compound N1=CN=C2C=C(OC)C(OC)=CC2=C1 FYMQPWWNOCENRN-UHFFFAOYSA-N 0.000 description 1
- POXXGTPTPULVDC-UHFFFAOYSA-N 6-(2-methoxyethoxy)-n-(3-methylphenyl)quinazolin-4-amine Chemical compound C12=CC(OCCOC)=CC=C2N=CN=C1NC1=CC=CC(C)=C1 POXXGTPTPULVDC-UHFFFAOYSA-N 0.000 description 1
- YIWFXXWSEKDDJR-UHFFFAOYSA-N 6-(anilinomethyl)-n-(3-methylphenyl)quinazolin-4-amine Chemical compound CC1=CC=CC(NC=2C3=CC(CNC=4C=CC=CC=4)=CC=C3N=CN=2)=C1 YIWFXXWSEKDDJR-UHFFFAOYSA-N 0.000 description 1
- OCAWACKWBYEOSN-UHFFFAOYSA-N 6-(methoxymethyl)-n-(3-methylphenyl)quinazolin-4-amine Chemical compound C12=CC(COC)=CC=C2N=CN=C1NC1=CC=CC(C)=C1 OCAWACKWBYEOSN-UHFFFAOYSA-N 0.000 description 1
- JNYLMODTPLSLIF-UHFFFAOYSA-N 6-(trifluoromethyl)pyridine-3-carboxylic acid Chemical group OC(=O)C1=CC=C(C(F)(F)F)N=C1 JNYLMODTPLSLIF-UHFFFAOYSA-N 0.000 description 1
- MBWSFACVGYJPPE-UHFFFAOYSA-N 6-[(dimethylamino)methyl]-n-(3-methylphenyl)quinazolin-4-amine Chemical compound C12=CC(CN(C)C)=CC=C2N=CN=C1NC1=CC=CC(C)=C1 MBWSFACVGYJPPE-UHFFFAOYSA-N 0.000 description 1
- TVHKDIOQVKDWQQ-UHFFFAOYSA-N 6-[2-(dimethylamino)ethoxy]-n-(3-methylphenyl)quinazolin-4-amine;hydrobromide Chemical compound Br.C12=CC(OCCN(C)C)=CC=C2N=CN=C1NC1=CC=CC(C)=C1 TVHKDIOQVKDWQQ-UHFFFAOYSA-N 0.000 description 1
- OJTOAMSTANUUMJ-UHFFFAOYSA-N 6-amino-1,3-benzodioxole-5-carboxylic acid Chemical compound C1=C(C(O)=O)C(N)=CC2=C1OCO2 OJTOAMSTANUUMJ-UHFFFAOYSA-N 0.000 description 1
- WWSGQFXMLMGYJK-UHFFFAOYSA-N 6-chloro-n-phenylquinazolin-4-amine Chemical class C12=CC(Cl)=CC=C2N=CN=C1NC1=CC=CC=C1 WWSGQFXMLMGYJK-UHFFFAOYSA-N 0.000 description 1
- QJRNXXLTDWMENM-UHFFFAOYSA-N 6-hydroxy-1h-quinazolin-4-one Chemical compound N1C=NC(=O)C2=CC(O)=CC=C21 QJRNXXLTDWMENM-UHFFFAOYSA-N 0.000 description 1
- KKAHSVDGWDURSJ-UHFFFAOYSA-N 6-methoxy-n-(3-methylphenyl)-7-(2-morpholin-4-ylethoxy)quinazolin-4-amine Chemical compound N1=CN=C2C=C(OCCN3CCOCC3)C(OC)=CC2=C1NC1=CC=CC(C)=C1 KKAHSVDGWDURSJ-UHFFFAOYSA-N 0.000 description 1
- PWWZQDDEXXYYHZ-UHFFFAOYSA-N 6-methoxy-n-(3-methylphenyl)-7-propan-2-yloxyquinazolin-4-amine Chemical compound N1=CN=C2C=C(OC(C)C)C(OC)=CC2=C1NC1=CC=CC(C)=C1 PWWZQDDEXXYYHZ-UHFFFAOYSA-N 0.000 description 1
- LNUACJNTNFFFCF-UHFFFAOYSA-N 6-morpholin-4-yl-1h-quinazolin-4-one Chemical compound C1=C2C(=O)NC=NC2=CC=C1N1CCOCC1 LNUACJNTNFFFCF-UHFFFAOYSA-N 0.000 description 1
- IWBVCRRXSCJLQC-UHFFFAOYSA-N 6-n-methyl-4-n-(3-methylphenyl)quinazoline-4,6-diamine Chemical compound C12=CC(NC)=CC=C2N=CN=C1NC1=CC=CC(C)=C1 IWBVCRRXSCJLQC-UHFFFAOYSA-N 0.000 description 1
- SVFHMJGZJXLEIF-UHFFFAOYSA-N 6-piperidin-1-yl-1h-quinazolin-4-one Chemical compound C1=C2C(=O)NC=NC2=CC=C1N1CCCCC1 SVFHMJGZJXLEIF-UHFFFAOYSA-N 0.000 description 1
- ITFLBRGWNXCRFJ-UHFFFAOYSA-N 6-piperidin-1-ylquinazoline Chemical compound C1CCCCN1C1=CC=C(N=CN=C2)C2=C1 ITFLBRGWNXCRFJ-UHFFFAOYSA-N 0.000 description 1
- NKLHAODPKDGWMZ-UHFFFAOYSA-N 7-(2-anilinoethoxy)-6-methoxy-n-(3-methylphenyl)quinazolin-4-amine Chemical compound N1=CN=C2C=C(OCCNC=3C=CC=CC=3)C(OC)=CC2=C1NC1=CC=CC(C)=C1 NKLHAODPKDGWMZ-UHFFFAOYSA-N 0.000 description 1
- CZUUUCCKUDTMKH-UHFFFAOYSA-N 7-[2-(dimethylamino)ethoxy]-6-methoxy-n-(3-methylphenyl)quinazolin-4-amine Chemical compound N1=CN=C2C=C(OCCN(C)C)C(OC)=CC2=C1NC1=CC=CC(C)=C1 CZUUUCCKUDTMKH-UHFFFAOYSA-N 0.000 description 1
- URDYTQYZXZKBQT-UHFFFAOYSA-N 7-chloro-6-nitro-1h-quinazolin-4-one Chemical compound N1C=NC(=O)C2=C1C=C(Cl)C([N+](=O)[O-])=C2 URDYTQYZXZKBQT-UHFFFAOYSA-N 0.000 description 1
- NBVNEDHQRFJKCG-UHFFFAOYSA-N 7-n-methyl-4-n-(3-methylphenyl)-6-nitroquinazoline-4,7-diamine Chemical compound C=12C=C([N+]([O-])=O)C(NC)=CC2=NC=NC=1NC1=CC=CC(C)=C1 NBVNEDHQRFJKCG-UHFFFAOYSA-N 0.000 description 1
- DYEVXLNQIXWWDH-UHFFFAOYSA-N 7-n-methyl-4-n-(3-methylphenyl)quinazoline-4,6,7-triamine Chemical compound C=12C=C(N)C(NC)=CC2=NC=NC=1NC1=CC=CC(C)=C1 DYEVXLNQIXWWDH-UHFFFAOYSA-N 0.000 description 1
- RZCJSVRGPHXBSM-UHFFFAOYSA-N 8-chloro-[1,3]dioxolo[4,5-g]quinazoline Chemical compound C1=C2C(Cl)=NC=NC2=CC2=C1OCO2 RZCJSVRGPHXBSM-UHFFFAOYSA-N 0.000 description 1
- MAORQWZHGHOAOK-UHFFFAOYSA-N 8-methoxyquinazoline Chemical class N1=CN=C2C(OC)=CC=CC2=C1 MAORQWZHGHOAOK-UHFFFAOYSA-N 0.000 description 1
- RSWGJHLUYNHPMX-UHFFFAOYSA-N Abietic-Saeure Natural products C12CCC(C(C)C)=CC2=CCC2C1(C)CCCC2(C)C(O)=O RSWGJHLUYNHPMX-UHFFFAOYSA-N 0.000 description 1
- 102000015790 Asparaginase Human genes 0.000 description 1
- 108010024976 Asparaginase Proteins 0.000 description 1
- WOVKYSAHUYNSMH-UHFFFAOYSA-N BROMODEOXYURIDINE Natural products C1C(O)C(CO)OC1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-UHFFFAOYSA-N 0.000 description 1
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 238000010599 BrdU assay Methods 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- JGLMVXWAHNTPRF-CMDGGOBGSA-N CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O Chemical compound CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O JGLMVXWAHNTPRF-CMDGGOBGSA-N 0.000 description 1
- KZHSNCMVWMKZLU-UHFFFAOYSA-N CN(CCNNC(C(NCCCN(CC)CC)(NCCCN(C)C)NCCN(CC)CC)=O)C Chemical compound CN(CCNNC(C(NCCCN(CC)CC)(NCCCN(C)C)NCCN(CC)CC)=O)C KZHSNCMVWMKZLU-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 208000003495 Coccidiosis Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 208000009849 Female Genital Neoplasms Diseases 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
- 102000009465 Growth Factor Receptors Human genes 0.000 description 1
- 108010009202 Growth Factor Receptors Proteins 0.000 description 1
- VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- 206010023076 Isosporiasis Diseases 0.000 description 1
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 1
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 description 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
- 239000012425 OXONE® Substances 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 229940127361 Receptor Tyrosine Kinase Inhibitors Drugs 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- KHPCPRHQVVSZAH-HUOMCSJISA-N Rosin Natural products O(C/C=C/c1ccccc1)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 KHPCPRHQVVSZAH-HUOMCSJISA-N 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- NYWDTNWEQNOENK-UHFFFAOYSA-N [1,3]dioxolo[4,5-h]quinazoline Chemical compound C1=NC=NC2=C(OCO3)C3=CC=C21 NYWDTNWEQNOENK-UHFFFAOYSA-N 0.000 description 1
- AGIOYQIKFISKCK-UHFFFAOYSA-N [4-(3-methylanilino)quinazolin-7-yl]methanol Chemical compound CC1=CC=CC(NC=2C3=CC=C(CO)C=C3N=CN=2)=C1 AGIOYQIKFISKCK-UHFFFAOYSA-N 0.000 description 1
- OECAAUNBQHKSFL-UHFFFAOYSA-N [6-methoxy-4-(3-methylanilino)quinazolin-7-yl] 2-methoxyacetate Chemical compound C=12C=C(OC)C(OC(=O)COC)=CC2=NC=NC=1NC1=CC=CC(C)=C1 OECAAUNBQHKSFL-UHFFFAOYSA-N 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 150000001266 acyl halides Chemical class 0.000 description 1
- 125000004442 acylamino group Chemical group 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 150000001348 alkyl chlorides Chemical class 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- GRKUXCWELVWVMZ-UHFFFAOYSA-N amino acetate Chemical group CC(=O)ON GRKUXCWELVWVMZ-UHFFFAOYSA-N 0.000 description 1
- SDBCCDNTZKHGBJ-UHFFFAOYSA-N amino butanoate Chemical group CCCC(=O)ON SDBCCDNTZKHGBJ-UHFFFAOYSA-N 0.000 description 1
- KTYVHLCLTPLSGC-UHFFFAOYSA-N amino propanoate Chemical group CCC(=O)ON KTYVHLCLTPLSGC-UHFFFAOYSA-N 0.000 description 1
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- HOPRXXXSABQWAV-UHFFFAOYSA-N anhydrous collidine Natural products CC1=CC=NC(C)=C1C HOPRXXXSABQWAV-UHFFFAOYSA-N 0.000 description 1
- 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 230000003288 anthiarrhythmic effect Effects 0.000 description 1
- 230000002280 anti-androgenic effect Effects 0.000 description 1
- 230000003388 anti-hormonal effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000078 anti-malarial effect Effects 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 230000001775 anti-pathogenic effect Effects 0.000 description 1
- 239000000051 antiandrogen Substances 0.000 description 1
- 229940030495 antiandrogen sex hormone and modulator of the genital system Drugs 0.000 description 1
- 238000011394 anticancer treatment Methods 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000000010 aprotic solvent Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 108010060350 arginyl-arginyl-leucyl-isoleucyl-glutamyl-aspartyl-alanyl-glutamyl-tyrosyl-alanyl-alanyl-arginyl-glycine Proteins 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 239000003849 aromatic solvent Substances 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- 229960003272 asparaginase Drugs 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 description 1
- 238000011717 athymic nude mouse Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- PXXJHWLDUBFPOL-UHFFFAOYSA-N benzamidine Chemical compound NC(=N)C1=CC=CC=C1 PXXJHWLDUBFPOL-UHFFFAOYSA-N 0.000 description 1
- CSKNSYBAZOQPLR-UHFFFAOYSA-N benzenesulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=CC=C1 CSKNSYBAZOQPLR-UHFFFAOYSA-N 0.000 description 1
- 125000005605 benzo group Chemical group 0.000 description 1
- AQIHMSVIAGNIDM-UHFFFAOYSA-N benzoyl bromide Chemical compound BrC(=O)C1=CC=CC=C1 AQIHMSVIAGNIDM-UHFFFAOYSA-N 0.000 description 1
- 235000019400 benzoyl peroxide Nutrition 0.000 description 1
- KCXMKQUNVWSEMD-UHFFFAOYSA-N benzyl chloride Chemical compound ClCC1=CC=CC=C1 KCXMKQUNVWSEMD-UHFFFAOYSA-N 0.000 description 1
- 229940073608 benzyl chloride Drugs 0.000 description 1
- RSDOASZYYCOXIB-UHFFFAOYSA-N beta-alaninamide Chemical group NCCC(N)=O RSDOASZYYCOXIB-UHFFFAOYSA-N 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 229910052796 boron Inorganic materials 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 125000005997 bromomethyl group Chemical group 0.000 description 1
- 229950004398 broxuridine Drugs 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- DNSISZSEWVHGLH-UHFFFAOYSA-N butanamide Chemical compound CCCC(N)=O DNSISZSEWVHGLH-UHFFFAOYSA-N 0.000 description 1
- SNCZNSNPXMPCGN-UHFFFAOYSA-N butanediamide Chemical group NC(=O)CCC(N)=O SNCZNSNPXMPCGN-UHFFFAOYSA-N 0.000 description 1
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 229940097647 casodex Drugs 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- KXZJHVJKXJLBKO-UHFFFAOYSA-N chembl1408157 Chemical compound N=1C2=CC=CC=C2C(C(=O)O)=CC=1C1=CC=C(O)C=C1 KXZJHVJKXJLBKO-UHFFFAOYSA-N 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- VXIVSQZSERGHQP-UHFFFAOYSA-N chloroacetamide Chemical compound NC(=O)CCl VXIVSQZSERGHQP-UHFFFAOYSA-N 0.000 description 1
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- UTBIMNXEDGNJFE-UHFFFAOYSA-N collidine Natural products CC1=CC=C(C)C(C)=N1 UTBIMNXEDGNJFE-UHFFFAOYSA-N 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 238000009109 curative therapy Methods 0.000 description 1
- XLJMAIOERFSOGZ-UHFFFAOYSA-M cyanate Chemical compound [O-]C#N XLJMAIOERFSOGZ-UHFFFAOYSA-M 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 125000004772 dichloromethyl group Chemical group [H]C(Cl)(Cl)* 0.000 description 1
- 125000001664 diethylamino group Chemical group [H]C([H])([H])C([H])([H])N(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000006264 diethylaminomethyl group Chemical group [H]C([H])([H])C([H])([H])N(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- IUNMPGNGSSIWFP-UHFFFAOYSA-N dimethylaminopropylamine Chemical compound CN(C)CCCN IUNMPGNGSSIWFP-UHFFFAOYSA-N 0.000 description 1
- 125000004914 dipropylamino group Chemical group C(CC)N(CCC)* 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000003534 dna topoisomerase inhibitor Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- SIHZWGODIRRSRA-ONEGZZNKSA-N erbstatin Chemical compound OC1=CC=C(O)C(\C=C\NC=O)=C1 SIHZWGODIRRSRA-ONEGZZNKSA-N 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 125000006627 ethoxycarbonylamino group Chemical group 0.000 description 1
- 125000005745 ethoxymethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])* 0.000 description 1
- UVSPVEYCSVXYBB-UHFFFAOYSA-N ethyl 3-amino-3-oxopropanoate Chemical compound CCOC(=O)CC(N)=O UVSPVEYCSVXYBB-UHFFFAOYSA-N 0.000 description 1
- AJZOXCVIKHPZEU-UHFFFAOYSA-N ethyl 4-amino-4-oxobutanoate Chemical compound CCOC(=O)CCC(N)=O AJZOXCVIKHPZEU-UHFFFAOYSA-N 0.000 description 1
- 125000006534 ethyl amino methyl group Chemical group [H]N(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 description 1
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 1
- 125000006125 ethylsulfonyl group Chemical group 0.000 description 1
- 125000006351 ethylthiomethyl group Chemical group [H]C([H])([H])C([H])([H])SC([H])([H])* 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- GTFMAONWNTUZEW-UHFFFAOYSA-N glutaramic acid Chemical group NC(=O)CCCC(O)=O GTFMAONWNTUZEW-UHFFFAOYSA-N 0.000 description 1
- BEBCJVAWIBVWNZ-UHFFFAOYSA-N glycinamide Chemical group NCC(N)=O BEBCJVAWIBVWNZ-UHFFFAOYSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 229960001330 hydroxycarbamide Drugs 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000012444 intercalating antibiotic Substances 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- PGLTVOMIXTUURA-UHFFFAOYSA-N iodoacetamide Chemical compound NC(=O)CI PGLTVOMIXTUURA-UHFFFAOYSA-N 0.000 description 1
- 150000002505 iron Chemical class 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- 150000002513 isocyanates Chemical class 0.000 description 1
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- CGJMROBVSBIBKP-UHFFFAOYSA-N malonamic acid Chemical group NC(=O)CC(O)=O CGJMROBVSBIBKP-UHFFFAOYSA-N 0.000 description 1
- WRIRWRKPLXCTFD-UHFFFAOYSA-N malonamide Chemical group NC(=O)CC(N)=O WRIRWRKPLXCTFD-UHFFFAOYSA-N 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 125000005948 methanesulfonyloxy group Chemical group 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 125000006626 methoxycarbonylamino group Chemical group 0.000 description 1
- MOVBJUGHBJJKOW-UHFFFAOYSA-N methyl 2-amino-5-methoxybenzoate Chemical compound COC(=O)C1=CC(OC)=CC=C1N MOVBJUGHBJJKOW-UHFFFAOYSA-N 0.000 description 1
- LSNSJCKGQREPDW-UHFFFAOYSA-N methyl 3-amino-3-oxopropanoate Chemical compound COC(=O)CC(N)=O LSNSJCKGQREPDW-UHFFFAOYSA-N 0.000 description 1
- MTLGWFNVNBMOFC-UHFFFAOYSA-N methyl 4-[[4-(3-methylanilino)quinazolin-6-yl]amino]-4-oxobutanoate Chemical compound C12=CC(NC(=O)CCC(=O)OC)=CC=C2N=CN=C1NC1=CC=CC(C)=C1 MTLGWFNVNBMOFC-UHFFFAOYSA-N 0.000 description 1
- MQQJAAAEIQKHAG-UHFFFAOYSA-N methyl 4-[[4-(3-methylanilino)quinazolin-6-yl]amino]butanoate Chemical compound C12=CC(NCCCC(=O)OC)=CC=C2N=CN=C1NC1=CC=CC(C)=C1 MQQJAAAEIQKHAG-UHFFFAOYSA-N 0.000 description 1
- HURZMSZDVGMYKJ-UHFFFAOYSA-N methyl 4-amino-4-oxobutanoate Chemical compound COC(=O)CCC(N)=O HURZMSZDVGMYKJ-UHFFFAOYSA-N 0.000 description 1
- ZZUYIRISBMWFMV-UHFFFAOYSA-N methyl 4-chlorobutanoate Chemical compound COC(=O)CCCCl ZZUYIRISBMWFMV-UHFFFAOYSA-N 0.000 description 1
- RUSVJCCYUALGPZ-UHFFFAOYSA-N methyl 4-oxo-1h-quinazoline-7-carboxylate Chemical compound N1C=NC(=O)C=2C1=CC(C(=O)OC)=CC=2 RUSVJCCYUALGPZ-UHFFFAOYSA-N 0.000 description 1
- UAPJKEJWOPOJJY-UHFFFAOYSA-N methyl 5-methoxy-2-nitrobenzoate Chemical compound COC(=O)C1=CC(OC)=CC=C1[N+]([O-])=O UAPJKEJWOPOJJY-UHFFFAOYSA-N 0.000 description 1
- 125000006533 methyl amino methyl group Chemical group [H]N(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000006216 methylsulfinyl group Chemical group [H]C([H])([H])S(*)=O 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- VFWKRMDOKBGBLF-UHFFFAOYSA-N n,n-dimethyl-4-(3-methylanilino)quinazoline-7-carboxamide Chemical compound N=1C=NC2=CC(C(=O)N(C)C)=CC=C2C=1NC1=CC=CC(C)=C1 VFWKRMDOKBGBLF-UHFFFAOYSA-N 0.000 description 1
- XXVNQHJAVBZSFX-UHFFFAOYSA-N n-(3,4-dichlorophenyl)-6-piperidin-1-ylquinazolin-4-amine;hydrochloride Chemical compound Cl.C1=C(Cl)C(Cl)=CC=C1NC1=NC=NC2=CC=C(N3CCCCC3)C=C12 XXVNQHJAVBZSFX-UHFFFAOYSA-N 0.000 description 1
- JDEKFVYZUIPHET-UHFFFAOYSA-N n-(3-chlorophenyl)-6-methoxyquinazolin-4-amine Chemical compound C12=CC(OC)=CC=C2N=CN=C1NC1=CC=CC(Cl)=C1 JDEKFVYZUIPHET-UHFFFAOYSA-N 0.000 description 1
- USAMIYATKINXLP-UHFFFAOYSA-N n-(3-chlorophenyl)-6-nitroquinazolin-4-amine Chemical compound C12=CC([N+](=O)[O-])=CC=C2N=CN=C1NC1=CC=CC(Cl)=C1 USAMIYATKINXLP-UHFFFAOYSA-N 0.000 description 1
- MKLLQFMZATXPIU-UHFFFAOYSA-N n-(3-methylphenyl)-6-(methylsulfanylmethyl)quinazolin-4-amine Chemical compound C12=CC(CSC)=CC=C2N=CN=C1NC1=CC=CC(C)=C1 MKLLQFMZATXPIU-UHFFFAOYSA-N 0.000 description 1
- LBRNXYNVMWRILO-UHFFFAOYSA-N n-(3-methylphenyl)-6-(morpholin-4-ylmethyl)quinazolin-4-amine Chemical compound CC1=CC=CC(NC=2C3=CC(CN4CCOCC4)=CC=C3N=CN=2)=C1 LBRNXYNVMWRILO-UHFFFAOYSA-N 0.000 description 1
- QUQRGGIZFWJIKA-UHFFFAOYSA-N n-(3-methylphenyl)-6-(phenylsulfanylmethyl)quinazolin-4-amine Chemical compound CC1=CC=CC(NC=2C3=CC(CSC=4C=CC=CC=4)=CC=C3N=CN=2)=C1 QUQRGGIZFWJIKA-UHFFFAOYSA-N 0.000 description 1
- YZOKGFVFCZZKBP-UHFFFAOYSA-N n-(3-methylphenyl)-6-(piperazin-1-ylmethyl)quinazolin-4-amine Chemical compound CC1=CC=CC(NC=2C3=CC(CN4CCNCC4)=CC=C3N=CN=2)=C1 YZOKGFVFCZZKBP-UHFFFAOYSA-N 0.000 description 1
- USXLZROFUIENBM-UHFFFAOYSA-N n-(3-methylphenyl)-6-morpholin-4-ylquinazolin-4-amine;hydrochloride Chemical compound Cl.CC1=CC=CC(NC=2C3=CC(=CC=C3N=CN=2)N2CCOCC2)=C1 USXLZROFUIENBM-UHFFFAOYSA-N 0.000 description 1
- JCKRUPOZHCVXTD-UHFFFAOYSA-N n-[3-[(6,7-dimethoxyquinazolin-4-yl)amino]phenyl]acetamide Chemical compound C=12C=C(OC)C(OC)=CC2=NC=NC=1NC1=CC=CC(NC(C)=O)=C1 JCKRUPOZHCVXTD-UHFFFAOYSA-N 0.000 description 1
- OWZVFFZPZXVPLM-UHFFFAOYSA-N n-[4-(3-chloroanilino)quinazolin-6-yl]acetamide Chemical compound C12=CC(NC(=O)C)=CC=C2N=CN=C1NC1=CC=CC(Cl)=C1 OWZVFFZPZXVPLM-UHFFFAOYSA-N 0.000 description 1
- XMNDQZSHZWDRLT-UHFFFAOYSA-N n-[4-(3-methylanilino)quinazolin-7-yl]benzenesulfonamide Chemical compound CC1=CC=CC(NC=2C3=CC=C(NS(=O)(=O)C=4C=CC=CC=4)C=C3N=CN=2)=C1 XMNDQZSHZWDRLT-UHFFFAOYSA-N 0.000 description 1
- JEZKOONZDJHDBD-UHFFFAOYSA-N n-[4-[3-(trifluoromethyl)anilino]quinazolin-6-yl]acetamide Chemical compound C12=CC(NC(=O)C)=CC=C2N=CN=C1NC1=CC=CC(C(F)(F)F)=C1 JEZKOONZDJHDBD-UHFFFAOYSA-N 0.000 description 1
- SILYXJFZBRKOIH-UHFFFAOYSA-N n-[7-methoxy-4-(3-methylanilino)quinazolin-6-yl]hydroxylamine Chemical compound C=12C=C(NO)C(OC)=CC2=NC=NC=1NC1=CC=CC(C)=C1 SILYXJFZBRKOIH-UHFFFAOYSA-N 0.000 description 1
- ANFDQKXMPFOSGL-UHFFFAOYSA-N n-methyl-n-phenylquinazolin-2-amine Chemical compound N=1C=C2C=CC=CC2=NC=1N(C)C1=CC=CC=C1 ANFDQKXMPFOSGL-UHFFFAOYSA-N 0.000 description 1
- VCLXUEIYTZFLMO-UHFFFAOYSA-N n-methyl-n-phenylquinazolin-4-amine Chemical compound N=1C=NC2=CC=CC=C2C=1N(C)C1=CC=CC=C1 VCLXUEIYTZFLMO-UHFFFAOYSA-N 0.000 description 1
- MTSNDBYBIZSILH-UHFFFAOYSA-N n-phenylquinazolin-4-amine Chemical compound N=1C=NC2=CC=CC=C2C=1NC1=CC=CC=C1 MTSNDBYBIZSILH-UHFFFAOYSA-N 0.000 description 1
- 229940085033 nolvadex Drugs 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 229940127084 other anti-cancer agent Drugs 0.000 description 1
- 229940127075 other antimetabolite Drugs 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- RCCYSVYHULFYHE-UHFFFAOYSA-N pentanediamide Chemical group NC(=O)CCCC(N)=O RCCYSVYHULFYHE-UHFFFAOYSA-N 0.000 description 1
- 150000004965 peroxy acids Chemical class 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N phenylbenzene Natural products C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 1
- 229940080469 phosphocellulose Drugs 0.000 description 1
- UHZYTMXLRWXGPK-UHFFFAOYSA-N phosphorus pentachloride Chemical compound ClP(Cl)(Cl)(Cl)Cl UHZYTMXLRWXGPK-UHFFFAOYSA-N 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- FJVZDOGVDJCCCR-UHFFFAOYSA-M potassium periodate Chemical compound [K+].[O-]I(=O)(=O)=O FJVZDOGVDJCCCR-UHFFFAOYSA-M 0.000 description 1
- OKBMCNHOEMXPTM-UHFFFAOYSA-M potassium peroxymonosulfate Chemical compound [K+].OOS([O-])(=O)=O OKBMCNHOEMXPTM-UHFFFAOYSA-M 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 125000006628 propoxycarbonylamino group Chemical group 0.000 description 1
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical group CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 1
- 125000004742 propyloxycarbonyl group Chemical group 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- DRYRBWIFRVMRPV-UHFFFAOYSA-N quinazolin-4-amine Chemical class C1=CC=C2C(N)=NC=NC2=C1 DRYRBWIFRVMRPV-UHFFFAOYSA-N 0.000 description 1
- BBPMVEXRMOAIKQ-UHFFFAOYSA-N quinazolin-6-ol Chemical compound N1=CN=CC2=CC(O)=CC=C21 BBPMVEXRMOAIKQ-UHFFFAOYSA-N 0.000 description 1
- LNNRQIKKDKDFRV-UHFFFAOYSA-N quinazolin-8-ol Chemical class N1=CN=C2C(O)=CC=CC2=C1 LNNRQIKKDKDFRV-UHFFFAOYSA-N 0.000 description 1
- ADYNJDNYIVZXNK-UHFFFAOYSA-N quinazoline;dihydrochloride Chemical compound Cl.Cl.N1=CN=CC2=CC=CC=C21 ADYNJDNYIVZXNK-UHFFFAOYSA-N 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 229940124617 receptor tyrosine kinase inhibitor Drugs 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000012502 risk assessment Methods 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- LHQPVHQIMISDRO-UHFFFAOYSA-N sodium;2-sulfanylethanol Chemical compound [Na].OCCS LHQPVHQIMISDRO-UHFFFAOYSA-N 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 125000005415 substituted alkoxy group Chemical group 0.000 description 1
- JDVPQXZIJDEHAN-UHFFFAOYSA-N succinamic acid Chemical group NC(=O)CCC(O)=O JDVPQXZIJDEHAN-UHFFFAOYSA-N 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- GFYHSKONPJXCDE-UHFFFAOYSA-N sym-collidine Natural products CC1=CN=C(C)C(C)=C1 GFYHSKONPJXCDE-UHFFFAOYSA-N 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- 238000003419 tautomerization reaction Methods 0.000 description 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 125000004149 thio group Chemical group *S* 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 208000013076 thyroid tumor Diseases 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 229940044693 topoisomerase inhibitor Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- KHPCPRHQVVSZAH-UHFFFAOYSA-N trans-cinnamyl beta-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OCC=CC1=CC=CC=C1 KHPCPRHQVVSZAH-UHFFFAOYSA-N 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- IHIXIJGXTJIKRB-UHFFFAOYSA-N trisodium vanadate Chemical compound [Na+].[Na+].[Na+].[O-][V]([O-])([O-])=O IHIXIJGXTJIKRB-UHFFFAOYSA-N 0.000 description 1
- 238000001665 trituration Methods 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- GFNNBHLJANVSQV-UHFFFAOYSA-N tyrphostin AG 1478 Chemical compound C=12C=C(OC)C(OC)=CC2=NC=NC=1NC1=CC=CC(Cl)=C1 GFNNBHLJANVSQV-UHFFFAOYSA-N 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
- Cosmetics (AREA)
- Treatments For Attaching Organic Compounds To Fibrous Goods (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB929201095A GB9201095D0 (en) | 1992-01-20 | 1992-01-20 | Quinazoline derivatives |
| GB929213572A GB9213572D0 (en) | 1992-06-26 | 1992-06-26 | Quinazoline derivatives |
| GB929223735A GB9223735D0 (en) | 1992-11-12 | 1992-11-12 | Quinazoline derivatives |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CZ4393A3 CZ4393A3 (en) | 1993-10-13 |
| CZ282038B6 true CZ282038B6 (cs) | 1997-04-16 |
Family
ID=27266013
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CZ9343A CZ282038B6 (cs) | 1992-01-20 | 1993-01-18 | Chinazolinové deriváty, způsob jejich přípravy a farmaceutické kompozice tyto deriváty obsahující |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US5457105A (show.php) |
| EP (1) | EP0566226B1 (show.php) |
| KR (1) | KR100229294B1 (show.php) |
| AT (1) | ATE130000T1 (show.php) |
| AU (1) | AU661533B2 (show.php) |
| CA (1) | CA2086968C (show.php) |
| CZ (1) | CZ282038B6 (show.php) |
| DE (1) | DE69300754T2 (show.php) |
| DK (1) | DK0566226T3 (show.php) |
| ES (1) | ES2078798T3 (show.php) |
| FI (1) | FI111631B (show.php) |
| GB (1) | GB9300059D0 (show.php) |
| GR (1) | GR3018143T3 (show.php) |
| HK (1) | HK36497A (show.php) |
| HU (2) | HU221622B1 (show.php) |
| IL (1) | IL104479A (show.php) |
| NO (1) | NO301541B1 (show.php) |
| NZ (1) | NZ245662A (show.php) |
| RU (1) | RU2127263C1 (show.php) |
| SK (1) | SK281551B6 (show.php) |
| TW (1) | TW283146B (show.php) |
| UA (1) | UA34426C2 (show.php) |
Families Citing this family (708)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5710158A (en) * | 1991-05-10 | 1998-01-20 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
| US5714493A (en) * | 1991-05-10 | 1998-02-03 | Rhone-Poulenc Rorer Pharmaceuticals, Inc. | Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase |
| US5721237A (en) * | 1991-05-10 | 1998-02-24 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties |
| US6645969B1 (en) | 1991-05-10 | 2003-11-11 | Aventis Pharmaceuticals Inc. | Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase |
| USRE37650E1 (en) | 1991-05-10 | 2002-04-09 | Aventis Pharmacetical Products, Inc. | Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase |
| US7772432B2 (en) | 1991-09-19 | 2010-08-10 | Astrazeneca Ab | Amidobenzamide derivatives which are useful as cytokine inhibitors |
| US5981569A (en) * | 1992-11-13 | 1999-11-09 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Substituted phenylacrylonitrile compounds and compositions thereof for the treatment of disease |
| US5712395A (en) * | 1992-11-13 | 1998-01-27 | Yissum Research Development Corp. | Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis |
| US5792771A (en) * | 1992-11-13 | 1998-08-11 | Sugen, Inc. | Quinazoline compounds and compositions thereof for the treatment of disease |
| US5763441A (en) * | 1992-11-13 | 1998-06-09 | Sugen, Inc. | Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis |
| GB9323290D0 (en) | 1992-12-10 | 1994-01-05 | Zeneca Ltd | Quinazoline derivatives |
| PH31122A (en) * | 1993-03-31 | 1998-02-23 | Eisai Co Ltd | Nitrogen-containing fused-heterocycle compounds. |
| GB9314893D0 (en) * | 1993-07-19 | 1993-09-01 | Zeneca Ltd | Quinazoline derivatives |
| GB9325217D0 (en) * | 1993-12-09 | 1994-02-09 | Zeneca Ltd | Pyrimidine derivatives |
| AU739382B2 (en) * | 1993-12-10 | 2001-10-11 | Aventis Pharmaceuticals Inc. | Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase |
| US5700823A (en) * | 1994-01-07 | 1997-12-23 | Sugen, Inc. | Treatment of platelet derived growth factor related disorders such as cancers |
| IL112249A (en) | 1994-01-25 | 2001-11-25 | Warner Lambert Co | Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds |
| IL112248A0 (en) | 1994-01-25 | 1995-03-30 | Warner Lambert Co | Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them |
| US5654307A (en) * | 1994-01-25 | 1997-08-05 | Warner-Lambert Company | Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family |
| US6524832B1 (en) * | 1994-02-04 | 2003-02-25 | Arch Development Corporation | DNA damaging agents in combination with tyrosine kinase inhibitors |
| EP0746554A1 (en) * | 1994-02-23 | 1996-12-11 | Pfizer Inc. | 4-heterocyclyl-substituted quinazoline derivatives, processes for their preparation and their use as anti-cancer agents |
| WO1995024190A2 (en) * | 1994-03-07 | 1995-09-14 | Sugen, Inc. | Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof |
| ATE159257T1 (de) * | 1994-05-03 | 1997-11-15 | Ciba Geigy Ag | Pyrrolopyrimidinderivate mit antiproliferativer wirkung |
| PT783505E (pt) * | 1994-09-29 | 2001-08-30 | Novartis Ag | Pirrolo¬2,3-d|pirimidinas e sua utilizacao |
| TW321649B (show.php) * | 1994-11-12 | 1997-12-01 | Zeneca Ltd | |
| GB9424233D0 (en) * | 1994-11-30 | 1995-01-18 | Zeneca Ltd | Quinazoline derivatives |
| EP1110953B1 (en) | 1995-03-30 | 2009-10-28 | Pfizer Products Inc. | Quinazoline derivatives |
| AU778961B2 (en) * | 1995-03-30 | 2004-12-23 | Osi Pharmaceuticals, Inc. | Intermediates for the preparation of 4-(substituted phenylamino)quinazoline derivatives |
| ES2150113T3 (es) * | 1995-04-03 | 2000-11-16 | Novartis Ag | Derivados de pirazol y procedimientos para la preparacion de los mismos. |
| US5721277A (en) * | 1995-04-21 | 1998-02-24 | Sugen, Inc. | Compounds and methods for inhibiting hyper-proliferative cell growth |
| GB9508565D0 (en) * | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quiazoline derivative |
| WO1996033977A1 (en) * | 1995-04-27 | 1996-10-31 | Zeneca Limited | Quinazoline derivatives |
| GB9508538D0 (en) * | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
| GB9508535D0 (en) * | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivative |
| GB9508537D0 (en) * | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
| US5639757A (en) * | 1995-05-23 | 1997-06-17 | Pfizer Inc. | 4-aminopyrrolo[2,3-d]pyrimidines as tyrosine kinase inhibitors |
| US6331555B1 (en) | 1995-06-01 | 2001-12-18 | University Of California | Treatment of platelet derived growth factor related disorders such as cancers |
| US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
| US5763470A (en) * | 1995-06-07 | 1998-06-09 | Sugen Inc. | Benzopyran compounds and methods for their use |
| JPH11507052A (ja) * | 1995-06-07 | 1999-06-22 | スージェン・インコーポレーテッド | キナゾリンおよび医薬組成物 |
| US5880141A (en) | 1995-06-07 | 1999-03-09 | Sugen, Inc. | Benzylidene-Z-indoline compounds for the treatment of disease |
| US6316635B1 (en) | 1995-06-07 | 2001-11-13 | Sugen, Inc. | 2-indolinone derivatives as modulators of protein kinase activity |
| US6147106A (en) | 1997-08-20 | 2000-11-14 | Sugen, Inc. | Indolinone combinatorial libraries and related products and methods for the treatment of disease |
| US7060808B1 (en) * | 1995-06-07 | 2006-06-13 | Imclone Systems Incorporated | Humanized anti-EGF receptor monoclonal antibody |
| US6716575B2 (en) | 1995-12-18 | 2004-04-06 | Sugen, Inc. | Diagnosis and treatment of AUR1 and/or AUR2 related disorders |
| GB9624482D0 (en) * | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| US7119174B2 (en) | 1995-12-18 | 2006-10-10 | Sugen, Inc. | Diagnosis and treatment of AUR1 and/or AUR2 related disorders |
| ZA9756B (en) * | 1996-01-16 | 1997-07-17 | Warner Lambert Co | Process for preparing 4,6-disubstituted pyrido[3,4-d]-pyrimidines |
| US5760041A (en) * | 1996-02-05 | 1998-06-02 | American Cyanamid Company | 4-aminoquinazoline EGFR Inhibitors |
| PL194689B1 (pl) * | 1996-02-13 | 2007-06-29 | Astrazeneca Uk Ltd | Pochodne chinazoliny, ich kompozycje farmaceutyczne oraz ich zastosowania |
| GB9603097D0 (en) * | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline compounds |
| GB9603095D0 (en) * | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
| EP0885198B1 (en) * | 1996-03-05 | 2001-12-19 | AstraZeneca AB | 4-anilinoquinazoline derivatives |
| RO121900B1 (ro) | 1996-04-12 | 2008-07-30 | Warner-Lambert Company | Compuşi inhibitori, ireversibili, ai tirozin kinazelor, compoziţie farmaceutică care îi conţine şi utilizarea acestora |
| GB9607729D0 (en) * | 1996-04-13 | 1996-06-19 | Zeneca Ltd | Quinazoline derivatives |
| WO1998002434A1 (en) | 1996-07-13 | 1998-01-22 | Glaxo Group Limited | Fused heterocyclic compounds as protein tyrosine kinase inhibitors |
| AU709203B2 (en) * | 1996-08-06 | 1999-08-26 | Pfizer Inc. | Substituted pyrido- or pyrimido-containing 6,6- or 6,7-bicyclic derivatives |
| RU2196137C2 (ru) * | 1996-08-08 | 2003-01-10 | Зенека Лимитед | Производные хиназолина и их применение в качестве ингибиторов фактора роста эндотелия сосудов |
| EP0954315A2 (en) * | 1996-09-13 | 1999-11-10 | Sugen, Inc. | Use of quinazoline derivatives for the manufacture of a medicament in the treatment of hyperproliferative skin disorders |
| US6004967A (en) * | 1996-09-13 | 1999-12-21 | Sugen, Inc. | Psoriasis treatment with quinazoline compounds |
| GB9718972D0 (en) * | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| EP0837063A1 (en) * | 1996-10-17 | 1998-04-22 | Pfizer Inc. | 4-Aminoquinazoline derivatives |
| US6225318B1 (en) | 1996-10-17 | 2001-05-01 | Pfizer Inc | 4-aminoquinazolone derivatives |
| US6413971B1 (en) * | 1996-11-27 | 2002-07-02 | Pfizer Inc | Fused bicyclic pyrimidine derivatives |
| US6002008A (en) * | 1997-04-03 | 1999-12-14 | American Cyanamid Company | Substituted 3-cyano quinolines |
| US6818440B2 (en) | 1997-04-28 | 2004-11-16 | Sugen, Inc. | Diagnosis and treatment of alk-7 related disorders |
| AR012634A1 (es) | 1997-05-02 | 2000-11-08 | Sugen Inc | Compuesto basado en quinazolina, composicion famaceutica que lo comprende, metodo para sintetizarlo, su uso, metodos de modulacion de la funcion deserina/treonina proteinaquinasa con dicho compuesto y metodo in vitro para identificar compuestos que modulan dicha funcion |
| US5929080A (en) * | 1997-05-06 | 1999-07-27 | American Cyanamid Company | Method of treating polycystic kidney disease |
| US6316429B1 (en) | 1997-05-07 | 2001-11-13 | Sugen, Inc. | Bicyclic protein kinase inhibitors |
| US6486185B1 (en) | 1997-05-07 | 2002-11-26 | Sugen, Inc. | 3-heteroarylidene-2-indolinone protein kinase inhibitors |
| US6316479B1 (en) | 1997-05-19 | 2001-11-13 | Sugen, Inc. | Isoxazole-4-carboxamide compounds active against protein tryosine kinase related disorders |
| US6228641B1 (en) | 1997-05-20 | 2001-05-08 | Sugen, Inc. | Diagnosis and treatment of PTP04 related disorders |
| US6987113B2 (en) | 1997-06-11 | 2006-01-17 | Sugen, Inc. | Tyrosine kinase inhibitors |
| US6342593B1 (en) | 1997-06-11 | 2002-01-29 | Sugen, Inc. | Diagnosis and treatment of ALP related disorders |
| US7115710B2 (en) | 1997-06-11 | 2006-10-03 | Sugen, Inc. | Diagnosis and treatment of PTP related disorders |
| US6388063B1 (en) | 1997-06-18 | 2002-05-14 | Sugen, Inc. | Diagnosis and treatment of SAD related disorders |
| US6313158B1 (en) | 1997-06-20 | 2001-11-06 | Sugen, Inc. | Bioavailability of 3-heteroarylidenyl-2-indolinones active as protein tyrosine kinase inhibitors |
| US6051593A (en) * | 1997-06-20 | 2000-04-18 | Sugen, Inc. | 3-(cycloalkanoheteroarylidenyl)-2- indolinone protein tyrosine kinase inhibitors |
| US6114371A (en) * | 1997-06-20 | 2000-09-05 | Sugen, Inc. | 3-(cyclohexanoheteroarylidenyl)-2-indolinone protein tyrosine kinase inhibitors |
| US6130238A (en) * | 1997-06-20 | 2000-10-10 | Sugen, Inc. | 3-(cyclohexanoheteroarylidenyl)-2-indolinone protein tyrosine kinase inhibitors |
| US6235769B1 (en) | 1997-07-03 | 2001-05-22 | Sugen, Inc. | Methods of preventing and treating neurological disorders with compounds that modulate the function of the C-RET receptor protein tyrosine kinase |
| ZA986729B (en) * | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitors of tyrosine kinases |
| ZA986732B (en) * | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitiors of tyrosine kinases |
| US6251912B1 (en) | 1997-08-01 | 2001-06-26 | American Cyanamid Company | Substituted quinazoline derivatives |
| TW436485B (en) * | 1997-08-01 | 2001-05-28 | American Cyanamid Co | Substituted quinazoline derivatives |
| WO1999007701A1 (en) | 1997-08-05 | 1999-02-18 | Sugen, Inc. | Tricyclic quinoxaline derivatives as protein tyrosine kinase inhibitors |
| JP2001515032A (ja) * | 1997-08-15 | 2001-09-18 | セフアロン・インコーポレーテツド | 前立腺がんを治療するためのチロシンキナーゼ阻害剤と化学的去勢術の組み合わせ法 |
| US6294532B1 (en) | 1997-08-22 | 2001-09-25 | Zeneca Limited | Oxindolylquinazoline derivatives as angiogenesis inhibitors |
| SK285357B6 (sk) | 1997-09-26 | 2006-11-03 | Zentaris Gmbh | Zlúčeniny na báze azabenzimidazolu modulujúce funkciu serínovej/treonínovej proteínkinázy |
| US6133305A (en) | 1997-09-26 | 2000-10-17 | Sugen, Inc. | 3-(substituted)-2-indolinones compounds and use thereof as inhibitors of protein kinase activity |
| UA71555C2 (en) | 1997-10-06 | 2004-12-15 | Zentaris Gmbh | Methods for modulating function of serine/threonine protein kinases by 5-azaquinoline derivatives |
| US6323209B1 (en) | 1997-11-06 | 2001-11-27 | American Cyanamid Company | Method of treating or inhibiting colonic polyps |
| GB9800569D0 (en) | 1998-01-12 | 1998-03-11 | Glaxo Group Ltd | Heterocyclic compounds |
| US6495353B1 (en) | 1998-01-21 | 2002-12-17 | Sugen, Inc. | Human orthologues of wart |
| US6531502B1 (en) | 1998-01-21 | 2003-03-11 | Sugen, Inc. | 3-Methylidenyl-2-indolinone modulators of protein kinase |
| US6943191B1 (en) | 1998-02-27 | 2005-09-13 | The United States Of America As Represented By The Department Of Health And Human Services | Disubstituted lavendustin A analogs and pharmaceutical composition comprising the analogs |
| US20030224001A1 (en) * | 1998-03-19 | 2003-12-04 | Goldstein Neil I. | Antibody and antibody fragments for inhibiting the growth of tumors |
| US6514981B1 (en) | 1998-04-02 | 2003-02-04 | Sugen, Inc. | Methods of modulating tyrosine protein kinase function with indolinone compounds |
| ATE302269T1 (de) | 1998-04-14 | 2005-09-15 | Sugen Inc | Ste20-verwandte proteinkinasen |
| US6706721B1 (en) | 1998-04-29 | 2004-03-16 | Osi Pharmaceuticals, Inc. | N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate |
| ZA200007412B (en) * | 1998-05-15 | 2002-03-12 | Imclone Systems Inc | Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases. |
| EP1082311A1 (en) | 1998-05-28 | 2001-03-14 | Parker Hughes Institute | Quinazolines for treating brain tumor |
| DK2020408T3 (da) | 1998-05-29 | 2013-09-30 | Sugen Inc | Pyrrol-substitueret 2-indolinon som proteinkinaseinhibitor |
| US6384223B1 (en) | 1998-07-30 | 2002-05-07 | American Home Products Corporation | Substituted quinazoline derivatives |
| US6184226B1 (en) | 1998-08-28 | 2001-02-06 | Scios Inc. | Quinazoline derivatives as inhibitors of P-38 α |
| CA2342222A1 (en) | 1998-08-31 | 2000-03-09 | Sugen, Inc. | Geometrically restricted 2-indolinone derivatives as modulators of protein kinase activity |
| US6680335B2 (en) | 1998-09-28 | 2004-01-20 | Sugen, Inc. | Methods of modulating protein tyrosine kinase function with substituted indolinone compounds |
| DK2253620T3 (da) | 1998-09-29 | 2014-03-31 | Wyeth Holdings Llc | Substituerede 3-cyanoquinoliner som protein-tyrosinkinase-inhibitorer |
| US6297258B1 (en) | 1998-09-29 | 2001-10-02 | American Cyanamid Company | Substituted 3-cyanoquinolines |
| US6288082B1 (en) | 1998-09-29 | 2001-09-11 | American Cyanamid Company | Substituted 3-cyanoquinolines |
| AU761552B2 (en) | 1998-10-01 | 2003-06-05 | Astrazeneca Ab | Chemical compounds |
| JP3270834B2 (ja) | 1999-01-27 | 2002-04-02 | ファイザー・プロダクツ・インク | 抗がん剤として有用なヘテロ芳香族二環式誘導体 |
| UA71945C2 (en) | 1999-01-27 | 2005-01-17 | Pfizer Prod Inc | Substituted bicyclic derivatives being used as anticancer agents |
| TR200500745T2 (tr) | 1999-02-10 | 2005-05-23 | Astrazeneca Ab | Damar gelişimi inhibitörleri olarak kuinazolin türevleri. |
| DE19911509A1 (de) * | 1999-03-15 | 2000-09-21 | Boehringer Ingelheim Pharma | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
| WO2000055153A1 (en) | 1999-03-17 | 2000-09-21 | Astrazeneca Ab | Amide derivatives |
| US7064114B2 (en) * | 1999-03-19 | 2006-06-20 | Parker Hughes Institute | Gel-microemulsion formulations |
| US6258820B1 (en) * | 1999-03-19 | 2001-07-10 | Parker Hughes Institute | Synthesis and anti-tumor activity of 6,7-dialkoxy-4-phenylamino-quinazolines |
| RS49836B (sr) * | 1999-03-31 | 2008-08-07 | Pfizer Products Inc., | Postupci i intermedijeri za dobijanje anti-kancernih jedinjenja |
| IT1312310B1 (it) * | 1999-05-07 | 2002-04-15 | Recordati Ind Chimica E Farma | Uso di antagonisti selettivi del recettore adrenergico a 1b per ilmiglioramento della disfunzione sessuale |
| WO2000069459A1 (en) * | 1999-05-14 | 2000-11-23 | Imclone Systems Incorporated | Treatment of refractory human tumors with epidermal growth factor receptor antagonists |
| US6126917A (en) * | 1999-06-01 | 2000-10-03 | Hadasit Medical Research Services And Development Ltd. | Epidermal growth factor receptor binding compounds for positron emission tomography |
| SK287010B6 (sk) | 1999-06-21 | 2009-09-07 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Bicyklické heterocyklické zlúčeniny, spôsob ich prípravy, farmaceutický prostriedok s ich obsahom a ich použitie |
| US6933299B1 (en) | 1999-07-09 | 2005-08-23 | Smithkline Beecham Corporation | Anilinoquinazolines as protein tyrosine kinase inhibitors |
| ATE377597T1 (de) | 1999-07-09 | 2007-11-15 | Glaxo Group Ltd | Anilinochinazoline als protein-tyrosin- kinasehemmer |
| US6432979B1 (en) | 1999-08-12 | 2002-08-13 | American Cyanamid Company | Method of treating or inhibiting colonic polyps and colorectal cancer |
| US6921763B2 (en) | 1999-09-17 | 2005-07-26 | Abbott Laboratories | Pyrazolopyrimidines as therapeutic agents |
| WO2001021596A1 (en) * | 1999-09-21 | 2001-03-29 | Astrazeneca Ab | Quinazoline derivatives and their use as pharmaceuticals |
| HUP0204413A3 (en) | 1999-09-21 | 2003-07-28 | Astrazeneca Ab | Quinazoline compounds, their preparation, their use and pharmaceutical compositions containing them |
| JP3868811B2 (ja) * | 1999-10-01 | 2007-01-17 | 大日本住友製薬株式会社 | 新規キナゾリン誘導体 |
| GB9924092D0 (en) | 1999-10-13 | 1999-12-15 | Zeneca Ltd | Pyrimidine derivatives |
| WO2001032632A2 (en) * | 1999-11-01 | 2001-05-10 | Eli Lilly And Company | Pharmaceutically active 4-substituted pyrimidine derivatives |
| GB9925958D0 (en) | 1999-11-02 | 1999-12-29 | Bundred Nigel J | Therapeutic use |
| JP3522727B2 (ja) * | 1999-11-05 | 2004-04-26 | アストラゼネカ アクチボラグ | Vegf阻害剤としてのキナゾリン誘導体 |
| UA74803C2 (uk) | 1999-11-11 | 2006-02-15 | Осі Фармасьютікалз, Інк. | Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування |
| US7087613B2 (en) | 1999-11-11 | 2006-08-08 | Osi Pharmaceuticals, Inc. | Treating abnormal cell growth with a stable polymorph of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride |
| US6878733B1 (en) | 1999-11-24 | 2005-04-12 | Sugen, Inc. | Formulations for pharmaceutical agents ionizable as free acids or free bases |
| UA75055C2 (uk) * | 1999-11-30 | 2006-03-15 | Пфайзер Продактс Інк. | Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі |
| SK12712002A3 (sk) | 2000-02-07 | 2003-02-04 | Abbott Gmbh & Co. Kg | Deriváty 2-benzotiazolylmočoviny a ich použitie ako inhibítorov proteínkináz |
| GB0002952D0 (en) * | 2000-02-09 | 2000-03-29 | Pharma Mar Sa | Process for producing kahalalide F compounds |
| PT1255752E (pt) | 2000-02-15 | 2007-10-17 | Pharmacia & Upjohn Co Llc | Inibidores de proteína quinases: 2-indolinonas substituídas com pirrolo |
| DE60121931T2 (de) | 2000-04-07 | 2007-03-01 | Astrazeneca Ab | Chinazolinverbindungen |
| UA73993C2 (uk) * | 2000-06-06 | 2005-10-17 | Астразенека Аб | Хіназолінові похідні для лікування пухлин та фармацевтична композиція |
| RU2276151C2 (ru) * | 2000-06-06 | 2006-05-10 | Астразенека Аб | Хиназолиновые производные для лечения опухолей |
| EE200200715A (et) * | 2000-06-28 | 2004-08-16 | Astrazeneca Ab | Asendatud kinasoliini derivaadid ja nende kasutamine inhibiitoritena |
| AU9500201A (en) * | 2000-08-09 | 2002-02-18 | Imclone Systems Inc | Treatment of hyperproliferative diseases with epidermal growth factor receptor antagonists |
| BR0113358A (pt) | 2000-08-21 | 2003-07-01 | Astrazeneca Ab | Derivado de quinazolina ou de um seu sal farmaceuticamente aceitável, processo para a sua preparação, composição farmacêutica, e, uso do derivado ou de um seu sal farmaceuticamente aceitável |
| US6617329B2 (en) | 2000-08-26 | 2003-09-09 | Boehringer Ingelheim Pharma Kg | Aminoquinazolines and their use as medicaments |
| DE10042059A1 (de) * | 2000-08-26 | 2002-03-07 | Boehringer Ingelheim Pharma | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
| DE60144284D1 (de) | 2000-11-01 | 2011-05-05 | Millennium Pharm Inc | Stickstoffhaltige heterozyklische verbindungen und verfahren zu deren herstellung |
| US6582919B2 (en) | 2001-06-11 | 2003-06-24 | Response Genetics, Inc. | Method of determining epidermal growth factor receptor and HER2-neu gene expression and correlation of levels thereof with survival rates |
| US7019012B2 (en) | 2000-12-20 | 2006-03-28 | Boehringer Ingelheim International Pharma Gmbh & Co. Kg | Quinazoline derivatives and pharmaceutical compositions containing them |
| AR042586A1 (es) | 2001-02-15 | 2005-06-29 | Sugen Inc | 3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la protein quinasa; sus composiciones farmaceuticas; un metodo para la modulacion de la actividad catalitica de la proteinquinasa; un metodo para tratar o prevenir una afeccion relacionada con la proteinquinasa |
| EP2762140B1 (en) | 2001-02-19 | 2017-03-22 | Novartis AG | Treatment of solid brain tumours with a rapamycin derivative |
| CA2439143A1 (en) * | 2001-02-26 | 2002-09-06 | Mcgill University | Combi-molecules having signal transduction inhibitory properties and dna damaging properties |
| US20080008704A1 (en) * | 2001-03-16 | 2008-01-10 | Mark Rubin | Methods of treating colorectal cancer with anti-epidermal growth factor antibodies |
| MXPA03008560A (es) | 2001-03-22 | 2004-06-30 | Abbot Gmbh & Co Kg | Pirazolopirimidinas como agentes terapeuticos. |
| WO2002079498A1 (en) * | 2001-04-02 | 2002-10-10 | Merck & Co., Inc. | In vivo methods of determining activity of receptor-type kinase inhibitors |
| KR100861466B1 (ko) | 2001-04-24 | 2008-10-02 | 메르크 파텐트 게엠베하 | 항혈관형성제 및 TNFα를 이용한 병용 요법 |
| JP4414142B2 (ja) | 2001-05-11 | 2010-02-10 | ルードヴィッヒ インスティテュート フォー キャンサー リサーチ | 特異的結合タンパク質およびその使用 |
| US20110313230A1 (en) | 2001-05-11 | 2011-12-22 | Terrance Grant Johns | Specific binding proteins and uses thereof |
| US20100056762A1 (en) | 2001-05-11 | 2010-03-04 | Old Lloyd J | Specific binding proteins and uses thereof |
| WO2002092577A1 (en) * | 2001-05-14 | 2002-11-21 | Astrazeneca Ab | Quinazoline derivatives |
| CA2444867C (en) | 2001-05-16 | 2010-08-17 | Novartis Ag | Combination comprising n-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2pyrimidine-amine and a chemotherapeutic agent |
| AU2002350105A1 (en) | 2001-06-21 | 2003-01-08 | Ariad Pharmaceuticals, Inc. | Novel quinazolines and uses thereof |
| KR100397792B1 (ko) | 2001-06-28 | 2003-09-13 | 한국과학기술연구원 | 4-(페닐아미노)-[1,4]디옥사노[2,3-g]퀴나졸린 유도체 및그의 제조방법 |
| EP1434774A1 (en) | 2001-10-10 | 2004-07-07 | Sugen, Inc. | 3-(4-substituted heterocyclyl)-pyrrol-2-ylmethylidene)-2-indolinone derivatives as protein kinase inhibitors |
| GB0126433D0 (en) * | 2001-11-03 | 2002-01-02 | Astrazeneca Ab | Compounds |
| ES2333702T3 (es) * | 2001-12-24 | 2010-02-26 | Astrazeneca Ab | Derivados de quinazolina sustituidos que actuan como unhibidores de cinasas aurora. |
| KR20040085151A (ko) * | 2002-01-17 | 2004-10-07 | 뉴로젠 코포레이션 | 캡사이신 조절자로서의 치환된 퀴나졸린-4-일 아민 유사체 |
| PL371486A1 (en) | 2002-02-01 | 2005-06-13 | Astrazeneca Ab | Quinazoline compounds |
| AU2003212500B2 (en) * | 2002-02-26 | 2008-01-03 | Astrazeneca Ab | Novel crystalline forms of the anti-cancer compound ZD1839 |
| GB0204392D0 (en) * | 2002-02-26 | 2002-04-10 | Astrazeneca Ab | Pharmaceutical compound |
| IL163642A0 (en) * | 2002-02-26 | 2005-12-18 | Astrazeneca Ab | Pharmaceutical formulation of iressa comprising a water-soluble cellulose derivative |
| GB0206215D0 (en) | 2002-03-15 | 2002-05-01 | Novartis Ag | Organic compounds |
| US7078409B2 (en) | 2002-03-28 | 2006-07-18 | Beta Pharma, Inc. | Fused quinazoline derivatives useful as tyrosine kinase inhibitors |
| TW200813014A (en) * | 2002-03-28 | 2008-03-16 | Astrazeneca Ab | Quinazoline derivatives |
| US6924285B2 (en) | 2002-03-30 | 2005-08-02 | Boehringer Ingelheim Pharma Gmbh & Co. | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them |
| JP2005530735A (ja) * | 2002-04-16 | 2005-10-13 | アストラゼネカ アクチボラグ | 癌の処置のための併用療法 |
| DE10221018A1 (de) | 2002-05-11 | 2003-11-27 | Boehringer Ingelheim Pharma | Verwendung von Hemmern der EGFR-vermittelten Signaltransduktion zur Behandlung von gutartiger Prostatahyperplasie (BPH)/Prostatahypertrophie |
| BR0311173A (pt) | 2002-05-16 | 2005-03-15 | Novartis Ag | Uso de agentes de ligação do receptor de edg em câncer |
| WO2003103581A2 (en) | 2002-06-05 | 2003-12-18 | Genentech, Inc. | Compositions and methods for liver growth and liver protection |
| GB0221245D0 (en) | 2002-09-13 | 2002-10-23 | Astrazeneca Ab | Chemical process |
| GB0223854D0 (en) * | 2002-10-12 | 2002-11-20 | Astrazeneca Ab | Therapeutic treatment |
| GB0304367D0 (en) * | 2003-02-26 | 2003-04-02 | Pharma Mar Sau | Methods for treating psoriasis |
| NZ539408A (en) * | 2002-11-04 | 2007-09-28 | Astrazeneca Ab | Quinazoline derivatives as SRC tyrosine kinase inhibitors for treating solid tumours |
| KR20050084292A (ko) * | 2002-12-13 | 2005-08-26 | 뉴로젠 코포레이션 | 캅사이신 수용체 조절체로서 2-치환된 퀴나졸린-4-일아민동족체 |
| ATE458731T1 (de) | 2002-12-20 | 2010-03-15 | Pfizer Prod Inc | Pyrimidin-derivate zur behandlung von anormalem zellwachstum |
| KR20050122199A (ko) * | 2003-01-23 | 2005-12-28 | 티.케이. 시그널 리미티드 | 표피성장인자 수용체 티로신 키나제의 비가역성 억제제 및 그의 용도 |
| US7223749B2 (en) | 2003-02-20 | 2007-05-29 | Boehringer Ingelheim International Gmbh | Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them |
| EP1622941A2 (en) * | 2003-03-20 | 2006-02-08 | ImClone Systems Incorporated | Method of producing an antibody to epidermal growth factor receptor |
| GB0309850D0 (en) | 2003-04-30 | 2003-06-04 | Astrazeneca Ab | Quinazoline derivatives |
| EP2644195A1 (en) | 2003-05-19 | 2013-10-02 | Irm Llc | Immunosuppressant Compounds and Compositions |
| MY150088A (en) | 2003-05-19 | 2013-11-29 | Irm Llc | Immunosuppressant compounds and compositions |
| EP2348110B1 (en) | 2003-05-30 | 2013-03-27 | OncoTherapy Science, Inc. | Process for screening a drug response in cancer patients |
| JP2007500248A (ja) | 2003-06-09 | 2007-01-11 | ワクサル,サムエル | 細胞外アンタゴニストおよび細胞内アンタゴニストによる受容体チロシンキナーゼの抑制方法 |
| EP1680426B1 (en) * | 2003-06-10 | 2007-09-19 | F. Hoffmann-La Roche Ag | 1.3.4-triaza-phenalene and 1,3,4,6-tetraazaphenalene derivatives |
| GB0317665D0 (en) | 2003-07-29 | 2003-09-03 | Astrazeneca Ab | Qinazoline derivatives |
| KR20060054388A (ko) * | 2003-07-29 | 2006-05-22 | 아스트라제네카 아베 | 티로신 키나아제 억제제로서의 피페리딜-퀴나졸린 유도체 |
| GB0317663D0 (en) * | 2003-07-29 | 2003-09-03 | Astrazeneca Ab | Pharmaceutical composition |
| DK1663982T3 (da) * | 2003-07-31 | 2008-03-17 | Sanofi Aventis | Aminoquinolinderivater og deres anvendelse som adenosin-A3-ligander |
| GB0318422D0 (en) | 2003-08-06 | 2003-09-10 | Astrazeneca Ab | Chemical compounds |
| BRPI0413281A (pt) | 2003-08-06 | 2006-10-10 | Sugen Inc | 3-ciclopentilideno-1,3,dihidroindol-2-onas geometricamente restringidas como potentes inibidores de proteìna cinase |
| GB0321066D0 (en) * | 2003-09-09 | 2003-10-08 | Pharma Mar Sau | New antitumoral compounds |
| EP1664030A1 (en) * | 2003-09-16 | 2006-06-07 | AstraZeneca AB | Quinazoline derivatives |
| DK1667991T3 (da) | 2003-09-16 | 2008-08-18 | Astrazeneca Ab | Quinazolinderivater som tyrosinkinaseinhibitorer |
| DE602004004553T2 (de) * | 2003-09-19 | 2007-10-25 | Astrazeneca Ab | Chinazolinderivate |
| EP1670782B1 (en) * | 2003-09-19 | 2007-02-14 | AstraZeneca AB | Quinazoline derivatives |
| GB0322409D0 (en) | 2003-09-25 | 2003-10-29 | Astrazeneca Ab | Quinazoline derivatives |
| EP1670786A1 (en) * | 2003-09-25 | 2006-06-21 | Astrazeneca AB | Quinazoline derivatives |
| WO2005032481A2 (en) * | 2003-09-30 | 2005-04-14 | Scios Inc. | Quinazoline derivatives as medicaments |
| US7456189B2 (en) | 2003-09-30 | 2008-11-25 | Boehringer Ingelheim International Gmbh | Bicyclic heterocycles, medicaments containing these compounds, their use and processes for their preparation |
| DE10349113A1 (de) | 2003-10-17 | 2005-05-12 | Boehringer Ingelheim Pharma | Verfahren zur Herstellung von Aminocrotonylverbindungen |
| GB0324790D0 (en) | 2003-10-24 | 2003-11-26 | Astrazeneca Ab | Amide derivatives |
| WO2005048928A2 (en) * | 2003-11-12 | 2005-06-02 | George Mason Intellectual Property | Methods for treating viral infection |
| GB0326459D0 (en) | 2003-11-13 | 2003-12-17 | Astrazeneca Ab | Quinazoline derivatives |
| US7750160B2 (en) * | 2003-11-13 | 2010-07-06 | Ambit Biosciences Corporation | Isoxazolyl urea derivatives as kinase modulators |
| JP2007537717A (ja) * | 2004-01-07 | 2007-12-27 | ブリストル−マイヤーズ スクイブ カンパニー | 上皮増殖因子受容体モデュレーターに対する感受性を決定するためのバイオマーカーおよび方法 |
| BRPI0400869B8 (pt) | 2004-03-02 | 2021-05-25 | Univ Estadual Campinas Unicamp | novos compostos derivados de 4-anilinoquinazolinas com propriedade inibidora de adenosinacinases |
| EP1713781B1 (en) | 2004-02-03 | 2008-11-05 | AstraZeneca AB | Quinazoline derivatives |
| JP4934432B2 (ja) | 2004-02-19 | 2012-05-16 | レクサン ファーマシューティカルズ インコーポレイテッド | キナゾリン誘導体およびキナゾリン誘導体の治療への使用 |
| RU2402569C2 (ru) * | 2004-03-19 | 2010-10-27 | Имклоун Элэлси | Человеческие антитела к рецептору эпидермального фактора роста |
| DK2439285T3 (da) | 2004-03-31 | 2019-07-29 | Massachusetts Gen Hospital | Fremgangsmåde til at bestemme reaktivitet af cancer på behandlinger målrettet mod epidermal vækstfaktor-receptor |
| ME02125B (me) | 2004-04-07 | 2013-04-30 | Novartis Ag | Inhibitori protein apoptoze (iap) |
| EP1746999B1 (en) | 2004-05-06 | 2011-11-16 | Warner-Lambert Company LLC | 4-phenylamino-quinazolin-6-yl-amides |
| US8080577B2 (en) | 2004-05-06 | 2011-12-20 | Bioresponse, L.L.C. | Diindolylmethane formulations for the treatment of leiomyomas |
| WO2005120557A2 (en) * | 2004-05-13 | 2005-12-22 | Imclone Systems Incorporated | Inhibition of macrophage-stimulating protein receptor (ron) |
| JP2008504292A (ja) | 2004-06-24 | 2008-02-14 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス, インコーポレイテッド | 免疫増強用の化合物 |
| GB0512324D0 (en) | 2005-06-16 | 2005-07-27 | Novartis Ag | Organic compounds |
| US8153643B2 (en) | 2004-10-12 | 2012-04-10 | Astrazeneca Ab | Quinazoline derivatives |
| DE602005026865D1 (de) | 2004-12-14 | 2011-04-21 | Astrazeneca Ab | Pyrazolopyrimidinverbindungen als antitumormittel |
| CA2593084C (en) | 2004-12-30 | 2014-03-18 | Bioresponse, Llc | Use of diindolylmethane-related indoles for the treatment and prevention of respiratory syncytial virus associated conditions |
| US20090155247A1 (en) * | 2005-02-18 | 2009-06-18 | Ashkenazi Avi J | Methods of Using Death Receptor Agonists and EGFR Inhibitors |
| US20060188498A1 (en) * | 2005-02-18 | 2006-08-24 | Genentech, Inc. | Methods of using death receptor agonists and EGFR inhibitors |
| CN101163684B (zh) | 2005-02-23 | 2012-08-29 | 盐野义制药株式会社 | 具有酪氨酸激酶抑制作用的喹唑啉衍生物 |
| ATE521603T1 (de) | 2005-02-26 | 2011-09-15 | Astrazeneca Ab | Chinazolinderivate als tyrosinkinaseinhibitoren |
| EP1863792B1 (en) * | 2005-03-28 | 2009-01-21 | Brystol-Myers Squibb Company | Atp competitive kinase inhibitors |
| WO2006110811A1 (en) * | 2005-04-12 | 2006-10-19 | Elan Pharma International Limited | Nanoparticulate quinazoline derivative formulations |
| GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| CN101287761A (zh) | 2005-06-15 | 2008-10-15 | 先灵公司 | 抗-igf1r抗体制剂 |
| CN101500597A (zh) | 2005-06-17 | 2009-08-05 | 伊姆克罗尼系统公司 | 治疗转移性骨癌的受体拮抗剂 |
| EP1917528B1 (en) * | 2005-08-24 | 2011-08-17 | Bristol-Myers Squibb Company | Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators |
| WO2007029251A2 (en) * | 2005-09-06 | 2007-03-15 | T.K. Signal Ltd. | Polyalkylene glycol derivatives of 4- (phenylamino)quinazolines useful as irreversible inhibitors of epidermal gr0wth fact0r receptor tyrosine kinase |
| EP1928861B1 (en) | 2005-09-20 | 2010-11-17 | AstraZeneca AB | 4- (ih-indazol-5-yl-amino)-quinazoline compounds as erbb receptor tyrosine kinase inhibitors for the treatment of cancer |
| AU2006201635A1 (en) * | 2005-10-20 | 2007-05-10 | Ludwig Institute For Cancer Research | Novel inhibitors and methods for their preparation |
| JP5688877B2 (ja) | 2005-11-11 | 2015-03-25 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 癌疾患の治療用キナゾリン誘導体 |
| EP2275103B1 (en) | 2005-11-21 | 2014-04-23 | Novartis AG | mTOR inhibitors in the treatment of endocrine tumors |
| BRPI0620462A2 (pt) * | 2005-12-22 | 2011-11-16 | Astrazeneca Ab | composto, processo para preparar um composto, composição farmacêutica, uso de um composto, e,métodos para produzir um efeito inibidor de b-raf e um efeito anti-cáncer em um animal de sangue quente, e para tratar uma doença |
| CN101003514A (zh) | 2006-01-20 | 2007-07-25 | 上海艾力斯医药科技有限公司 | 喹唑啉衍生物、其制备方法及用途 |
| JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
| KR101353706B1 (ko) | 2006-02-03 | 2014-02-18 | 유니버시티 오브 워싱톤 | 전립선 암 치료용 보강제로서의 ⅰgf-ⅰr 길항제 |
| PE20070978A1 (es) * | 2006-02-14 | 2007-11-15 | Novartis Ag | COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASAS (PI3Ks) |
| TWI404709B (zh) * | 2006-02-21 | 2013-08-11 | Eisai R&D Man Co Ltd | 4- (3-benzamidophenyl) -6,7-dimethoxy-2-methylamine quinazoline derivatives |
| UY30183A1 (es) | 2006-03-02 | 2007-10-31 | Astrazeneca Ab | Derivados de quinolina |
| EP1994024A2 (en) * | 2006-03-02 | 2008-11-26 | AstraZeneca AB | Quinoline derivatives |
| GB0605120D0 (en) | 2006-03-14 | 2006-04-26 | Novartis Ag | Organic Compounds |
| US20070231298A1 (en) * | 2006-03-31 | 2007-10-04 | Cell Genesys, Inc. | Cytokine-expressing cancer immunotherapy combinations |
| CN102671196B (zh) | 2006-04-05 | 2014-12-03 | 诺华股份有限公司 | 用于治疗癌症的治疗剂的组合 |
| AU2007234382B2 (en) | 2006-04-05 | 2011-06-09 | Novartis Ag | Combinations comprising BCR-ABL/C-KIT/PDGF-R TK inhibitors for treating cancer |
| TW200808739A (en) * | 2006-04-06 | 2008-02-16 | Novartis Vaccines & Diagnostic | Quinazolines for PDK1 inhibition |
| BRPI0710510A2 (pt) | 2006-04-19 | 2011-08-16 | Novartis Ag | compostos indazol e processos para inibição de cdc7 |
| EA200802058A1 (ru) | 2006-05-09 | 2009-06-30 | Пфайзер Продактс Инк. | Производные циклоалкиламинокислот и их фармацевтические композиции |
| NZ572299A (en) | 2006-05-09 | 2010-07-30 | Novartis Ag | Combination comprising a substituted 3,5-diphenyl-1,2,4-triazole and a platinum compound and use thereof |
| JP5399900B2 (ja) | 2006-06-30 | 2014-01-29 | メルク・シャープ・アンド・ドーム・コーポレーション | Igfbp2インヒビター |
| CN101100466B (zh) | 2006-07-05 | 2013-12-25 | 天津和美生物技术有限公司 | 不可逆蛋白质酪氨酸磷酰化酶抑制剂及其制备和应用 |
| EP2061469B8 (en) * | 2006-09-11 | 2014-02-26 | Curis, Inc. | Quinazoline based egfr inhibitors |
| US7547781B2 (en) * | 2006-09-11 | 2009-06-16 | Curis, Inc. | Quinazoline based EGFR inhibitors containing a zinc binding moiety |
| EP2061772A4 (en) * | 2006-09-11 | 2011-06-29 | Curis Inc | MULTIFUNCTIONAL SMALL MOLECULES AS PROLIFERATION-ACTIVE ACTIVE SUBSTANCES |
| US8604044B2 (en) * | 2006-09-11 | 2013-12-10 | Curis, Inc. | Quinazoline based EGFR inhibitors containing a zinc binding moiety |
| EP2845912A1 (en) | 2006-09-12 | 2015-03-11 | Genentech, Inc. | Methods and compositions for the diagnosis and treatment of lung cancer using KIT gene as genetic marker |
| CA2663599A1 (en) | 2006-09-18 | 2008-03-27 | Boehringer Ingelheim International Gmbh | Method for treating cancer harboring egfr mutations |
| JP2010504974A (ja) * | 2006-09-28 | 2010-02-18 | フォリカ,インコーポレーテッド | 新しい毛嚢を生成させ毛髪を成長させる方法、キット、及び組成物 |
| AU2007302263A1 (en) | 2006-09-29 | 2008-04-03 | Novartis Ag | Pyrazolopyrimidines as P13K lipid kinase inhibitors |
| JO3598B1 (ar) | 2006-10-10 | 2020-07-05 | Infinity Discovery Inc | الاحماض والاسترات البورونية كمثبطات اميد هيدروليز الحامض الدهني |
| BRPI0717753B1 (pt) | 2006-10-27 | 2022-04-12 | Bioresponse, Llc | Uso de uma composição compreendendo 50-250 mg de um ou mais indóis relacionados com dim e um ou mais agentes anti-protozoários, e, composição |
| EP1921070A1 (de) | 2006-11-10 | 2008-05-14 | Boehringer Ingelheim Pharma GmbH & Co. KG | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung |
| CN104013956B (zh) | 2007-01-25 | 2018-12-18 | 达娜-法勃肿瘤研究所公司 | 抗egfr抗体在治疗egfr突变体介导的疾病中的用途 |
| AU2008212999A1 (en) | 2007-02-06 | 2008-08-14 | Boehringer Ingelheim International Gmbh | Bicyclic heterocycles, drugs containing said compounds, use thereof, and method for production thereof |
| CN101245050A (zh) | 2007-02-14 | 2008-08-20 | 上海艾力斯医药科技有限公司 | 4-苯胺喹唑啉衍生物的盐 |
| EP2120900A2 (en) | 2007-02-15 | 2009-11-25 | Novartis AG | Combination of lbh589 with other therapeutic agents for treating cancer |
| CA2680854C (en) | 2007-03-15 | 2017-02-14 | Ludwig Institute For Cancer Research | Treatment method using egfr antibodies and src inhibitors and related formulations |
| CA2684470C (en) * | 2007-04-16 | 2016-02-09 | Hutchison Medipharma Enterprises Limited | Pyrimidine derivatives |
| JP4782239B2 (ja) | 2007-04-18 | 2011-09-28 | ファイザー・プロダクツ・インク | 異常細胞増殖治療のためのスルホニルアミド誘導体 |
| US8003787B2 (en) * | 2007-05-24 | 2011-08-23 | Bayer Schering Pharma Ag | Sulphoximine-substituted quinoline and quinazoline derivatives as kinase inhibitors |
| CN108424454B (zh) * | 2007-08-14 | 2022-05-31 | 路德维格癌症研究所有限公司 | 靶向egf受体的单克隆抗体175及其衍生物和用途 |
| US8119616B2 (en) * | 2007-09-10 | 2012-02-21 | Curis, Inc. | Formulation of quinazoline based EGFR inhibitors containing a zinc binding moiety |
| WO2009035718A1 (en) | 2007-09-10 | 2009-03-19 | Curis, Inc. | Tartrate salts or complexes of quinazoline based egfr inhibitors containing a zinc binding moiety |
| MX2010004259A (es) * | 2007-10-19 | 2010-08-31 | Pharma Mar Sa | Tratamientos antitumorales mejorados. |
| RU2010120674A (ru) * | 2007-10-22 | 2011-11-27 | Шеринг Корпорейшн (US) | Полностью человеческие анти-vegf-антитела и способы их применения |
| EA018716B1 (ru) * | 2007-10-29 | 2013-10-30 | Натко Фарма Лимитед | Новые 4-(тетразол-5-ил) хиназолиновые производные в качестве противораковых средств |
| CN101909630A (zh) | 2007-11-02 | 2010-12-08 | 新加坡科技研究局 | 预防和治疗肿瘤的方法和化合物 |
| EP2060565A1 (en) | 2007-11-16 | 2009-05-20 | 4Sc Ag | Novel bifunctional compounds which inhibit protein kinases and histone deacetylases |
| WO2009067543A2 (en) * | 2007-11-19 | 2009-05-28 | The Regents Of The University Of Colorado | Treatment of histone deacetylase mediated disorders |
| WO2009067242A2 (en) * | 2007-11-20 | 2009-05-28 | Imclone Llc | Co-crystal of antibody 11f8 fab fragment and egfr extracellular domain and uses thereof |
| CL2008003449A1 (es) * | 2007-11-21 | 2010-02-19 | Imclone Llc | Anticuerpo o fragmentos del mismo contra el receptor de proteína estimulante de macrófagos/ron; composición farmacéutica que lo comprende; uso para inhibir angiogénesis, crecimiento tumoral, proliferación, migración e invasión de células tumorales, activación de ron o fosforilación de mapk y/o akt; y uso para tratar cáncer. |
| US8940771B2 (en) | 2007-12-20 | 2015-01-27 | Novartis Ag | Organic compounds |
| EP2072502A1 (de) * | 2007-12-20 | 2009-06-24 | Bayer Schering Pharma Aktiengesellschaft | Sulfoximid-substituierte Chinolin- und Chinazolinderivate als Kinase-Inhibitoren |
| DK3012251T3 (en) | 2008-01-18 | 2017-10-09 | Natco Pharma Ltd | PROCEDURE FOR PREPARATION 6,7-DIALCOXY-QUINAZOLINE DERIVATIVES |
| EP2252315A1 (en) * | 2008-01-30 | 2010-11-24 | Pharma Mar, S.A. | Improved antitumoral treatments |
| TWI472339B (zh) | 2008-01-30 | 2015-02-11 | Genentech Inc | 包含結合至her2結構域ii之抗體及其酸性變異體的組合物 |
| EP2245026B1 (de) | 2008-02-07 | 2012-08-01 | Boehringer Ingelheim International GmbH | Spirocyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung |
| DE102008009609A1 (de) | 2008-02-18 | 2009-08-20 | Freie Universität Berlin | Substituierte 4-(Indol-3-yl)chinazoline und deren Verwendung und Herstellung |
| PL2259800T3 (pl) * | 2008-03-05 | 2014-09-30 | Novartis Ag | Zastosowanie 5-(2,6-dimorfolin-4-ylopirymidyn-4-ylo)-4-trifluorometylopirydyn-2-yloaminy do leczenia niedrobnokomórkowego raka płuca wykazującego nabytą oporność wobec modulatorów receptora dla naskórkowego czynnika wzrostu (EGFR) |
| JP2011513370A (ja) * | 2008-03-07 | 2011-04-28 | ファルマ・マール・ソシエダード・アノニマ | 改善された抗腫瘍治療法 |
| ES2524259T3 (es) | 2008-03-24 | 2014-12-04 | Novartis Ag | Inhibidores de metaloproteinasa de matriz a base de arilsulfonamida |
| PL2260020T3 (pl) | 2008-03-26 | 2015-01-30 | Novartis Ag | Hydroksamianowe inhibitory deacetylaz B |
| TW201000107A (en) * | 2008-04-09 | 2010-01-01 | Infinity Pharmaceuticals Inc | Inhibitors of fatty acid amide hydrolase |
| US7829574B2 (en) * | 2008-05-09 | 2010-11-09 | Hutchison Medipharma Enterprises Limited | Substituted quinazoline compounds and their use in treating angiogenesis-related diseases |
| AU2009247782C1 (en) | 2008-05-13 | 2013-09-19 | Astrazeneca Ab | Fumarate salt of 4- (3-chloro-2-fluoroanilino) -7-methoxy-6- { [1- (N-methylcarbamoylmethyl) piperidin- 4-yl] oxy } quinazoline |
| CN101584696A (zh) * | 2008-05-21 | 2009-11-25 | 上海艾力斯医药科技有限公司 | 包含喹唑啉衍生物的组合物及制备方法、用途 |
| US8426430B2 (en) * | 2008-06-30 | 2013-04-23 | Hutchison Medipharma Enterprises Limited | Quinazoline derivatives |
| CA2733153C (en) | 2008-08-08 | 2016-11-08 | Boehringer Ingelheim International Gmbh | Cyclohexyloxy substituted heterocycles, pharmaceutical compositions containing these compounds and processes for preparing them |
| TW201008933A (en) * | 2008-08-29 | 2010-03-01 | Hutchison Medipharma Entpr Ltd | Pyrimidine compounds |
| EP2344161B1 (en) | 2008-10-16 | 2018-12-19 | Celator Pharmaceuticals, Inc. | Combinations of a liposomal water-soluble camptothecin with cetuximab or bevacizumab |
| MX2011004824A (es) | 2008-11-07 | 2012-01-12 | Triact Therapeutics Inc | Uso de derivados de butano catecólico en terapia contra el cáncer. |
| US20100222371A1 (en) * | 2008-11-20 | 2010-09-02 | Children's Medical Center Corporation | Prevention of surgical adhesions |
| WO2010080455A1 (en) | 2008-12-18 | 2010-07-15 | Novartis Ag | New salts |
| JP2012512884A (ja) | 2008-12-18 | 2012-06-07 | ノバルティス アーゲー | 1−(4−{1−[(e)−4−シクロヘキシル−3−トリフルオロメチル−ベンジルオキシイミノ]−エチル}−2−エチル−ベンジル)−アゼチジン−3−カルボン酸の新規の多形相 |
| PL2379497T3 (pl) | 2008-12-18 | 2014-01-31 | Novartis Ag | Sól hemifumaranowa kwasu 1-[4[1-(4-cykloheksylo-3trifluorometylobenzyloksyimino)etylo]2-etylobenzylo]-azetydyno-3-karboksylowego |
| WO2010083617A1 (en) | 2009-01-21 | 2010-07-29 | Oncalis Ag | Pyrazolopyrimidines as protein kinase inhibitors |
| SI2391366T1 (sl) | 2009-01-29 | 2013-01-31 | Novartis Ag | Substituirani benzimidazoli za zdravljenje astrocitomov |
| EP2400985A2 (en) | 2009-02-25 | 2012-01-04 | OSI Pharmaceuticals, LLC | Combination of an either an anti-igf-1r antibody or an igf binding protein and a small molecule igf-1r kinase inhibitor |
| JP2012519170A (ja) | 2009-02-26 | 2012-08-23 | オーエスアイ・ファーマシューティカルズ,エルエルシー | 生体内の腫瘍細胞のemtステータスをモニターするためのinsitu法 |
| WO2010099138A2 (en) | 2009-02-27 | 2010-09-02 | Osi Pharmaceuticals, Inc. | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
| EP2401614A1 (en) | 2009-02-27 | 2012-01-04 | OSI Pharmaceuticals, LLC | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
| WO2010099364A2 (en) | 2009-02-27 | 2010-09-02 | Osi Pharmaceuticals, Inc. | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
| US20120064072A1 (en) | 2009-03-18 | 2012-03-15 | Maryland Franklin | Combination Cancer Therapy Comprising Administration of an EGFR Inhibitor and an IGF-1R Inhibitor |
| NZ594665A (en) | 2009-03-20 | 2013-08-30 | Genentech Inc | Bispecific anti-her antibodies |
| US8546564B2 (en) | 2009-04-07 | 2013-10-01 | Infinity Pharmaceuticals, Inc. | Inhibitors of fatty acid amide hydrolase |
| EP2417115A4 (en) | 2009-04-07 | 2012-10-31 | Infinity Pharmaceuticals Inc | FATTY ACID AMIDE HYDROLASE INHIBITORS |
| WO2010149755A1 (en) | 2009-06-26 | 2010-12-29 | Novartis Ag | 1, 3-disubstituted imidazolidin-2-one derivatives as inhibitors of cyp 17 |
| US8293753B2 (en) | 2009-07-02 | 2012-10-23 | Novartis Ag | Substituted 2-carboxamide cycloamino ureas |
| JP5963672B2 (ja) | 2009-07-06 | 2016-08-03 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Bibw2992、その塩及びこの活性成分を含む固体医薬製剤の乾燥方法 |
| US9050341B2 (en) | 2009-07-14 | 2015-06-09 | Natco Pharma Limited | Methods of treating drug resistant and other tumors by administering 6,7-dialkoxy quinazoline derivatives |
| US8389526B2 (en) | 2009-08-07 | 2013-03-05 | Novartis Ag | 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives |
| KR20120089643A (ko) | 2009-08-12 | 2012-08-13 | 노파르티스 아게 | 헤테로시클릭 히드라존 화합물, 및 암 및 염증을 치료하기 위한 그의 용도 |
| US9085560B2 (en) | 2009-08-17 | 2015-07-21 | Intellikine, Inc. | Heterocyclic compounds and uses thereof |
| JP5775871B2 (ja) | 2009-08-20 | 2015-09-09 | ノバルティス アーゲー | ヘテロ環式オキシム化合物 |
| MX2012002420A (es) | 2009-08-26 | 2012-06-27 | Novartis Ag | Compuestos de heteroarilo tetra-sustituidos y su uso como moduladores de mdm2 y/o mdm4. |
| EP2473500A2 (en) | 2009-09-01 | 2012-07-11 | Pfizer Inc. | Benzimidazole derivatives |
| EP3575288B1 (en) | 2009-09-03 | 2021-10-27 | Bristol-Myers Squibb Company | Quinazolines as potassium ion channel inhibitors |
| JP2013504543A (ja) | 2009-09-10 | 2013-02-07 | ノバルティス アーゲー | 二環ヘテロアリール類のエーテル誘導体 |
| US20110076232A1 (en) | 2009-09-29 | 2011-03-31 | Ludwig Institute For Cancer Research | Specific binding proteins and uses thereof |
| EA020151B1 (ru) | 2009-10-23 | 2014-09-30 | Эли Лилли Энд Компани | Ингибиторы akt и фармацевтические составы, их содержащие |
| US20120220594A1 (en) | 2009-10-30 | 2012-08-30 | Bristol-Meyers Squibb Company | Methods for treating cancer in patients having igf-1r inhibitor resistance |
| NZ599565A (en) | 2009-11-04 | 2013-05-31 | Novartis Ag | Heterocyclic sulfonamide derivatives useful as mek inhibitors |
| EP2498817A2 (en) | 2009-11-12 | 2012-09-19 | F. Hoffmann-La Roche AG | A method of promoting dendritic spine density |
| CA2780875A1 (en) | 2009-11-13 | 2011-05-19 | Pangaea Biotech, S.L. | Molecular biomarkers for predicting response to tyrosine kinase inhibitors in lung cancer |
| US20110130711A1 (en) * | 2009-11-19 | 2011-06-02 | Follica, Inc. | Hair growth treatment |
| CA2781669A1 (en) | 2009-11-23 | 2011-05-26 | Cerulean Pharma Inc. | Cyclodextrin-based polymers for therapeutic delivery |
| US20120289501A1 (en) | 2009-11-25 | 2012-11-15 | Novartis Ag | Benzene-fused 6-membered oxygen-containing heterocyclic derivatives of bicyclic heteroaryls |
| EA201200823A1 (ru) | 2009-12-08 | 2013-02-28 | Новартис Аг | Гетероциклические производные сульфонамидов |
| US8440693B2 (en) | 2009-12-22 | 2013-05-14 | Novartis Ag | Substituted isoquinolinones and quinazolinones |
| CU24130B1 (es) | 2009-12-22 | 2015-09-29 | Novartis Ag | Isoquinolinonas y quinazolinonas sustituidas |
| EP2523957A1 (en) | 2010-01-12 | 2012-11-21 | F. Hoffmann-La Roche AG | Tricyclic heterocyclic compounds, compositions and methods of use thereof |
| US20110178287A1 (en) | 2010-01-19 | 2011-07-21 | Cerulean Pharma Inc. | Cyclodextrin-based polymers for therapeutic delivery |
| CA2788587C (en) | 2010-02-03 | 2020-03-10 | Infinity Pharmaceuticals, Inc. | Fatty acid amide hydrolase inhibitors |
| ES2519348T3 (es) | 2010-02-18 | 2014-11-06 | Genentech, Inc. | Antagonistas de neurregulina y uso de los mismos en el tratamiento del cáncer |
| CN102803227B (zh) | 2010-03-16 | 2016-01-20 | 默克专利有限公司 | 吗啉基喹唑啉 |
| RU2012141536A (ru) | 2010-03-17 | 2014-04-27 | Ф. Хоффманн-Ля Рош Аг | Имидазопиридины, композиции и способы применения |
| US20110237686A1 (en) | 2010-03-26 | 2011-09-29 | Cerulean Pharma Inc | Formulations and methods of use |
| TWI406853B (zh) * | 2010-04-07 | 2013-09-01 | Dev Center Biotechnology | Egfr與vegfr-2雙重抑制劑及其用途與製法 |
| CN103038643A (zh) | 2010-04-16 | 2013-04-10 | 基因泰克公司 | 作为pi3k/akt激酶途径抑制剂效能的预测性生物标记的foxo3a |
| US20130085161A1 (en) | 2010-06-17 | 2013-04-04 | Novartis Ag | Piperidinyl substituted 1,3-dihydro-benzoimidazol-2-ylideneamine derivatives |
| WO2011157787A1 (en) | 2010-06-17 | 2011-12-22 | Novartis Ag | Biphenyl substituted 1,3-dihydro-benzoimidazol-2-ylideneamine derivatives |
| UA112517C2 (uk) | 2010-07-06 | 2016-09-26 | Новартіс Аг | Тетрагідропіридопіримідинові похідні |
| AR082418A1 (es) | 2010-08-02 | 2012-12-05 | Novartis Ag | Formas cristalinas de 1-(4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il)-amida de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico |
| BR112013004673A8 (pt) | 2010-08-31 | 2018-01-02 | Genentech Inc | biomarcadores e métodos de tratamento. |
| CN103209695A (zh) | 2010-09-15 | 2013-07-17 | 弗·哈夫曼-拉罗切有限公司 | 氮杂苯并噻唑化合物、组合物及应用方法 |
| CN103108871B (zh) | 2010-09-16 | 2014-09-10 | 诺华股份有限公司 | 17α-羟化酶/C17,20-裂合酶抑制剂 |
| WO2012052948A1 (en) | 2010-10-20 | 2012-04-26 | Pfizer Inc. | Pyridine- 2- derivatives as smoothened receptor modulators |
| KR20140009259A (ko) | 2010-11-19 | 2014-01-22 | 에프. 호프만-라 로슈 아게 | 피라졸로피리딘 및 tyk2 억제제로서 이의 용도 |
| MX2013007336A (es) | 2010-12-21 | 2013-08-01 | Novartis Ag | Compuestos de bi-heteroarilo como inhibidores de vps34. |
| EP2468883A1 (en) | 2010-12-22 | 2012-06-27 | Pangaea Biotech S.L. | Molecular biomarkers for predicting response to tyrosine kinase inhibitors in lung cancer |
| WO2012085176A1 (en) | 2010-12-23 | 2012-06-28 | F. Hoffmann-La Roche Ag | Tricyclic pyrazinone compounds, compositions and methods of use thereof as janus kinase inhibitors |
| US9134297B2 (en) | 2011-01-11 | 2015-09-15 | Icahn School Of Medicine At Mount Sinai | Method and compositions for treating cancer and related methods |
| EP2670753B1 (en) | 2011-01-31 | 2016-10-19 | Novartis AG | Novel heterocyclic derivatives |
| EP2673277A1 (en) | 2011-02-10 | 2013-12-18 | Novartis AG | [1, 2, 4]triazolo [4, 3 -b]pyridazine compounds as inhibitors of the c-met tyrosine kinase |
| JP5808826B2 (ja) | 2011-02-23 | 2015-11-10 | インテリカイン, エルエルシー | 複素環化合物およびその使用 |
| EP2492688A1 (en) | 2011-02-23 | 2012-08-29 | Pangaea Biotech, S.A. | Molecular biomarkers for predicting response to antitumor treatment in lung cancer |
| EA023998B1 (ru) | 2011-03-04 | 2016-08-31 | Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед | Аминохинолины в качестве ингибиторов киназ |
| EP2680850B1 (en) | 2011-03-04 | 2018-05-23 | Newgen Therapeutics, Inc. | Alkyne substituted quinazoline compound and methods of use |
| US20130338152A1 (en) | 2011-03-08 | 2013-12-19 | Irm Llc | Fluorophenyl bicyclic heteroaryl compounds |
| US9321759B2 (en) | 2011-03-17 | 2016-04-26 | The Trustees Of The University Of Pennsylvania | Methods and use of bifunctional enzyme-building clamp-shaped molecules |
| WO2012125904A1 (en) | 2011-03-17 | 2012-09-20 | The Trustees Of The University Of Pennsylvania | Mutation mimicking compounds that bind to the kinase domain of egfr |
| WO2012129145A1 (en) | 2011-03-18 | 2012-09-27 | OSI Pharmaceuticals, LLC | Nscle combination therapy |
| JP2014519813A (ja) | 2011-04-25 | 2014-08-21 | オーエスアイ・ファーマシューティカルズ,エルエルシー | 癌薬剤発見、診断、および治療におけるemt遺伝子シグネチャーの使用 |
| GB201106870D0 (en) | 2011-04-26 | 2011-06-01 | Univ Belfast | Marker |
| EA023064B1 (ru) | 2011-04-28 | 2016-04-29 | Новартис Аг | ИНГИБИТОРЫ 17α-ГИДРОКСИЛАЗЫ/C-ЛИАЗЫ |
| WO2012155339A1 (zh) | 2011-05-17 | 2012-11-22 | 江苏康缘药业股份有限公司 | 4-苯胺-6-丁烯酰胺-7-烷醚喹唑啉衍生物及其制备方法和用途 |
| MX2013014398A (es) | 2011-06-09 | 2014-03-21 | Novartis Ag | Derivados de sulfonamida heterociclicos. |
| US8859535B2 (en) | 2011-06-20 | 2014-10-14 | Novartis Ag | Hydroxy substituted isoquinolinone derivatives |
| EP2721007B1 (en) | 2011-06-20 | 2015-04-29 | Novartis AG | Cyclohexyl isoquinolinone compounds |
| EP2723740A1 (en) | 2011-06-27 | 2014-04-30 | Novartis AG | Solid forms and salts of tetrahydro-pyrido-pyrimidine derivatives |
| WO2013007765A1 (en) | 2011-07-13 | 2013-01-17 | F. Hoffmann-La Roche Ag | Fused tricyclic compounds for use as inhibitors of janus kinases |
| WO2013007768A1 (en) | 2011-07-13 | 2013-01-17 | F. Hoffmann-La Roche Ag | Tricyclic heterocyclic compounds, compositions and methods of use thereof as jak inhibitors |
| JP5855253B2 (ja) | 2011-08-12 | 2016-02-09 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | インダゾール化合物、組成物及び使用方法 |
| WO2013025853A1 (en) | 2011-08-17 | 2013-02-21 | Genentech, Inc. | Neuregulin antibodies and uses thereof |
| EP2758043A4 (en) | 2011-08-17 | 2016-02-24 | Dennis M Brown | COMPOSITIONS AND METHODS FOR INCREASING THE THERAPEUTIC UTILITY OF SUBOPTIMALLY APPLIED CHEMICAL COMPOUNDS INCLUDING SUBSTITUTED HEXITOLS SUCH AS DIBROMODULCITOL |
| TWI547494B (zh) | 2011-08-18 | 2016-09-01 | 葛蘭素史克智慧財產發展有限公司 | 作為激酶抑制劑之胺基喹唑啉類 |
| CA2845179A1 (en) | 2011-08-31 | 2013-03-07 | Genentech, Inc. | Diagnostic markers |
| US9062045B2 (en) | 2011-09-15 | 2015-06-23 | Novartis Ag | Triazolopyridine compounds |
| WO2013041539A1 (en) | 2011-09-20 | 2013-03-28 | F. Hoffmann-La Roche Ag | Imidazopyridine compounds, compositions and methods of use |
| KR20140059246A (ko) | 2011-09-22 | 2014-05-15 | 화이자 인코포레이티드 | 피롤로피리미딘 및 퓨린 유도체 |
| EP2761025A1 (en) | 2011-09-30 | 2014-08-06 | Genentech, Inc. | Diagnostic methylation markers of epithelial or mesenchymal phenotype and response to egfr kinase inhibitor in tumours or tumour cells |
| US20140309229A1 (en) | 2011-10-13 | 2014-10-16 | Bristol-Myers Squibb Company | Methods for selecting and treating cancer in patients with igf-1r/ir inhibitors |
| PH12014500912A1 (en) | 2011-10-28 | 2014-06-09 | Novartis Ag | Novel purine derivatives and their use in the treatment of disease |
| EP2785717B1 (en) | 2011-11-29 | 2016-01-13 | Novartis AG | Pyrazolopyrrolidine compounds |
| CA2857114A1 (en) | 2011-11-30 | 2013-06-06 | Genentech, Inc. | Erbb3 mutations in cancer |
| US9408885B2 (en) | 2011-12-01 | 2016-08-09 | Vib Vzw | Combinations of therapeutic agents for treating melanoma |
| US9546179B2 (en) | 2011-12-20 | 2017-01-17 | Wei Qian | Heterocycle amido alkyloxy substituted quinazoline derivative and use thereof |
| WO2013093850A1 (en) | 2011-12-22 | 2013-06-27 | Novartis Ag | Quinoline derivatives |
| CA2859764C (en) | 2011-12-22 | 2019-12-31 | Novartis Ag | Dihydro-benzo-oxazine and dihydro-pyrido-oxazine derivatives |
| US20130178520A1 (en) | 2011-12-23 | 2013-07-11 | Duke University | Methods of treatment using arylcyclopropylamine compounds |
| MX2014007731A (es) | 2011-12-23 | 2015-01-12 | Novartis Ag | Compuestos para inhibir la interaccion de bcl2 con los componentes de enlace. |
| MX2014007729A (es) | 2011-12-23 | 2015-01-12 | Novartis Ag | Compuestos para inhibir la interaccion de bcl2 con los componentes de enlace. |
| EA201491259A1 (ru) | 2011-12-23 | 2014-11-28 | Новартис Аг | Соединения и композиции для ингибирования взаимодействия bcl2 с партнерами связывания |
| US9126979B2 (en) | 2011-12-23 | 2015-09-08 | Novartis Ag | Compounds for inhibiting the interaction of BCL2 with binding partners |
| EA201491265A1 (ru) | 2011-12-23 | 2014-11-28 | Новартис Аг | Соединения для ингибирования взаимодействия bcl-2 с партнерами по связыванию |
| US8815926B2 (en) | 2012-01-26 | 2014-08-26 | Novartis Ag | Substituted pyrrolo[3,4-D]imidazoles for the treatment of MDM2/4 mediated diseases |
| WO2013143057A1 (zh) | 2012-03-26 | 2013-10-03 | 中国科学院福建物质结构研究所 | 喹唑啉衍生物及用途 |
| EP2831115A1 (en) | 2012-03-27 | 2015-02-04 | F. Hoffmann-La Roche AG | Diagnosis and treatments relating to her3 inhibitors |
| ES2894830T3 (es) | 2012-04-03 | 2022-02-16 | Novartis Ag | Productos combinados con inhibidores de tirosina·cinasa y su uso |
| WO2013152252A1 (en) | 2012-04-06 | 2013-10-10 | OSI Pharmaceuticals, LLC | Combination anti-cancer therapy |
| CN103373966A (zh) * | 2012-04-17 | 2013-10-30 | 南京大学 | 一类4-苯胺喹唑啉类酰胺衍生物及其制备方法与用途 |
| SG10201608469RA (en) | 2012-05-16 | 2016-11-29 | Novartis Ag | Dosage regimen for a pi-3 kinase inhibitor |
| US9365576B2 (en) | 2012-05-24 | 2016-06-14 | Novartis Ag | Pyrrolopyrrolidinone compounds |
| AU2013274101B2 (en) | 2012-06-15 | 2017-09-07 | The Brigham And Women's Hospital, Inc. | Compositions for treating cancer and methods for making the same |
| WO2013190089A1 (en) | 2012-06-21 | 2013-12-27 | Pangaea Biotech, S.L. | Molecular biomarkers for predicting outcome in lung cancer |
| WO2014025395A1 (en) | 2012-08-06 | 2014-02-13 | Duke University | Compounds and methods for targeting hsp90 |
| US9637523B2 (en) | 2012-08-31 | 2017-05-02 | Westfaelische Wilhelms-Universitaet Muenster | Methods and peptides for preventing and treating a BCR-ABL and a C-ABL associated disease |
| AR092530A1 (es) | 2012-09-13 | 2015-04-22 | Glaxosmithkline Llc | Compuesto de amino-quinolina, composicion farmaceutica que lo comprende y uso de dicho compuesto para la preparacion de un medicamento |
| TWI592417B (zh) | 2012-09-13 | 2017-07-21 | 葛蘭素史克智慧財產發展有限公司 | 胺基喹唑啉激酶抑制劑之前藥 |
| EP2914278B1 (en) | 2012-11-05 | 2021-06-02 | Dana-Farber Cancer Institute, Inc. | Xbp1, cd138, and cs1 peptides, pharmaceutical compositions that include the peptides, and methods of using such peptides and compositions |
| TW201422625A (zh) | 2012-11-26 | 2014-06-16 | Novartis Ag | 二氫-吡啶并-□衍生物之固體形式 |
| US9556180B2 (en) | 2013-01-22 | 2017-01-31 | Novartis Ag | Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the P53/MDM2 interaction |
| EP2948451B1 (en) | 2013-01-22 | 2017-07-12 | Novartis AG | Substituted purinone compounds |
| ES2790675T3 (es) | 2013-02-01 | 2020-10-28 | Wellstat Therapeutics Corp | Compuestos de amina que tienen actividad anti-inflamatoria, antifúngica, antiparasitaria y anticáncer |
| WO2014130657A1 (en) | 2013-02-20 | 2014-08-28 | The Trustees Of The University Of Pennsylvania | Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor |
| WO2014128612A1 (en) | 2013-02-20 | 2014-08-28 | Novartis Ag | Quinazolin-4-one derivatives |
| TWI630203B (zh) | 2013-02-21 | 2018-07-21 | 葛蘭素史克智慧財產發展有限公司 | 做為激酶抑制劑的喹唑啉類 |
| MX2015010791A (es) | 2013-02-22 | 2015-11-26 | Hoffmann La Roche | Metodos para tratar el cancer y prevenir la resistencia a farmacos. |
| US9834575B2 (en) | 2013-02-26 | 2017-12-05 | Triact Therapeutics, Inc. | Cancer therapy |
| US9468681B2 (en) | 2013-03-01 | 2016-10-18 | California Institute Of Technology | Targeted nanoparticles |
| MY186126A (en) | 2013-03-06 | 2021-06-24 | Astrazeneca Ab | Quinazoline inhibitors of activating mutant forms of epidermal growth factor receptor |
| CN105246511A (zh) | 2013-03-06 | 2016-01-13 | 豪夫迈·罗氏有限公司 | 治疗和预防癌症药物抗性的方法 |
| EP2970307B1 (en) | 2013-03-13 | 2020-03-11 | Genentech, Inc. | Pyrazolo compounds and uses thereof |
| SG11201507477XA (en) | 2013-03-14 | 2015-10-29 | Genentech Inc | Combinations of a mek inhibitor compound with an her3/egfr inhibitor compound and methods of use |
| HK1220916A1 (zh) | 2013-03-14 | 2017-05-19 | 基因泰克公司 | 治疗癌症和预防癌症药物抗性的方法 |
| WO2014151147A1 (en) | 2013-03-15 | 2014-09-25 | Intellikine, Llc | Combination of kinase inhibitors and uses thereof |
| KR20150130451A (ko) | 2013-03-15 | 2015-11-23 | 제넨테크, 인크. | 암 치료 방법 및 항암제 내성 예방을 위한 방법 |
| WO2014147246A1 (en) | 2013-03-21 | 2014-09-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method and pharmaceutical composition for use in the treatment of chronic liver diseases associated with a low hepcidin expression |
| WO2014147631A1 (en) | 2013-03-22 | 2014-09-25 | Natco Pharma Limited | Formulation comprising gefitinib as oral suspension |
| WO2014155268A2 (en) | 2013-03-25 | 2014-10-02 | Novartis Ag | Fgf-r tyrosine kinase activity inhibitors - use in diseases associated with lack of or reduced snf5 activity |
| ES2638317T3 (es) | 2013-04-04 | 2017-10-19 | Janssen Pharmaceutica Nv | Nuevos derivados de N-(2,3-dihidro-1H-pirrolo[2,3-b]piridin-5-il)-4-quinazolinamina y N-(2,3-dihidro-1H-indol-5-il)-4-quinazolinamina como inhibidores de PERK |
| CN103275019B (zh) * | 2013-04-26 | 2016-05-18 | 浙江工业大学 | 4-[3-氯-4-取代苯胺基]-6-取代甲氧基甲酰氨基喹唑啉类化合物及制备和应用 |
| CN103382182B (zh) * | 2013-05-17 | 2016-08-10 | 河北医科大学 | 苯基脲偶联喹唑啉类化合物及其制备方法、药物组合物及药物用途 |
| US20150018376A1 (en) | 2013-05-17 | 2015-01-15 | Novartis Ag | Pyrimidin-4-yl)oxy)-1h-indole-1-carboxamide derivatives and use thereof |
| CN103304491A (zh) * | 2013-06-17 | 2013-09-18 | 连云港盛和生物科技有限公司 | 一种吉非替尼的制备方法 |
| UY35675A (es) | 2013-07-24 | 2015-02-27 | Novartis Ag | Derivados sustituidos de quinazolin-4-ona |
| US9227969B2 (en) | 2013-08-14 | 2016-01-05 | Novartis Ag | Compounds and compositions as inhibitors of MEK |
| WO2015022663A1 (en) | 2013-08-14 | 2015-02-19 | Novartis Ag | Compounds and compositions as inhibitors of mek |
| WO2015022664A1 (en) | 2013-08-14 | 2015-02-19 | Novartis Ag | Compounds and compositions as inhibitors of mek |
| EP3041474B1 (en) | 2013-09-05 | 2020-03-18 | Genentech, Inc. | Antiproliferative compounds |
| EP3044593A4 (en) | 2013-09-09 | 2017-05-17 | Triact Therapeutics, Inc. | Cancer therapy |
| CN103483276B (zh) * | 2013-09-22 | 2018-04-17 | 南京恒道医药科技有限公司 | 一种凡德他尼杂质的制备方法 |
| RU2675105C9 (ru) | 2013-09-22 | 2019-01-09 | Саншайн Лейк Фарма Ко., Лтд. | Замещенные аминопиримидиновые соединения и способы их использования |
| WO2015049325A1 (en) | 2013-10-03 | 2015-04-09 | F. Hoffmann-La Roche Ag | Therapeutic inhibitors of cdk8 and uses thereof |
| EP3057615B1 (en) | 2013-10-18 | 2021-02-24 | F.Hoffmann-La Roche Ag | Anti-rspo antibodies and methods of use |
| UA115388C2 (uk) | 2013-11-21 | 2017-10-25 | Пфайзер Інк. | 2,6-заміщені пуринові похідні та їх застосування в лікуванні проліферативних захворювань |
| WO2015084804A1 (en) | 2013-12-03 | 2015-06-11 | Novartis Ag | Combination of mdm2 inhibitor and braf inhibitor and their use |
| PL3076969T3 (pl) | 2013-12-06 | 2022-01-17 | Novartis Ag | Schemat dawkowania selektywnego inhibitora 3-kinazy fosfatydynozytolu alfa-izoformy |
| JP6841656B2 (ja) | 2013-12-17 | 2021-03-10 | ジェネンテック, インコーポレイテッド | Pd−1軸結合アンタゴニスト及びタキサンを使用する癌の治療方法 |
| BR112016013963A2 (pt) | 2013-12-17 | 2017-10-10 | Genentech Inc | terapia de combinação compreendendo agonistas de ligação de ox40 e antagonistas de ligação do eixo de pd-1 |
| US9242965B2 (en) | 2013-12-31 | 2016-01-26 | Boehringer Ingelheim International Gmbh | Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors |
| EP3122900A1 (en) | 2014-03-24 | 2017-02-01 | F. Hoffmann-La Roche AG | Cancer treatment with c-met antagonists and correlation of the latter with hgf expression |
| WO2015148714A1 (en) | 2014-03-25 | 2015-10-01 | Duke University | Heat shock protein 70 (hsp-70) receptor ligands |
| MX370099B (es) | 2014-03-26 | 2019-12-02 | Astex Therapeutics Ltd | Combinación que comprende un inhibidor de fgfr y un inhibidor de cmet para el tratamiento del cáncer. |
| WO2015145388A2 (en) | 2014-03-27 | 2015-10-01 | Novartis Ag | Methods of treating colorectal cancers harboring upstream wnt pathway mutations |
| MX2016012574A (es) | 2014-03-28 | 2017-09-26 | Calitor Sciences Llc | Compuestos heteroarilo sustituidos y metodos de uso. |
| CA2943834A1 (en) | 2014-03-31 | 2015-10-08 | Genentech, Inc. | Combination therapy comprising anti-angiogenesis agents and ox40 binding agonists |
| HRP20192285T1 (hr) | 2014-03-31 | 2020-03-06 | F. Hoffmann - La Roche Ag | Anti-ox40 protutijela i postupci uporabe |
| US10426753B2 (en) | 2014-04-03 | 2019-10-01 | Invictus Oncology Pvt. Ltd. | Supramolecular combinatorial therapeutics |
| US20170027940A1 (en) | 2014-04-10 | 2017-02-02 | Stichting Het Nederlands Kanker Instituut | Method for treating cancer |
| WO2015155624A1 (en) | 2014-04-10 | 2015-10-15 | Pfizer Inc. | Dihydropyrrolopyrimidine derivatives |
| EA033919B1 (ru) | 2014-04-30 | 2019-12-10 | Пфайзер Инк. | Соединённые циклоалкилом дигетероциклические производные |
| US9388239B2 (en) | 2014-05-01 | 2016-07-12 | Consejo Nacional De Investigation Cientifica | Anti-human VEGF antibodies with unusually strong binding affinity to human VEGF-A and cross reactivity to human VEGF-B |
| WO2016001789A1 (en) | 2014-06-30 | 2016-01-07 | Pfizer Inc. | Pyrimidine derivatives as pi3k inhibitors for use in the treatment of cancer |
| WO2016011658A1 (en) | 2014-07-25 | 2016-01-28 | Novartis Ag | Combination therapy |
| KR20170036037A (ko) | 2014-07-31 | 2017-03-31 | 노파르티스 아게 | 조합 요법 |
| CN107074823B (zh) | 2014-09-05 | 2021-05-04 | 基因泰克公司 | 治疗性化合物及其用途 |
| EP3193866A1 (en) | 2014-09-19 | 2017-07-26 | Genentech, Inc. | Use of cbp/ep300 and bet inhibitors for treatment of cancer |
| JP6783230B2 (ja) | 2014-10-10 | 2020-11-11 | ジェネンテック, インコーポレイテッド | ヒストンデメチラーゼのインヒビターとしてのピロリドンアミド化合物 |
| WO2016073380A1 (en) | 2014-11-03 | 2016-05-12 | Genentech, Inc. | Method and biomarkers for predicting efficacy and evaluation of an ox40 agonist treatment |
| BR112017009151A2 (pt) | 2014-11-03 | 2018-03-06 | Genentech, Inc. | ensaios para detectar subgrupos imunológicos de célula t e métodos de uso dos mesmos |
| CN107073126A (zh) | 2014-11-06 | 2017-08-18 | 豪夫迈·罗氏有限公司 | 包含ox40结合激动剂和tigit抑制剂的组合疗法 |
| JP6639497B2 (ja) | 2014-11-10 | 2020-02-05 | ジェネンテック, インコーポレイテッド | ブロモドメインインヒビターおよびその使用 |
| MA40940A (fr) | 2014-11-10 | 2017-09-19 | Constellation Pharmaceuticals Inc | Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines |
| MA40943A (fr) | 2014-11-10 | 2017-09-19 | Constellation Pharmaceuticals Inc | Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines |
| KR20170096112A (ko) | 2014-11-17 | 2017-08-23 | 제넨테크, 인크. | Ox40 결합 효능제 및 pd-1 축 결합 길항제를 포함하는 조합 요법 |
| WO2016086200A1 (en) | 2014-11-27 | 2016-06-02 | Genentech, Inc. | 4,5,6,7-tetrahydro-1 h-pyrazolo[4,3-c]pyridin-3-amine compounds as cbp and/or ep300 inhibitors |
| CA2968359A1 (en) | 2014-12-23 | 2016-06-30 | Genentech, Inc. | Compositions and methods for treating and diagnosing chemotherapy-resistant cancers |
| AU2015371312B2 (en) | 2014-12-24 | 2022-01-27 | Genentech, Inc. | Therapeutic, diagnostic and prognostic methods for cancer of the bladder |
| WO2016109546A2 (en) | 2014-12-30 | 2016-07-07 | Genentech, Inc. | Methods and compositions for prognosis and treatment of cancers |
| WO2016112284A1 (en) | 2015-01-09 | 2016-07-14 | Genentech, Inc. | (piperidin-3-yl)(naphthalen-2-yl)methanone derivatives and related compounds as inhibitors of the histone demethylase kdm2b for the treatment of cancer |
| WO2016112251A1 (en) | 2015-01-09 | 2016-07-14 | Genentech, Inc. | 4,5-dihydroimidazole derivatives and their use as histone demethylase (kdm2b) inhibitors |
| CN107406429B (zh) | 2015-01-09 | 2021-07-06 | 基因泰克公司 | 哒嗪酮衍生物及其在治疗癌症中的用途 |
| JP6709792B2 (ja) | 2015-01-29 | 2020-06-17 | ジェネンテック, インコーポレイテッド | 治療用化合物およびその使用 |
| JP6636031B2 (ja) | 2015-01-30 | 2020-01-29 | ジェネンテック, インコーポレイテッド | 治療用化合物およびその使用 |
| JOP20200201A1 (ar) | 2015-02-10 | 2017-06-16 | Astex Therapeutics Ltd | تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين |
| MA41598A (fr) | 2015-02-25 | 2018-01-02 | Constellation Pharmaceuticals Inc | Composés thérapeutiques de pyridazine et leurs utilisations |
| WO2016164480A1 (en) | 2015-04-07 | 2016-10-13 | Genentech, Inc. | Antigen binding complex having agonistic activity and methods of use |
| PT3294770T (pt) | 2015-05-12 | 2020-12-04 | Hoffmann La Roche | Métodos terapêuticos e diagnósticos para o cancro |
| PL3303632T5 (pl) | 2015-05-29 | 2023-07-03 | F. Hoffmann-La Roche Ag | Terapeutyczne i diagnostyczne sposoby stosowane w nowotworze |
| AU2016274585A1 (en) | 2015-06-08 | 2017-12-14 | Genentech, Inc. | Methods of treating cancer using anti-OX40 antibodies |
| MX2017015937A (es) | 2015-06-08 | 2018-12-11 | Genentech Inc | Métodos de tratamiento del cáncer con anticuerpos anti-ox40 y antagonistas de unión al eje de pd-1. |
| WO2016205320A1 (en) | 2015-06-17 | 2016-12-22 | Genentech, Inc. | Methods of treating locally advanced or metastatic breast cancers using pd-1 axis binding antagonists and taxanes |
| US10287401B2 (en) | 2015-07-01 | 2019-05-14 | California Institute Of Technology | Cationic mucic acid polymer-based delivery systems |
| WO2017009751A1 (en) | 2015-07-15 | 2017-01-19 | Pfizer Inc. | Pyrimidine derivatives |
| CN105001167B (zh) * | 2015-07-16 | 2018-01-05 | 西安交通大学 | 1‑取代苯基‑3‑(4‑取代苯基氨基‑6‑喹唑啉基)脲类化合物及制备方法和用途 |
| ES2862727T3 (es) | 2015-08-26 | 2021-10-07 | Fundacion Del Sector Publico Estatal Centro Nac De Investigaciones Oncologicas Carlos Iii F S P Cnio | Compuestos tricíclicos condensados como inhibidores de proteínas quinasas |
| EP3347097B1 (en) | 2015-09-11 | 2021-02-24 | Sunshine Lake Pharma Co., Ltd. | Substituted aminopyrimidine derivatives as modulators of the kinases jak, flt3 and aurora |
| SI3353210T1 (sl) | 2015-09-25 | 2025-03-31 | F. Hoffmann-La Roche Ag | Protitelesa proti TIGIT in postopki uporabe |
| BR112018006873A2 (pt) | 2015-10-05 | 2018-11-06 | The Trustees Of Columbia University In The City Of New York | ativadores do fluxo autofágico e fosfolipase d e depuração de agregados de proteína incluindo tau e tratamento de proteinopatias |
| DK3362462T3 (da) | 2015-10-12 | 2021-10-11 | Advanced Cell Diagnostics Inc | In situ-detektion af nukleotidvarianter i prøver med højt støjniveau, og sammensætninger og fremgangsmåder relateret dertil |
| MX2018005298A (es) | 2015-11-02 | 2018-06-22 | Novartis Ag | Regimen de dosificacion para un inhibidor de fosfatidilinositol 3-quinasa. |
| DK3389662T3 (da) | 2015-12-16 | 2022-02-28 | Genentech Inc | Fremgangsmåde til fremstilling af tricykliske PI3K-inhibitorforbindelser og fremgangsmåder til anvendelse af disse til behandling af cancer |
| ES2851499T3 (es) | 2015-12-30 | 2021-09-07 | Synthon Bv | Proceso para fabricar una forma cristalina de gefitinib |
| AU2017205089B2 (en) | 2016-01-08 | 2023-10-05 | F. Hoffmann-La Roche Ag | Methods of treating CEA-positive cancers using PD-1 axis binding antagonists and anti-CEA/anti-CD3 bispecific antibodies |
| WO2017122205A1 (en) | 2016-01-13 | 2017-07-20 | Hadasit Medical Research Services And Development Ltd. | Radiolabeled erlotinib analogs and uses thereof |
| CN114395624A (zh) | 2016-02-29 | 2022-04-26 | 基因泰克公司 | 用于癌症的治疗和诊断方法 |
| EP3865511A1 (en) | 2016-04-14 | 2021-08-18 | F. Hoffmann-La Roche AG | Anti-rspo3 antibodies and methods of use |
| ES2850428T3 (es) | 2016-04-15 | 2021-08-30 | Hoffmann La Roche | Procedimientos de monitorización y tratamiento del cáncer |
| CN109072311A (zh) | 2016-04-15 | 2018-12-21 | 豪夫迈·罗氏有限公司 | 用于癌症的诊断和治疗方法 |
| WO2017181079A2 (en) | 2016-04-15 | 2017-10-19 | Genentech, Inc. | Methods for monitoring and treating cancer |
| WO2017184956A1 (en) | 2016-04-22 | 2017-10-26 | Duke University | Compounds and methods for targeting hsp90 |
| JP7014736B2 (ja) | 2016-05-24 | 2022-02-01 | ジェネンテック, インコーポレイテッド | がんの処置のためのピラゾロピリジン誘導体 |
| CN115028617A (zh) | 2016-05-24 | 2022-09-09 | 基因泰克公司 | Cbp/ep300的杂环抑制剂及其在治疗癌症中的用途 |
| WO2017214373A1 (en) | 2016-06-08 | 2017-12-14 | Genentech, Inc. | Diagnostic and therapeutic methods for cancer |
| EP3494139B1 (en) | 2016-08-05 | 2022-01-12 | F. Hoffmann-La Roche AG | Multivalent and multiepitopic anitibodies having agonistic activity and methods of use |
| CN109476748B (zh) | 2016-08-08 | 2023-05-23 | 豪夫迈·罗氏有限公司 | 用于癌症的治疗和诊断方法 |
| CA3034666A1 (en) | 2016-08-23 | 2018-03-01 | Oncopep, Inc. | Peptide vaccines and durvalumab for treating breast cancer |
| WO2018039203A1 (en) | 2016-08-23 | 2018-03-01 | Oncopep, Inc. | Peptide vaccines and durvalumab for treating multiple myeloma |
| JP7730008B2 (ja) | 2016-09-27 | 2025-08-27 | セロ・セラピューティクス・ホールディングス・インコーポレイテッド | キメラエンガルフメント受容体分子 |
| WO2018060833A1 (en) | 2016-09-27 | 2018-04-05 | Novartis Ag | Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib |
| US10207998B2 (en) | 2016-09-29 | 2019-02-19 | Duke University | Substituted benzimidazole and substituted benzothiazole inhibitors of transforming growth factor-β kinase and methods of use thereof |
| US10927083B2 (en) | 2016-09-29 | 2021-02-23 | Duke University | Substituted benzimidazoles as inhibitors of transforming growth factor-β kinase |
| AU2017339517B2 (en) | 2016-10-06 | 2024-03-14 | Foundation Medicine, Inc. | Therapeutic and diagnostic methods for cancer |
| WO2018078143A1 (en) | 2016-10-28 | 2018-05-03 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Means and methods for determining efficacy of anti-egfr inhibitors in colorectal cancer (crc) therapy |
| JP2019535250A (ja) | 2016-10-29 | 2019-12-12 | ジェネンテック, インコーポレイテッド | 抗mic抗体及び使用方法 |
| PL3558955T3 (pl) | 2016-12-22 | 2021-12-27 | Amgen Inc. | Pochodne benzoizotiazolu, izotiazolo[3,4-b]pirydyny, chinazoliny, ftalazyny, pirydo[2,3-d]pirydazyny i pirydo[2,3-d]pirymidyny jako inhibitory kras g12c do leczenia raka płuc, trzustki lub jelita grubego |
| EP3567030B1 (en) * | 2016-12-30 | 2022-02-09 | Medshine Discovery Inc. | Quinazoline compound for egfr inhibition |
| WO2018160841A1 (en) | 2017-03-01 | 2018-09-07 | Genentech, Inc. | Diagnostic and therapeutic methods for cancer |
| EP3609537A1 (en) | 2017-04-13 | 2020-02-19 | H. Hoffnabb-La Roche Ag | An interleukin-2 immunoconjugate, a cd40 agonist, and optionally a pd-1 axis binding antagonist for use in methods of treating cancer |
| JOP20190272A1 (ar) | 2017-05-22 | 2019-11-21 | Amgen Inc | مثبطات kras g12c وطرق لاستخدامها |
| WO2018234808A1 (en) | 2017-06-22 | 2018-12-27 | Curadev Pharma Limited | Small molecule modulators of human sting |
| CN111492245A (zh) | 2017-07-21 | 2020-08-04 | 基因泰克公司 | 癌症的治疗和诊断方法 |
| JP2020530297A (ja) | 2017-08-11 | 2020-10-22 | ジェネンテック, インコーポレイテッド | 抗cd8抗体及びその使用 |
| ES2928576T3 (es) | 2017-09-08 | 2022-11-21 | Amgen Inc | Inhibidores de KRAS G12C y métodos de uso de los mismos |
| WO2019051296A1 (en) | 2017-09-08 | 2019-03-14 | Genentech, Inc. | DIAGNOSTIC AND THERAPEUTIC METHODS OF CANCER |
| MX2020007266A (es) | 2017-09-26 | 2020-09-07 | Cero Therapeutics Inc | Moleculas del receptor quimerico de engullido y metodos de uso. |
| WO2019083960A1 (en) | 2017-10-24 | 2019-05-02 | Oncopep, Inc. | PEPTIDE VACCINES AND HDAC INHIBITORS FOR THE TREATMENT OF MULTIPLE MYELOMA |
| EP3700575A1 (en) | 2017-10-24 | 2020-09-02 | Oncopep, Inc. | Peptide vaccines and pembrolizumab for treating breast cancer |
| EP3710001B1 (en) | 2017-10-27 | 2025-06-18 | University Of Virginia Patent Foundation | Compounds and methods for regulating, limiting, or inhibiting avil expression |
| WO2019090263A1 (en) | 2017-11-06 | 2019-05-09 | Genentech, Inc. | Diagnostic and therapeutic methods for cancer |
| JP7254076B2 (ja) | 2017-11-19 | 2023-04-07 | サンシャイン・レイク・ファーマ・カンパニー・リミテッド | 置換ヘテロアリール化合物及び使用方法 |
| US11708335B2 (en) | 2017-12-18 | 2023-07-25 | Sterngreene, Inc. | Pyrimidine compounds useful as tyrosine kinase inhibitors |
| US11602534B2 (en) | 2017-12-21 | 2023-03-14 | Hefei Institutes Of Physical Science, Chinese Academy Of Sciences | Pyrimidine derivative kinase inhibitors |
| EP3740756A4 (en) | 2018-01-15 | 2021-10-27 | Epiaxis Therapeutics Pty Ltd | AGENTS AND METHODS FOR PREDICTING THE THERAPEUTIC RESPONSE |
| US10751339B2 (en) | 2018-01-20 | 2020-08-25 | Sunshine Lake Pharma Co., Ltd. | Substituted aminopyrimidine compounds and methods of use |
| MX2020008882A (es) | 2018-02-26 | 2021-01-08 | Genentech Inc | Dosificación para tratamiento con anticuerpos antagonistas anti-tigit y anti-pd-l1. |
| EP3774865A1 (en) | 2018-03-28 | 2021-02-17 | Cero Therapeutics, Inc. | Cellular immunotherapy compositions and uses thereof |
| US12291557B2 (en) | 2018-03-28 | 2025-05-06 | Cero Therapeutics Holdings, Inc. | Chimeric TIM4 receptors and uses thereof |
| JP7549533B2 (ja) | 2018-03-28 | 2024-09-11 | セロ・セラピューティクス・インコーポレイテッド | キメラ貪食受容体のための発現ベクター、遺伝子改変宿主細胞およびそれらの使用 |
| CA3099118A1 (en) | 2018-05-04 | 2019-11-07 | Amgen Inc. | Kras g12c inhibitors and methods of using the same |
| MX2020010836A (es) | 2018-05-04 | 2021-01-08 | Amgen Inc | Inhibidores de kras g12c y métodos para su uso. |
| MA52564A (fr) | 2018-05-10 | 2021-03-17 | Amgen Inc | Inhibiteurs de kras g12c pour le traitement du cancer |
| EP3797173A2 (en) | 2018-05-21 | 2021-03-31 | Nanostring Technologies, Inc. | Molecular gene signatures and methods of using same |
| WO2019232419A1 (en) | 2018-06-01 | 2019-12-05 | Amgen Inc. | Kras g12c inhibitors and methods of using the same |
| EP4268898A3 (en) | 2018-06-11 | 2024-01-17 | Amgen Inc. | Kras g12c inhibitors for treating cancer |
| MA51848A (fr) | 2018-06-12 | 2021-04-21 | Amgen Inc | Inhibiteurs de kras g12c et leurs procédés d'utilisation |
| WO2019241327A1 (en) | 2018-06-13 | 2019-12-19 | California Institute Of Technology | Nanoparticles for crossing the blood brain barrier and methods of treatment using the same |
| MA52968A (fr) | 2018-06-23 | 2021-04-28 | Hoffmann La Roche | Méthodes de traitement du cancer du poumon à l'aide d'un antagoniste de liaison à l'axe pd-1, d'un agent de platine et d'un inhibiteur de la topoisomérase ii |
| KR20210034622A (ko) | 2018-07-18 | 2021-03-30 | 제넨테크, 인크. | Pd-1 축 결합 길항제, 항 대사제, 및 백금 제제를 이용한 폐암 치료 방법 |
| EP3826988A4 (en) | 2018-07-24 | 2023-03-22 | Hygia Pharmaceuticals, LLC | COMPOUNDS, DERIVATIVES AND ANALOGUES FOR CANCER |
| EP3847154A1 (en) | 2018-09-03 | 2021-07-14 | F. Hoffmann-La Roche AG | Carboxamide and sulfonamide derivatives useful as tead modulators |
| CN113195470B (zh) * | 2018-09-13 | 2024-12-03 | 南加州大学 | 作为治疗剂的新型单磷酸鸟苷合成酶抑制剂 |
| MX2021003214A (es) | 2018-09-19 | 2021-05-12 | Genentech Inc | Metodos terapeuticos y de diagnostico para el cancer de vejiga. |
| PL3857230T3 (pl) | 2018-09-21 | 2023-10-16 | F. Hoffmann-La Roche Ag | Sposoby diagnostyczne dla potrójnie ujemnego raka piersi |
| CN113194954A (zh) | 2018-10-04 | 2021-07-30 | 国家医疗保健研究所 | 用于治疗角皮病的egfr抑制剂 |
| EP3867405A4 (en) | 2018-10-17 | 2022-07-20 | The University of Queensland | Epigenetic biomarker and uses therefor |
| CN113196061A (zh) | 2018-10-18 | 2021-07-30 | 豪夫迈·罗氏有限公司 | 肉瘤样肾癌的诊断和治疗方法 |
| JP7516029B2 (ja) | 2018-11-16 | 2024-07-16 | アムジエン・インコーポレーテツド | Kras g12c阻害剤化合物の重要な中間体の改良合成法 |
| CA3117222A1 (en) | 2018-11-19 | 2020-05-28 | Amgen Inc. | Kras g12c inhibitors and methods of using the same |
| JP7377679B2 (ja) | 2018-11-19 | 2023-11-10 | アムジエン・インコーポレーテツド | がん治療のためのkrasg12c阻害剤及び1種以上の薬学的に活性な追加の薬剤を含む併用療法 |
| US12180207B2 (en) | 2018-12-19 | 2024-12-31 | Array Biopharma Inc. | Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of FGFR tyrosine kinases |
| CN113474337A (zh) | 2018-12-19 | 2021-10-01 | 奥瑞生物药品公司 | 作为fgfr抑制剂用于治疗癌症的7-((3,5-二甲氧基苯基)氨基)喹喔啉衍生物 |
| US12441736B2 (en) | 2018-12-20 | 2025-10-14 | Amgen Inc. | KIF18A inhibitors |
| CA3123042A1 (en) | 2018-12-20 | 2020-06-25 | Amgen Inc. | Kif18a inhibitors |
| JP2022513967A (ja) | 2018-12-20 | 2022-02-09 | アムジエン・インコーポレーテツド | Kif18a阻害剤として有用なヘテロアリールアミド |
| IL283639B2 (en) | 2018-12-20 | 2024-06-01 | Amgen Inc | Kif18a inhibitors |
| WO2020163589A1 (en) | 2019-02-08 | 2020-08-13 | Genentech, Inc. | Diagnostic and therapeutic methods for cancer |
| EP3931565A4 (en) | 2019-02-27 | 2023-04-12 | Epiaxis Therapeutics Pty Ltd | METHODS AND MEANS OF EVALUATING T-CELL FUNCTION AND PREDICTING RESPONSE TO THERAPY |
| AU2020228383A1 (en) | 2019-02-27 | 2021-09-23 | Genentech, Inc. | Dosing for treatment with anti-tigit and anti-CD20 or anti-CD38 antibodies |
| AU2020232616A1 (en) | 2019-03-01 | 2021-09-09 | Revolution Medicines, Inc. | Bicyclic heterocyclyl compounds and uses thereof |
| US20230148450A9 (en) | 2019-03-01 | 2023-05-11 | Revolution Medicines, Inc. | Bicyclic heteroaryl compounds and uses thereof |
| CN109796415B (zh) * | 2019-03-29 | 2020-10-30 | 武汉德诺美生物医药股份有限公司 | Egfr抑制剂及其应用 |
| WO2020223233A1 (en) | 2019-04-30 | 2020-11-05 | Genentech, Inc. | Prognostic and therapeutic methods for colorectal cancer |
| JP2022530674A (ja) | 2019-05-03 | 2022-06-30 | ジェネンテック, インコーポレイテッド | 抗pd-l1抗体を用いたがんの処置方法 |
| EP3738593A1 (en) | 2019-05-14 | 2020-11-18 | Amgen, Inc | Dosing of kras inhibitor for treatment of cancers |
| NZ782284A (en) | 2019-05-21 | 2024-11-29 | Amgen Inc | Solid state forms |
| CN112300279A (zh) | 2019-07-26 | 2021-02-02 | 上海复宏汉霖生物技术股份有限公司 | 针对抗cd73抗体和变体的方法和组合物 |
| JP7756070B2 (ja) | 2019-08-02 | 2025-10-17 | アムジエン・インコーポレーテツド | Kif18a阻害剤としてのピリジン誘導体 |
| WO2021026098A1 (en) | 2019-08-02 | 2021-02-11 | Amgen Inc. | Kif18a inhibitors |
| CN114269731A (zh) | 2019-08-02 | 2022-04-01 | 美国安进公司 | Kif18a抑制剂 |
| JP7699100B2 (ja) | 2019-08-02 | 2025-06-26 | アムジエン・インコーポレーテツド | Kif18a阻害剤 |
| EP4025608A1 (en) | 2019-09-04 | 2022-07-13 | F. Hoffmann-La Roche AG | Cd8 binding agents and uses thereof |
| WO2021062085A1 (en) | 2019-09-27 | 2021-04-01 | Genentech, Inc. | Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies |
| EP4038097A1 (en) | 2019-10-03 | 2022-08-10 | Cero Therapeutics, Inc. | Chimeric tim4 receptors and uses thereof |
| MX2022004656A (es) | 2019-10-24 | 2022-05-25 | Amgen Inc | Derivados de piridopirimidina utiles como inhibidores de kras g12c y kras g12d en el tratamiento del cancer. |
| WO2021083949A1 (en) | 2019-10-29 | 2021-05-06 | F. Hoffmann-La Roche Ag | Bifunctional compounds for the treatment of cancer |
| EP4055028A1 (en) | 2019-11-04 | 2022-09-14 | Revolution Medicines, Inc. | Ras inhibitors |
| KR20220109406A (ko) | 2019-11-04 | 2022-08-04 | 레볼루션 메디슨즈, 인크. | Ras 억제제 |
| CA3159561A1 (en) | 2019-11-04 | 2021-05-14 | Revolution Medicines, Inc. | Ras inhibitors |
| EP4055388A1 (en) | 2019-11-06 | 2022-09-14 | Genentech, Inc. | Diagnostic and therapeutic methods for treatment of hematologic cancers |
| EP4620531A3 (en) | 2019-11-08 | 2025-11-26 | Revolution Medicines, Inc. | Bicyclic heteroaryl compounds and uses thereof |
| AU2020381458A1 (en) | 2019-11-13 | 2022-05-12 | Genentech, Inc. | Therapeutic compounds and methods of use |
| US20220395553A1 (en) | 2019-11-14 | 2022-12-15 | Cohbar, Inc. | Cxcr4 antagonist peptides |
| AR120457A1 (es) | 2019-11-14 | 2022-02-16 | Amgen Inc | Síntesis mejorada del compuesto inhibidor de g12c de kras |
| JP2023501522A (ja) | 2019-11-14 | 2023-01-18 | アムジエン・インコーポレーテツド | Kras g12c阻害剤化合物の改良合成法 |
| WO2021108683A1 (en) | 2019-11-27 | 2021-06-03 | Revolution Medicines, Inc. | Covalent ras inhibitors and uses thereof |
| US11845799B2 (en) | 2019-12-13 | 2023-12-19 | Genentech, Inc. | Anti-Ly6G6D antibodies and methods of use |
| AU2020408562A1 (en) | 2019-12-20 | 2022-06-23 | Erasca, Inc. | Tricyclic pyridones and pyrimidones |
| TW202140011A (zh) | 2020-01-07 | 2021-11-01 | 美商銳新醫藥公司 | Shp2抑制劑給藥和治療癌症的方法 |
| KR20220133243A (ko) | 2020-01-27 | 2022-10-04 | 제넨테크, 인크. | 항 tigit 길항제 항체를 이용한 암의 치료 방법 |
| WO2021194481A1 (en) | 2020-03-24 | 2021-09-30 | Genentech, Inc. | Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies |
| WO2021177980A1 (en) | 2020-03-06 | 2021-09-10 | Genentech, Inc. | Combination therapy for cancer comprising pd-1 axis binding antagonist and il6 antagonist |
| WO2021233534A1 (en) | 2020-05-20 | 2021-11-25 | Pvac Medical Technologies Ltd | Use of substance and pharmaceutical composition thereof, and medical treatments or uses thereof |
| WO2021185844A1 (en) | 2020-03-16 | 2021-09-23 | Pvac Medical Technologies Ltd | Use of substance and pharmaceutical composition thereof, and medical treatments or uses thereof |
| CN115698717A (zh) | 2020-04-03 | 2023-02-03 | 基因泰克公司 | 癌症的治疗和诊断方法 |
| CN115768890A (zh) | 2020-04-15 | 2023-03-07 | 加州理工学院 | 通过分子和物理启动对t细胞免疫疗法的热控制 |
| JP2023523450A (ja) | 2020-04-28 | 2023-06-05 | ジェネンテック, インコーポレイテッド | 非小細胞肺がん免疫療法のための方法及び組成物 |
| CN111499583B (zh) * | 2020-05-22 | 2022-02-15 | 沈阳工业大学 | 喹唑啉衍生物及其作为抗肿瘤药物的应用 |
| EP4164627A1 (en) | 2020-06-16 | 2023-04-19 | Genentech, Inc. | Methods and compositions for treating triple-negative breast cancer |
| AU2021293228A1 (en) | 2020-06-18 | 2023-02-09 | Revolution Medicines, Inc. | Methods for delaying, preventing, and treating acquired resistance to RAS inhibitors |
| US20210395366A1 (en) | 2020-06-18 | 2021-12-23 | Genentech, Inc. | Treatment with anti-tigit antibodies and pd-1 axis binding antagonists |
| US11787775B2 (en) | 2020-07-24 | 2023-10-17 | Genentech, Inc. | Therapeutic compounds and methods of use |
| CN116568824A (zh) | 2020-08-03 | 2023-08-08 | 基因泰克公司 | 淋巴瘤的诊断和治疗方法 |
| WO2022029220A1 (en) | 2020-08-05 | 2022-02-10 | Ellipses Pharma Ltd | Treatment of cancer using a cyclodextrin-containing polymer-topoisomerase inhibitor conjugate and a parp inhibitor |
| EP4196612A1 (en) | 2020-08-12 | 2023-06-21 | Genentech, Inc. | Diagnostic and therapeutic methods for cancer |
| WO2022036265A1 (en) | 2020-08-14 | 2022-02-17 | Cero Therapeutics, Inc. | Chimeric tim receptors and uses thereof |
| WO2022036285A1 (en) | 2020-08-14 | 2022-02-17 | Cero Therapeutics, Inc. | Compositions and methods for treating cancer with chimeric tim receptors in combination with inhibitors of poly (adp-ribose) polymerase |
| WO2022036287A1 (en) | 2020-08-14 | 2022-02-17 | Cero Therapeutics, Inc. | Anti-cd72 chimeric receptors and uses thereof |
| US11999964B2 (en) | 2020-08-28 | 2024-06-04 | California Institute Of Technology | Synthetic mammalian signaling circuits for robust cell population control |
| US20250195521A1 (en) | 2020-09-03 | 2025-06-19 | Revolution Medicines, Inc. | Use of sos1 inhibitors to treat malignancies with shp2 mutations |
| IL301298A (en) | 2020-09-15 | 2023-05-01 | Revolution Medicines Inc | Indole derivatives as RAS inhibitors in cancer therapy |
| WO2022066805A1 (en) | 2020-09-23 | 2022-03-31 | Erasca, Inc. | Tricyclic pyridones and pyrimidones |
| CA3193952A1 (en) | 2020-10-05 | 2022-04-14 | Bernard Martin Fine | Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies |
| TW202237638A (zh) | 2020-12-09 | 2022-10-01 | 日商武田藥品工業股份有限公司 | 烏苷酸環化酶c(gcc)抗原結合劑之組成物及其使用方法 |
| WO2022133345A1 (en) | 2020-12-18 | 2022-06-23 | Erasca, Inc. | Tricyclic pyridones and pyrimidones |
| JP2024501280A (ja) | 2020-12-22 | 2024-01-11 | キル・レガー・セラピューティクス・インコーポレーテッド | Sos1阻害剤およびその使用 |
| CA3210553A1 (en) | 2021-02-12 | 2022-08-18 | F. Hoffmann-La Roche Ag | Bicyclic tetrahydroazepine derivatives for the treatment of cancer |
| CA3212006A1 (en) | 2021-02-26 | 2022-09-01 | Kelonia Therapeutics, Inc. | Lymphocyte targeted lentiviral vectors |
| WO2022235870A1 (en) | 2021-05-05 | 2022-11-10 | Revolution Medicines, Inc. | Ras inhibitors for the treatment of cancer |
| TW202309052A (zh) | 2021-05-05 | 2023-03-01 | 美商銳新醫藥公司 | Ras抑制劑 |
| EP4334324A1 (en) | 2021-05-05 | 2024-03-13 | Revolution Medicines, Inc. | Covalent ras inhibitors and uses thereof |
| EP4347603A1 (en) | 2021-05-25 | 2024-04-10 | Erasca, Inc. | Sulfur-containing heteroaromatic tricyclic kras inhibitors |
| US20240293558A1 (en) | 2021-06-16 | 2024-09-05 | Erasca, Inc. | Kras inhibitor conjugates |
| WO2023010097A1 (en) | 2021-07-28 | 2023-02-02 | Cero Therapeutics, Inc. | Chimeric tim4 receptors and uses thereof |
| TW202321261A (zh) | 2021-08-10 | 2023-06-01 | 美商伊瑞斯卡公司 | 選擇性kras抑制劑 |
| AR127308A1 (es) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | Inhibidores ras |
| EP4436969A2 (en) | 2021-11-24 | 2024-10-02 | Genentech, Inc. | Bicyclic therapeutic compounds and methods of use in the treatment of cancer |
| JP2024541508A (ja) | 2021-11-24 | 2024-11-08 | ジェネンテック, インコーポレイテッド | 治療用インダゾール化合物およびがんの治療における使用方法 |
| TW202340214A (zh) | 2021-12-17 | 2023-10-16 | 美商健臻公司 | 做為shp2抑制劑之吡唑并吡𠯤化合物 |
| EP4227307A1 (en) | 2022-02-11 | 2023-08-16 | Genzyme Corporation | Pyrazolopyrazine compounds as shp2 inhibitors |
| JP2025509217A (ja) | 2022-03-07 | 2025-04-11 | アムジエン・インコーポレーテツド | 4-メチル-2-プロパン-2-イル-ピリジン-3-カルボニトリルを調製するための方法 |
| WO2023172940A1 (en) | 2022-03-08 | 2023-09-14 | Revolution Medicines, Inc. | Methods for treating immune refractory lung cancer |
| EP4504780A1 (en) | 2022-04-01 | 2025-02-12 | Genentech, Inc. | Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies |
| WO2023219613A1 (en) | 2022-05-11 | 2023-11-16 | Genentech, Inc. | Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies |
| KR20250022049A (ko) | 2022-06-07 | 2025-02-14 | 제넨테크, 인크. | 항-pd-l1 길항제 및 항-tigit 길항제 항체를 포함하는, 폐암 치료의 효율을 결정하는 방법 |
| KR20250022133A (ko) | 2022-06-10 | 2025-02-14 | 레볼루션 메디슨즈, 인크. | 거대고리 ras 억제제 |
| EP4554978A1 (en) | 2022-07-13 | 2025-05-21 | Genentech, Inc. | Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies |
| JP2025523845A (ja) | 2022-07-19 | 2025-07-25 | ジェネンテック, インコーポレイテッド | 抗fcrh5/抗cd3二重特異性抗体による処置のための投薬 |
| CN119816589A (zh) | 2022-08-02 | 2025-04-11 | 国立大学法人北海道大学 | 使用细胞器复合体改善细胞疗法的方法 |
| CR20250042A (es) | 2022-08-11 | 2025-03-25 | Hoffmann La Roche | Derivados de tetrahidrotiazepina bicíclicos |
| TW202417001A (zh) | 2022-08-11 | 2024-05-01 | 瑞士商赫孚孟拉羅股份公司 | 雙環四氫吖呯衍生物 |
| CN119677733A (zh) | 2022-08-11 | 2025-03-21 | 豪夫迈·罗氏有限公司 | 双环四氢硫氮杂䓬衍生物 |
| AR130169A1 (es) | 2022-08-11 | 2024-11-13 | Hoffmann La Roche | Derivados de tetrahidrotiazepina bicíclicos |
| AU2023358792A1 (en) | 2022-10-14 | 2025-04-17 | Black Diamond Therapeutics, Inc. | Methods of treating cancers using isoquinoline or 6-aza-quinoline derivatives |
| JP2025538859A (ja) | 2022-10-21 | 2025-12-02 | 公益財団法人川崎市産業振興財団 | 非吸着性またはスーパーステルス小胞 |
| AU2023367741A1 (en) | 2022-10-25 | 2025-05-01 | Genentech, Inc. | Therapeutic and diagnostic methods for multiple myeloma |
| WO2024173842A1 (en) | 2023-02-17 | 2024-08-22 | Erasca, Inc. | Kras inhibitors |
| KR20250164828A (ko) | 2023-03-30 | 2025-11-25 | 레볼루션 메디슨즈, 인크. | Ras gtp 가수분해 유도를 위한 조성물 및 이의 용도 |
| WO2024211663A1 (en) | 2023-04-07 | 2024-10-10 | Revolution Medicines, Inc. | Condensed macrocyclic compounds as ras inhibitors |
| AU2024243852A1 (en) | 2023-04-07 | 2025-11-06 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| KR20250169290A (ko) | 2023-04-14 | 2025-12-02 | 레볼루션 메디슨즈, 인크. | Ras 억제제의 결정형, 이를 함유하는 조성물 및 이의 사용 방법 |
| KR20250172857A (ko) | 2023-04-14 | 2025-12-09 | 레볼루션 메디슨즈, 인크. | Ras 억제제의 결정형 |
| AU2024265078A1 (en) | 2023-05-04 | 2025-12-11 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| AU2024270495A1 (en) | 2023-05-05 | 2025-10-09 | Genentech, Inc. | Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies |
| TW202504641A (zh) | 2023-06-08 | 2025-02-01 | 美商建南德克公司 | 用於淋巴瘤之診斷及治療方法的巨噬細胞特徵 |
| WO2025024257A1 (en) | 2023-07-21 | 2025-01-30 | Genentech, Inc. | Diagnostic and therapeutic methods for cancer |
| WO2025034702A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Rmc-6291 for use in the treatment of ras protein-related disease or disorder |
| TW202515614A (zh) | 2023-08-25 | 2025-04-16 | 美商建南德克公司 | 治療非小細胞肺癌之方法及組成物 |
| WO2025080946A2 (en) | 2023-10-12 | 2025-04-17 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025137507A1 (en) | 2023-12-22 | 2025-06-26 | Regor Pharmaceuticals, Inc. | Sos1 inhibitors and uses thereof |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US398749A (en) * | 1889-02-26 | Harvey d | ||
| US3985742A (en) * | 1971-12-01 | 1976-10-12 | Merck & Co., Inc. | Process for preparing 3-hydroxymethyl cephalosporins |
| US3985749A (en) * | 1975-12-22 | 1976-10-12 | Eastman Kodak Company | Process for preparation of 4-aminoquinazoline |
| JPS5538325A (en) * | 1978-09-11 | 1980-03-17 | Sankyo Co Ltd | 4-anilinoquinazoline derivative and its preparation |
| JPS5620577A (en) * | 1979-07-27 | 1981-02-26 | Sankyo Co Ltd | 4- n-alkylanilino quinazoline derivative and its preparation |
| US4510307A (en) * | 1980-08-20 | 1985-04-09 | Asahi Kasei Kogyo Kabushiki Kaisha | 6-Quinazolinesulfonyl derivatives and process for preparation thereof |
| JPS57143266A (en) * | 1981-02-27 | 1982-09-04 | Shin Kobe Electric Mach Co Ltd | Plate for lead acid battery |
| JPS57143296A (en) * | 1981-02-28 | 1982-09-04 | Matsushita Electric Works Ltd | Switching unit |
| JPS5913765A (ja) * | 1982-07-15 | 1984-01-24 | Kyorin Pharmaceut Co Ltd | 2−(4−キナゾリル)アミノ安息香酸誘導体 |
| GB2160201B (en) * | 1984-06-14 | 1988-05-11 | Wyeth John & Brother Ltd | Quinazoline and cinnoline derivatives |
| GB8424979D0 (en) * | 1984-10-03 | 1984-11-07 | Wyeth John & Brother Ltd | Benzenesulphonamide derivatives |
| HU207287B (en) * | 1989-01-17 | 1993-03-29 | Biosignal Kutato Fejlesztoe Kf | Polyene fatty acid derivatives of tyrozine-quinaze inhibiting activity and pharmaceutical composition containing them as active component |
| DE69202243T2 (de) * | 1991-02-20 | 1995-08-31 | Pfizer | 2,4-Diaminochinazolin-Derivate, um die Antitumorwirkung zu erhöhen. |
| DK0584222T3 (da) * | 1991-05-10 | 1998-02-23 | Rhone Poulenc Rorer Int | Bis-mono- og bicycliske aryl- og heteroarylforbindelser, som inhiberer EGF- og/eller PDGF-receptor-tyrosinkinase |
| NZ243082A (en) * | 1991-06-28 | 1995-02-24 | Ici Plc | 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof |
| PT100905A (pt) * | 1991-09-30 | 1994-02-28 | Eisai Co Ltd | Compostos heterociclicos azotados biciclicos contendo aneis de benzeno, ciclo-hexano ou piridina e de pirimidina, piridina ou imidazol substituidos e composicoes farmaceuticas que os contem |
-
1993
- 1993-01-04 AU AU31010/93A patent/AU661533B2/en not_active Expired
- 1993-01-04 GB GB939300059A patent/GB9300059D0/en active Pending
- 1993-01-08 CA CA002086968A patent/CA2086968C/en not_active Expired - Lifetime
- 1993-01-12 NZ NZ245662A patent/NZ245662A/en not_active IP Right Cessation
- 1993-01-15 AT AT93300270T patent/ATE130000T1/de active
- 1993-01-15 DE DE69300754T patent/DE69300754T2/de not_active Expired - Lifetime
- 1993-01-15 DK DK93300270.1T patent/DK0566226T3/da active
- 1993-01-15 ES ES93300270T patent/ES2078798T3/es not_active Expired - Lifetime
- 1993-01-15 EP EP93300270A patent/EP0566226B1/en not_active Expired - Lifetime
- 1993-01-15 HU HU9300094A patent/HU221622B1/hu unknown
- 1993-01-18 CZ CZ9343A patent/CZ282038B6/cs not_active IP Right Cessation
- 1993-01-18 TW TW082100292A patent/TW283146B/zh not_active IP Right Cessation
- 1993-01-19 FI FI930208A patent/FI111631B/fi not_active IP Right Cessation
- 1993-01-19 SK SK16-93A patent/SK281551B6/sk not_active IP Right Cessation
- 1993-01-19 NO NO930178A patent/NO301541B1/no not_active IP Right Cessation
- 1993-01-19 RU RU93004423/04A patent/RU2127263C1/ru active
- 1993-01-20 KR KR1019930000645A patent/KR100229294B1/ko not_active Expired - Lifetime
- 1993-01-21 IL IL10447993A patent/IL104479A/en not_active IP Right Cessation
- 1993-04-22 UA UA93002840A patent/UA34426C2/uk unknown
-
1994
- 1994-08-02 US US08/284,293 patent/US5457105A/en not_active Expired - Lifetime
-
1995
- 1995-06-12 HU HU95P/P00185P patent/HU211311A9/hu unknown
- 1995-06-15 US US08/490,666 patent/US5616582A/en not_active Expired - Lifetime
- 1995-11-21 GR GR950403262T patent/GR3018143T3/el unknown
-
1997
- 1997-03-27 HK HK36497A patent/HK36497A/en not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CZ282038B6 (cs) | Chinazolinové deriváty, způsob jejich přípravy a farmaceutické kompozice tyto deriváty obsahující | |
| EP0602851B1 (en) | Quinazoline derivatives | |
| US5475001A (en) | Quinazoline derivatives | |
| US6015814A (en) | Quinazoline derivative | |
| US5770599A (en) | Quinazoline derivatives | |
| JP2994165B2 (ja) | キナゾリン誘導体、その製造法および該キナゾリン誘導体を含有する抗癌作用を得るための医薬調剤 | |
| JPH05208911A (ja) | 抗癌作用を有する医薬組成物、キナゾリン誘導体及びその製法 | |
| HK1005371B (en) | Quinazoline derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| IF00 | In force as of 2000-06-30 in czech republic | ||
| MK4A | Patent expired |
Effective date: 20130118 |